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Summary
The aim of this thesis was to test the hypothesis that curcuminoids induce
potent growth inhibitory activity on acute promyelocytic leukemia (APL) via
the misfolded N-CoR pathway. Six series of curcumin analogs comprising of
78 compounds were synthesized and evaluated on two APL cell lines (NB4
and NB4-R1), two leukemic non-APL cell lines (HL60 and K562) and two non-
malignant cell lines (IMR90 and MCF10A). An assessment of structural
features contributing to activity and selectivity for APL over non-APL was as
follows; (i) an unhindered carbonyl group in the central linker is necessary for
activity; (ii) a six-membered ring is preferred as the central linker and
introduction of a heteroatom improves activity in the CH2 < S < NH < SO2; (iii)
replacement of aryl rings with 2- or 3-pyridyl rings is favored for activity while
the resultant selectivity depends on the central linker; (iv) ring substitutions
such as 3-fluoro, 3-hydroxyl and 3-methoxy is beneficial for activity (v)
substitution in 4-position of aryl rings lead to diminished activity compared to
the 3-position.
Compounds from series II (11), series III (22) and series V (41) were found to
induce accumulation of misfolded N-CoR at concentrations significantly lower
than curcumin. A global gene expression profile was established for
curcumin- and 41-treated APL cells, at 5µM and 50nM concentrations
respectively. Microarray results show that the second most significantly
regulated pathway is the protein processing in the endoplasmic reticulum
pathway which, on treatment with curcumin and 41, resulted in the
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upregulation of protein transporters, chaperones, ubiquitin ligases as well as
activated unfolded protein response (UPR) pathway. These results were
supported with the discovery that selected curcuminoids inhibited
endogenous 26S proteasome at concentrations up to 30 times lower than
curcumin. The functional relevance of 26S proteasomal inhibition by
curcuminoids was demonstrated by subsequent inhibition of the NF-ĸB
signaling pathway in APL cells. These results showed the ability of compounds
to inhibit the proteasome and induce an inhibitory downstream effect on the
important pro-survival NF-ĸB signaling pathway. Further evaluation of the
effect of lead compounds 41, 219 and 227 on the downstream cellular
pathways was carried out and our findings supported the view that these
three compounds activated ER stress-induced apoptosis, at concentrations
significantly lower than that of curcumin.
In conclusion, the findings of this thesis supported the hypothesis that
curcuminoids were potentially promising candidates that induce APL growth
inhibitory activity via the novel misfolded N-CoR pathway. Structural
requirements for activity and APL selectivity were well-established and
analogs with at least 120-fold improvement in potency than curcumin while
maintaining 6-fold APL selectivity and 13-fold selectivity for malignant cells
versus non-malignant cells were identified. Three candidates were
extensively investigated and their cellular mechanism of action leading to
apoptosis has been elucidated. Compounds 41, 219 and 227 were identified
as promising leads and further improvements to metabolic stability of these
17
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Leukemia is a malignant disorder of the blood forming cells in the bone
marrow characterized by the accumulation of non-functional cells in the
marrow and blood. As the disease progresses, the production of platelets,
red and white cells by the bone marrow are halted, leading to easy bleeding,
anemia and lowered immunity. Children and adolescents are more
susceptible to leukemia than adults.  In 2012, almost one-third of cancer
deaths in children younger than 15 years were caused by leukemia. In 2012,
hematopoietic malignancies (leukemia, lymphoma and myeloma) accounted
for 40,000 cases diagnosed in USA.1
There are four main classes of leukemia:  acute lymphoblastic leukemia (ALL),
acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL) and
chronic myeloid leukemia (CML). Acute leukemias are characterized by
rapidly growing cells that are immature and undifferentiated, whereas
chronic leukemic cells are slow growing and largely differentiated. A
systematic classification of the various classes and subtypes of leukemia was
proposed by the French-American-British (FAB) Cooperative group in 1976
and is still widely employed today.2 Lymphoblastic leukemias are categorized
into L1 – L3 subtypes base on cytological features such as size, nuclear shape
and amount of cytoplasm. Myeloid leukemias are categorized into six main
types, M1 to M6, depending on the differentiation direction and degree of
maturation.
1.2.Acute Promyelocytic Leukemia (APL)
Acute promyelocytic leukemia (APL) accounts for 10 – 15 % of acute myeloid
leukemia (AML) and is classified as an M3-subtype of AML. APL cells are
distinguished by   their non-uniform nuclear size and shape, and the presence
in the cytoplasm of closely packed large granules  that are stained  bright pink
to purple by Romanowsky dyes.2 The genetic hallmark of APL is a specific
chromosomal translocation t(15;17) that fuses the retinoic acid receptor α
(RARα) gene on chromosome 17 to the promyelocytic leukemia (PML) gene
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on chromosome 15.3 The result is a fusion protein (PML-RARα) that is found
in 98 % of APL. The remaining 2% involve less common chromosomal
translocations of the RARα gene such as t(11,17) and t(5,17) to give different
fusion partners of RARα. 4,5 In the recent years, there is a growing incidence
of therapy-related APL (tAPL) in which APL was induced in patients following
chemotherapy for existing malignancies.6 The emergence of tAPL was
attributed to the therapeutic use of topoisomerase II inhibitors
(anthracyclins, ebirubicin, mitoxantrone). Topoisomerase II relaxes
supercoiled DNA by cleaving and religating strands of the double helix.
Topoisomerase II inhibitors disrupt this cleavage-religation equilibrium and
increase the concentration of breakpoint complexes, some of which result in
the chomosomal translocation t(15;17) that is  characteristic of  APL.
1.2.1. The molecular pathogenesis of APL
The molecular pathogenesis of APL is strongly linked to the attenuation of
RARα signaling and the repression of retinoid target genes by PML-RARα.3, 7, 8
RARα contains a retinoic acid (RA) response element that enables
transcription of RA target genes required for cell differentiation.7
Homodimerization of PML-RARα greatly enhances its affinity for receptor
corepressors such as nuclear receptor co-repressor (N-CoR).8 The increase in
local concentrations of repression complexes at RA target promoters lead to
transcriptional repression of RA target genes and ultimately, differentiation
arrest of promyelocytic cells.  The role of N-CoR in APL pathogenesis is of
particular relevance in this thesis and is elaborated in the following section.
1.2.2. The role of N-CoR in APL pathogenesis
N-CoR is a component of the generic corepressor protein complex that is
involved in transcriptional control of many developmentally regulated genes.
It forms a stable adapter protein complex with histone deacetylase 3 (HDAC3)
for the deacetylation of histones.9 N-CoR/HDAC complexes also regulate
other classes of transcription factors. Hence, N-CoR contributes to the
regulation of essential biological processes such as cell proliferation,
differentiation and apoptosis.10 N-CoR has well defined roles in
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hematopoiesis. It is essential for the transcriptional repression mediated by
the tumor suppressor Mad, an important regulator of the growth and
maturation of cells of myeloid lineage.11-13 It also plays a role in the
differentiation of thymocytes and cells of erythroid lineage.14
N-CoR is involved in the pathogenesis of APL in two distinct ways. First, PML-
RARα fulfills its role as the dominant negative repressor of retinoic acid (RA)
responsive genes by recruiting the N-CoR-containing chromatin remodeling
complex to the gene promoters, hence repressing transcription and arresting
differentiation of APL cells. These events occur in the nuclear compartment
and involve the functional, stable and natively folded N-CoR.  Second, PML-
RARα induces the misfolding and cytosolic export of N-CoR. Misfolding is
induced when N-CoR is physically engaged at two sites on the fusion protein:
the coiled coil domain of PML and the N-CoR box located at the RAR moiety.8
The interaction at the N-CoR box is dependent on phosphorylation of
serine/threonine residues. There was a marked reduction in N-CoR misfolding
capacity when serine/threonine residues at that site were mutated.15 Export
of the resulting complex from the nucleus to the cytosol activates the
transcription of self-renewal genes originally repressed by N-CoR. Thus by
inducing two contrasting transcriptional outcomes (repressing differentiation
and reactivating self-renewal potential of myeloid cells), the N-CoR fusion
protein complex contributes to transformation in APL.16
The fate of the misfolded N-CoR-fusion protein complex in the cytosol has
been investigated in elegant detail by Khan and coworkers.8, 17-19 They found
that in cell lysates derived from NB4 (an APL cell line), misfolded N-CoR
existed almost exclusively as cleaved fragments which were detergent-
insoluble.17 Full length misfolded N-CoR (also detergent insoluble) was
conspicuously absent.  In contrast, only full length misfolded N-CoR was
detected in human embryonic kidney cells 293T co-transfected with PML-
RARα and Flag-N-CoR expression plasmids. Thus, in cells that maintained a
permissive environment for PML-RARa (namely APL cells), misfolded N-CoR
was largely fragmented whereas in cells that lacked this environment
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(transfected 293T cells), intact misfolded N-CoR predominated. In non-APL
cells that lack PML-RARa, N-CoR was detected exclusively in its full length
non-misfolded (detergent soluble) state.17
A common pathological event in many neurodegenerative diseases
(Alzheimer’s, Parkinson’s, Huntington‘s diseases) is the accumulation of
highly ubiquitinated misfolded proteins that are toxic to cells.  Consequently,
the cytotoxic unfolded protein response (UPR) is activated to eliminate cells
harbouring the misfolded proteins by apoptosis. Khan and co-workers
reasoned that APL cells averted a similar fate by promoting the cleavage of
misfolded N-CoR, which presumably arrested the UPR at its early
cytoprotective phase (cell survival) and prevented its progression to the late
cytotoxic phase (cell death) (Figure 1-1).  The cytoprotective UPR is a
constitutive response to mounting endoplasmic reticulum (ER) stress arising
from imbalances in misfolded protein load and the capacity of the ER to
handle the load. The cytoprotective defenses involve activating signaling
molecules to transiently arrest protein translation, promote chaperone-
mediated refolding of misfolded proteins and endoplasmic reticulum
associated degradation (ERAD) in which proteins that could not be refolded
are ubiquinated and degraded by the proteasome.  APL cells have an added
cytoprotective UPR backup in the form of aberrant proteases such as O-
sialoglycoprotein endopeptidase (OSGEP) to degrade misfolded proteins.  The
contribution of OSGEP was validated in experiments where its inhibition or
knockdown  resulted in the accumulation of misfolded N-CoR and cell
death.17, 19 Furthermore, it was proposed that the N-CoR fragments
generated by cleavage would self-aggregate and be a source of growth-
promoting stimuli.17 The overarching model supports a key role for N-CoR
and its conformational state in the pathogenesis of APL. Specifically,
neutralizing the cytotoxic effects of misfolded N-CoR is crucial to maintaining
the permissive cellular environment for PML-RARα in APL cells, hence
ensuring their survivability. The corollary is that rescuing the native
conformation (and function) of N-CoR or aggravating the accumulation of
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misfolded N-CoR would compromise viability of APL cells and thus constitute








































Figure 1-1. Role of N-CoR in the regulation of endoplasmic reticulumstress and unfolded protein response in acute promyelocytic leukemia.
1.2.3. Therapeutic Modulation of N-CoR misfolding
All-trans-retinoic acid (ATRA) (Figure 1-2) is currently the treatment of choice
for APL. Acquired resistance and troubling side effects (leukocytosis, “retinoic
acid syndrome”) are the main drawbacks to its use.20 The mode of action of
ATRA  centers on its ability to induce a conformational change in PML-RARα ,
leading to the release of  N-CoR,  derepression of the RA target genes and
continued differentiation of  promyelocytic cells.21 Interestingly, the
cytoprotective UPR was attenuated in APL cells treated with ATRA.8Khan et
al proposed that this may reflect ATRA-induced refolding of the released N-
CoR protein, leading to a lower load of misfolded protein, and hence less ER
stress.16
Another agent that is reputed to restore N-CoR to its native conformation is
genistein, a natural product obtained from soy protein.18 (Figure 1-2)
Genistein arrested the growth of APL cells by multiple growth inhibitory
mechanisms (cell cycle arrest, apoptosis, differentiation) that were unlikely to
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be dependent on N-CoR function.  However, genistein also targeted the
misfolding of N-CoR in ways that could arrest APL cell survivability. Genistein
inhibited the binding of N-CoR to PML-RARα and abrogated serine/threonine
phosphorylation of PML-RARα. It also promoted the degradation of PML-
RARα and inhibited the cleavage of N-CoR by downregulating OSGEP
expression.  These findings led the authors to propose that inhibition of
serine/threonine phosphorylation by genistein caused a conformational
change in PML-RARα that disrupted the physical association of N-CoR and
PML-RARα. This would destabilize the fusion protein and cause N-CoR to
refold to its native conformation. Like ATRA, genistein intercepts the
association between N-CoR and PML-RARα through conformational effects
and in this way circumvents the transcriptional outcomes (repression of RA
target genes, derepression of self renewal genes) that are central to APL
pathogenesis. It is however, less potent than ATRA in vitro and has not been
clinically endorsed for APL.
Besides restoring the native conformation of N-CoR, another means of
modulating N-CoR misfolding is to paradoxically aggravate misfolding to the
point that the cytoprotective UPR is overwhelmed and switches to the
cytotoxic UPR. This is true of aminoethylbenzenesulfonyl fluoride (AEBSF), a
broad spectrum protease inhibitor, that blocked the cleavage of N-CoR in APL
cells.17 (Figure 1-2) AEBSF also inhibited ER stress-induced cleavage of
activating transcription factor-6 (ATF6) in Hela cells, resulting in inhibition of
transcription induction of the ATF6 target gene, glucose regulating protein-78
(GRP78).22 ATF6 is an important marker of UPR activation and GRP78 is a
chaperone protein involved in the refolding of misfolded proteins. In view of
these findings, it was proposed that AEBSF-treated cells would have high
levels of ER stress that would ultimately lead to apoptosis.17
Curcumin (Figure 1-2), a hydrophobic polyphenol and active substance of
turmeric (Curcuma longa), is known to rescue the native conformations of
several misfolded proteins. 23-25 When screened for growth inhibitory effects
on APL cells, it was found to stabilize the N-CoR protein by inhibiting its
degradation rather than by preventing its misfolding (like genistein).19
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Curcumin behaved like AEBSF in many respects:  it inhibited proteases
responsible for cleavage of N-CoR and intercepted degradation of misfolded
N-CoR by the proteasome. Consequently, curcumin increased ER stress levels
in APL cells and triggered the cytotoxic UPR response which led to cell death.
The cytotoxic UPR is initiated by the activation of c-Jun N-terminal kinase
(JNK) by apoptosis signal regulating kinase-1 (ASK1) and upregulation of
C/EBP homologous protein (CHOP) by protein kinase RNA-like endoplasmic
reticulum kinase (PERK). Each of these steps was intercepted by curcumin.19
The final stage of UPR-induced apoptosis involves activation and processing
of caspases 3 and 9. These were duly affected by curcumin.19 Thus the results
strongly supported the notion that curcumin affected survivability of APL cells
by promoting buildup of misfolded proteins, activation of the cytotoxic UPR
and apoptotic cell death.
Of the agents mentioned in this section, only ATRA is clinically endorsed for
the treatment of APL.  Arsenic trioxide (ATO) is also used in the clinics, either
in combination with ATRA or in patients with relapses. Interestingly, ATO is
effective only against APL but not other subtypes of leukemia. Wang and
coworkers reported that ATO induced the degradation of PML-RARα fusion
protein and wild-type PML, but not RARα in APL cells, thus suggesting that
ATO may target the PML moiety for degradation.26 In spite of its clinical
efficacy, ATO may cause potentially fatal side effects such as leukocyte
activation syndrome and arrhythmia.27
The efficacies of AEBSF, genistein and curcumin in APL have only been
demonstrated in vitro. Nonethess, they give valuable insight on the potential
of N-CoR as a drug target, and in particular, how manipulation of N-CoR
conformation (folded vesus misfolded) may provide a means of intercepting
the course of the disease.
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Figure 1-2:  Chemical Structures of ABSEF, genistein, curcumin and all-trans-retinoic acid (ATRA)
1.3. Endoplasmic reticulum (ER) stress and the Unfolded
Protein Response (UPR)
In the preceding section, reference was made to the unfolded protein
response (UPR) in relation to N-CoR and the pathogenesis of APL. In Chapter
5, the effects of selected target compounds on the UPR were investigated.
The key features of this important phenomenon are presented in the
following paragraphs.
1.3.1 ER stress mechanism
The endoplasmic reticulum (ER) is the central cellular site for the synthesis,
folding and post- translational modification of proteins. In order to perform
these functions, the ER must maintain a tightly regulated oxidizing and Ca2+-
rich environment. This carefully balanced environment is highly sensitive to
changes in cellular energy levels, the redox state or Ca2+ content. When these
occur, the folding capacity of the ER is compromised, resulting in the
accumulation and aggregation of unfolded proteins. The resulting condition is
described as ER stress and the ER responds to this state by activating the
unfolded protein response (UPR), an evolutionary conserved quality control
mechanism aimed at restoring ER homeostasis. The UPR is essentially a pro-
survival response aimed at reducing the amount of misfolded protein and
34
restoring ER homeostasis (“cytoprotective UPR”). However, if ER stress is not
rectified by these measures, UPR signaling switches from pro-survival to pro-
apoptotic (“cytotoxic UPR”) in an attempt to remove cells harboring the
misfolded proteins (Figure 1-1).
The cytoprotective UPR involves a cascade of signaling molecules that are
transiently activated to arrest protein translation, induce ER molecular
chaperones and enzymes that enhance protein folding capacity, and initiate a
process to export and degrade the misfolded ER proteins.28, 29 There are three
canonical branches in the UPR signaling pathway and these are mediated by
three transmembrane ER stress sensors: PERK (pancreatic ER kinase), IRE1
(inositol requiring enzyme 1) and ATF6 (activating transcription factor 6).30 In
non-stress conditions, these proteins are sequestered by an ER chaperone
glucose regulated protein 78 / immunoglobulin heavy chain binding protein
(GRP78) and maintained in an inactive state. GRP78 is one of the most highly
expressed ER chaperones. It is a master regulator of the UPR through its
direct interactions with all three ER sensors.  In the presence of ER stress,
GRP78 is titrated away from these sensors by the misfolded proteins. The
liberated sensors are then activated in a sequential manner, starting with
PERK, rapidly followed by ATF6 and then IRE1. The roles of these ER stress
sensors are described in the Section 1.3.2.
Besides GRP78, other abundant and well characterized ER chaperone
proteins include protein disulfide isomerase (PDI, a foldase) and the lectins
calnexin and calreticulin.30 The ER chaperone proteins are primarily
responsible for the folding, assembly and transport of membrane and
secretory proteins. As mentioned earlier, the chaperone proteins are
released from binding to the ER stress sensors in the face of mounting ER
stress. GRP78 binds to misfolded proteins in the ER and initiates their
refolding in an energy dependent process. The N-terminal of GRP78 functions
as an ATPase that promotes ATP hydrolysis which, in turn induces a
conformational change in the C-terminal region, increasing its binding affinity
to the hydrophobic regions of proteins. The foldase PDI is primarily
responsible for the export of misfolded or unfolded proteins from the ER to
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the cytosol.31 It also catalyzes the formation and breakage of disulfide bonds
during protein folding. Calnexin and calreticulin are ER proteins that
recognize monoglucosylated N-linked glycan groups on partially folded
proteins. Like PDI, they catalyze the formation of disulfide bonds. Misfolded
proteins exported to the cytosol are processed by cytosolic chaperones such
as heat shock protein 60 (HSP60) which when activated, break down the
aggregated misfolded proteins. It was found that the loss of HSP60 in cells
resulted in a pronounced increase in aggregated proteins in the
mitochondrial.32 In addition to disaggregating misfolded proteins, HSP60 is








































1.3.2. Activation of UPR-induced apoptosis
The ER stress sensors PERK, ATF6 and IRE1 play an important role in UPR
signaling (Figure 1-3). Each sensor has a dual role in propagating adaptive or
toxic signals that will result in the cytoprotective or cytotoxic UPR
respectively.
The activation of the serine/threonine kinase PERK is an early event in the
UPR. PERK mediates phosphorylation of eIF2α (eukaryotic initiation factor 2)
leading to inhibition of cap-dependent protein translation which provides
cells with a temporary “rest point” by suppressing protein synthesis.
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Phosphorylation of eIF2α also increases translation of ATF4 which is
responsible for the transcription of UPR target genes that promote ER folding
capacity and adaption to stress.33, 34 But not all genes induced by ATF4 are
pro-survival. A notable exception is the pro-apoptotic transcription factor
CHOP whose induction strongly depends on ATF4. The PERK-eIF2α-ATF4
pathway is canonically regarded as the translational controlling arm of the
UPR. While it is initially protective, it has the potential to switch from pro-
survival to pro-death signaling.
The activation of PERK is followed closely by the activation of ATF6. Upon its
release from GRP78, ATF6 translocates to the Golgi apparatus where it is
cleaved into its active nuclear form by proteases. Active ATF6 induces genes
that have an ER stress response element in their promoters. Some of the
identified targets of ATF6 are the ER chaperone proteins (GFP78, PDI), CHOP
and X-box binding protein 1 (XBP1) which is important in IRE1 signaling.
Although ATF6 induces CHOP expression, it is generally viewed as a pro-
survival signaling arm of the UPR.35i
IRE1 is thought to be the last arm of the UPR to be activated. IRE1 has both
pro- and anti-apoptotic functions. When activated, it initially aids the UPR by
splicing XBP1 which was previously induced by ATF6. The splice variant of
XBP1 (sXBP1) is a more stable and potent transcription factor of target genes
involved in protein folding and ERAD. An important target gene of sXBP1 is
the HSP40 family member P58.36 P58 inhibits PERK and thus provides a
negative feedback loop that relieves PERK-mediated translational block. The
upregulation of P58 occurs several hours after PERK and ATF6 activation. If
the PERK and ATF6 signaling have succeeded in curtailing ER stress by then,
the UPR will be terminated but if ER stress persists, relieving the translation
block by P58 will result in the synthesis of pro-apoptotic proteins.
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Figure 1-3. Unfolded protein response between non-stressed and stressedconditions. Left panel: Under non-stressed conditions, GRP78 is bound to
IRE1α, PERK and ATF6 and is inactive. Right panel: When cells experience ER
stress, GRP78 is titrated away in order to bind to misfolded proteins, resulting
in activation of IRE1α, ATF6 and PERK signaling pathway, ultimately leading to
apoptosis.
Signaling through PERK, ATF6 and IRE1 trigger pro-apoptotic signals during
prolonged ER stress but do not directly cause cell death. Rather they initiate
the activation of downstream molecules that will ultimately commit cells to
ER stress induced apoptosis. The important downstream molecules involved
in this commitment phase are CHOP and JNK.
CHOP is a shared target gene of all three arms of the UPR (Figure 1-3).  It has
been proposed that GADD34 (growth arrest and DNA damage-inducible 34)
contributes to the pro-apoptotic effects of CHOP.37 CHOP induces the
expression of GADD34. GADD34 recruits PP1 (protein phosphatase 1) and
causes it to dephosphorylate eIF2α, thus re-initiating protein synthesis and in
effect, switching off the PERK mediated pathway.38 If ER homeostasis is not
restored, the resumption of protein synthesis will further amplify ER stress
with predictable consequences.
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JNK (c-Jun N-terminal kinase) is a master regulator of apoptotic and
autophagic pathways in response to ER stress. Under severe ER stress,
activated IRE1 forms the IRE1-TRAF2 (TNF-receptor associated factor 2)
complex which recruits ASK1 (apoptosis signal regulating kinase 1).
Importantly, ASK1 phosphorylates and activates JNK (c-Jun N-terminal kinase.
Both CHOP and JNK eliminate the anti-apoptotic effects of BCL2. CHOP blocks
the expression of BCL2 whereas JNK phosphorylates BCL2. JNK also
phosphorylates Bim which enhances its pro-apoptotic potential. Collectively,
these changes result in the activation of the pro-apoptotic Bax and Bak,
transmission of the signal from the ER to the mitochondria and the final
execution phase of ER stress-induced apoptosis.39
The upstream signals described in the preceding paragraph ultimately lead to
caspase activation which executes the final phase of ER stress induced
apoptosis. In the presence of cell death signals, the apoptosome is formed
from the association of cytochrome c and Apaf-1. The apoptosome interacts
with caspase-9 which subsequently activates the executioner caspase-3
leading to apoptosis.40 While this cascade is proposed to be the primary
apoptotic cascade, other caspases such as caspase-4 and caspase-8 have
been implicated in the initiation of ER-mediated apoptosis.41
The uncontrolled growth and proliferation of cancer cells require increased
levels of protein synthesis which can only be sustained if the ER capacity and
function are optimal. As UPR signaling plays an important role in controlling
ER stress levels, targeting the UPR represents an attractive strategy in cancer
therapy. Disrupting PERK or IRE1 signalling are possible options. The PERK-
eIF2a-ATF4 axis is responsible for adapting tumors to hypoxic stress. PERK-
deficient murine embryonic fibroblasts (MEF) were found to display reduced
angiogenesis and were sensitized to apoptosis42 whereas IRE1-deficient MEFs
inhibited the upregulation of vascular endothelial growth factor A (VEGF-A)
during hypoxia , resulting in reduced angiogenesis and growth inhibition.43 An
important caveat to this approach is the existence of functional redundancy
and overlap between the three arms of the UPR pathway. It is possible that
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when one arm is blocked, the remaining arms is activated or upregulated to
compensate for the loss and this may have unexpected outcomes.
In a true tumor environment, the UPR pathway is already activated to cope
with ER stress. What if ER stress is aggravated to the point that all three arms
of the UPR pathway are activated? The current thinking is that this would tilt
the balance in favor of ER stress induced apoptosis. Indeed, proteasomal
inhibitors which block the 26S proteasome increase protein load on the
already burdened ER and induce apoptosis via the UPR pathway. The
proteasome inhibitor bortezomib when used in  combination with cisplatin
sensitized pancreatic cancer cells to UPR-induced apoptosis.44 Another
proteasome inhibitor MG132  upregulated the ER stress marker GRP78 and
activated CHOP (PERK axis), JNK and Bak (IRE1 axis).45 Other options are to
block protein transport from ER to Golgi, inhibit important molecular
chaperones such as Hsp90 or the ER stress marker GRP78. Brefeldin A (BFA),
a small molecule lactone produced by fungi organism Eupenicillium
bredelfianum, provided proof of concept that intercepting the transport of
proteins from the ER to the Golgi led to the activation of the pro-apoptotic
UPR 46
1.4. The Proteasome
Proteasome inhibitors like ABSEF and curcumin were identified as agents that
triggered UPR-induced apoptosis by increasing the cellular load of misfolded
proteins (Section 1.3).   In view of the relevance of this mechanism to the
target compounds reported in the present thesis, an overview of the
proteasome and its role in cancer chemotherapy is provided in this section.
Protein degradation occurs through complex signaling pathways that control
the segregation of misfolded proteins from folded proteins and identifying
misfolded members for transport to the protein degradation machinery. To
date, two protein degradation machineries are known, the lysosome and the
proteasome. Lysosomes are cytoplasmic membrane-bound vesicles that are
responsible for degradation of extracellular and transmembrane proteins
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while proteasomes are located in the cytoplasm of the cells and are
responsible for degradation of intracellular proteins.47
The proteasome, a 2.4 MDa protease complex, is ubiquitous in mammalian
cells. It plays a critical role in controlling cellular protein  levels, especially in
malignant cells which have  high protein turnover and hence rely heavily  on
the proteasome to remove toxic, defective proteins.48 Consequently,  cancer
cells are more dependent on the proteasome for their survival as compared
to non-malignant cells.48, 49 Up to 80% of cellular proteasomal activity have
been inhibited in peripheral blood mononuclear cells50,  preclinical models51
and  Phase I clinical trials52, 53 without undue toxicity , thus allaying fears that
targeting the proteasome would be poorly tolerated.  Besides its role in
processing proteins in the ER30, the proteasome has several other regulatory
functions in malignant cells, such as regulating proteins (cyclins, murine
double minute 2 Mdm2) involved in cell cycle progression 54, growth and
proliferation, pro-apoptotic and anti-apoptotic signaling (Bcl-255, 56, p5354),
caspases and nuclear factor of kappa B (NF-ĸB)57, 58.
1.4.1. Structure and function of the proteasome
The 26S proteasome is a proteolytic complex consisting of a 20S cylindrical
core capped at both ends by 19S regulatory complexes. The 700 kDa 20S core
contain four heptameric rings stacked together in a cylindrical structure
where the top and bottom rings are formed by 7 α-subunits and the two
inner rings comprise 7 β-subunits. The catalytic sites which are located in the
β-subunits facing the inner regions of the cylinder, are caspase-like (β1,
cleaves after acidic residues), trypsin-like (β2, cleaves after basic residues)
and chymotrypsin-like (β5, cleaves after hydrophobic residues). The complex
exposes an N-terminal threonine residue from each of these catalytic sites
which functions as a catalytic nucleophile. The 19S complex comprises
approximately 20 different subunits, six of which have ATPase activity. One of
the non-ATPase subunits is responsible for the recognition and binding of
multi-ubiquitin chains.59 The 76 amino acid polypeptide, ubiquitin, is used to
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target a protein for degradation by the 26S proteasome. Ubiquitin is
covalently bonded to misfolded proteins at a lysine residue. Tagging ubiquitin
chains to proteins requires the sequential contribution of three enzymes, E1,
E2 and E3 (Figure 1-4). E1 oversees the ubiquitin-activating step where the
enzyme first binds to ubiquitin in an ATP-dependent process. The
ubiquitinated enzyme is then transferred to E2. E3 ligases recognise and bind
the misfolded protein substrates and with the help of E2, catalyse the
transfer of ubiquitin from E2 to the protein. This process is repeated several
times to yield the polyubiquitinated misfolded protein which is then
recognised by the proteasome for degradation.60 A second proteasome
regulatory complex (11S) is reported to  activate the peptidase activities of
the 20S proteasome, but the mechanism of activation is not  well
understood.59
Figure 1-4: Illustration of enzyme cascade involved in ubiquitin-proteasome system
1.4.2. Current FDA approved proteasome inhibitors
Regulatory approval of the proteasomal inhibitors bortezomib (Velcade)
and carfilzomib (Kryprolis) as therapeutics for multiple myeloma
underscore the validity of the proteasome as a drug target.  Preclinical
studies with bortezomib have shown that proteasome inhibition led to
pleiotropic effects on multiple signaling pathways such as inhibition of the
prosurvival NF-ĸB signaling. Structurally, bortezomib is a pyrazinoic acid
dipeptide containing an electrophilic boronic acid warhead. In silico studies of
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bortezomib with proteasome showed that bortezomib binds to the catalytic
threonine residue in the active site via the electrophilic boron. Bortezomib is
a covalent, slow-reversible inhibitor of the proteasome. In vitro studies show
that bortezomib inhibits proteasome potently at nanomolar potencies with
IC50 values ranging from 2.4 – 7.9 nM (chymotrypsin-like), 590 – 4200 nM
(caspase-like) and 24 – 74 nM (trypsin-like).61, 62 The main limitations of
bortezomib are the  need for intravenous administration, acquired
resistance63 and    peripheral neuropathy. 64 Structurally, carfilzomib is an
epoxyketone tripeptide analog of the natural product epoxomicin (Figure 1-5)
and contain a terminal epoxide group that functions as the electrophilic
centre for irreversible covalent binding with catalytic threonine in the
proteasome active site. Like bortezomib, carfilzomib preferentially inhibits
chymotrypsin-like activity (IC50 6 nM) as compared to caspase-like (IC50 3600
nM) and trypsin-like (IC50 2400 nM) activities.61 It  was found to activate c-
Jun-N-terminal kinase, facilitated the release of cytochrome c and activated
caspase-dependent apoptosis.65 Unlike bortezomib which inhibited the
proteasome reversibly but could not be dosed frequently because of side
effects, carfilzomib inhibited the proteasome irreversibly and when dosed
daily, induced sustained inhibition of the proteasome (up to 80%)  for 5
consecutive days.66 Side effects are milder and the incidence of peripheral
neuropathy was low.67 Taken together, carfilzomin is more  drug-like than
bortezomib, has substantially fewer off-target effects and is active on
bortezomib-resistant multiple myeloma cells.65
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Figure 1-5: Current FDA approved proteasome inhibitors Bortezomib andCarfilzomib (derived from Epoxomicin)
1.5. Curcumin
Several excellent reviews of curcumin and its analogs have been published
and they provide a comprehensive overview of structure, reactivity,
physicochemical properties and biological activities.68-70 As the thesis is based
on analogs derived from curcumin, this section will focus on structural and
pharmacological aspects of curcumin that are relevant to the present
investigation.
1.5.1. Overview of structure, stability and bioavailability of curcumin
Curcumin, a hydrophobic polyphenol, is the active ingredient of turmeric
(Curcuma longa), a rhizome belonging to the ginger family.  Tumeric has been
an integral ingredient of Ayurvedic medicine since ancient times and it
continues to be widely used today, either as the whole spice or the isolated
ingredient curcumin, for a spectrum of diseases and common ailments such
as stomach upset, arthritis, infections and sprains. Curcumin is available as an
over-the-counter supplement in many countries.
Structurally, curcumin is a diarylheptadienedione (Figure 1-6). A readily
recognized feature of curcumin is keto-enol tautomerism in the central linker.
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Tautomeric preference is determined by the type of solvent and pH.  In non-
polar solvents, almost 90% of curcumin exists as the enol tautomer due to
stabilization by intramolecular hydrogen (H) bonding between the enolic OH
and the keto carbonyl oxygen. In polar solvents, the keto tautomer
predominates. In acidic and neutral aqueous solutions (pH 3-7), curcumin
exists as the keto tautomer while in alkaline solutions (pH > 8), it is present as
the enol tautomer.71 pH affects the stability and free radical scavenging
properties of curcumin. Curcumin is stable in acidic to neutral solutions but
not in alkaline solutions (pH> 8), presumably due to the ionization of the
phenolic groups in alkali (pKa values of phenolic groups  9-10).72 Others
have proposed that alkaline instability stemmed from a nucleophilic attack by
hydroxide ions on the carbonyl carbon of the enol tautomer.73 The
unsaturated state of the central linker also contributes to instability since
tetrahydrocurcumin is significantly more stable than curcumin at
physiological pH.74
The radical scavenging property of curcumin is reportedly greater in acidic
solutions due to the loss (transfer) of a proton from the labile methylene
group flanked by the keto groups in the central linker. In alkaline solutions,
the enol tautomer predominates which makes proton transfer from the
methylene group less likely. An alternative proposal states that radical
scavenging occurs via electron loss from the ionized phenolic groups.71 A
recent report has disputed the role of the methylene group in proton transfer
and had instead attributed it primarily to proton loss from the phenolic
hydroxyl groups present in curcumin and its analogs.75
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Figure 1-6: Keto-enol tautomers of curcumin
Another recognizable feature in curcumin are the two Michael acceptor
motifs (α,β-unsaturated dienone) embedded in the central linker (Figure 1-7).
Michael acceptors add nucleophiles to the electrophilic β-position of the
unsaturated system. Physiological nucleophiles contain Lewis basic sulfur,
oxygen and nitrogen atoms, of which the sulfhydryl group of cysteines in
proteins is best known.
Figure 1-7: Michael acceptor motifs in curcumin
The Michael acceptor reactivity of curcumin has been implicated in several of
its pharmacological properties. Inhibition of the p300 family of histone
acetyltransferases by curcumin was attributed to a covalent association
mediated by the Michael addition reactivity of curcumin.76 The sterically
accessible electrophilic β-carbons of curcumin was identified as a key
molecular feature associated with the inhibition of ubiquitin isopeptidases, a
family of cysteine proteases that hydrolyze the isopeptide bond between the
C-terminal carboxylate of ubiquitin and the ε amino of a lysine residue on an
adjacent protein. The hydrolytic activity of ubiquitin isopeptidases dissemble
ubiquintin oligomers, increase the pool of free ubiquitin for reuse by the 26S
proteasome and modulate substrate activity by altering their ubiquitination
status. Inhibition of isopeptidases occur when the active site cysteine
residues of the enzyme react with sterically accessible Michael acceptor
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functionalities, resulting in unfettered polyubiquitin chain growth and a
diminished pool of monoubiquitin. The accumulation of misfolded proteins
that are not ubiquinated as well as polyubiquinated proteins that are not
deubiquinated would invariably trigger the UPR. Alteration of monoubiquitin-
polyubiquitin dynamics also affects transcription factors like p53.77
Interestingly, curcumin analogs with sterically accessible electrophilic β-
carbon atoms were reportedly inhibitors of ubiquitin isopeptidases (Figure 1-
8)
Figure 1-8: Curcumin analogs reported to inhibit ubiquitin isopeptidaseactivity77, 78
The terminal phenyl rings of curcumin are symmetrically substituted with 3-
methoxy-4-hydroxy groups. The phenolic hydroxyl groups have been
implicated in radical scavenging activity, either through electron donation or
proton loss. It is also the site of extensive phase 2 gluronidation and sulfation
which accounts for the metabolic susceptibility of curcumin. Phase 1
metabolism is mediated by hepatic reductases and result in the formation of
dihydro, tetrahydro and hexahydro metabolites.  The metabolic susceptibility
of curcumin is one reason for its poor bioavailability. Bioavailability (F) is
defined as the fraction of the administered dose that reaches systemic
circulation as intact or unchanged drug. A drug that is administered
intravenously has optimal bioavailability (F = 1) while drugs given orally will
have F < 1. Oral bioavailability is determined by 3 factors – the fraction
absorbed after oral administration which is primarily influenced by the
solubility and permeability characteristics of the drug, the fraction that
escapes intestinal metabolism and the fraction that escapes hepatic
metabolism. The metabolic susceptibility of curcumin would adversely affect
the last two factors. The poor solubility of curcumin would compromise the
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fraction absorbed since dissolution in the unstirred water layer in the gut is a
prerequisite for permeation across the cellular barrier. It has been reported
that oral ingestion of gram quantities of curcumin resulted in significant
amounts of curcumin in the plasma.69 Although curcumin is well tolerated at
these mega doses, the long term effects of such dosing could be a matter of
concern.
1.5.2. Biological activities of curcumin
Curcumin is widely recognized as a multi-targeting agent with a wide
spectrum of pharmacological activities.  Its pleiotropic profile owes more to
the fact that curcumin intercepts critical signaling pathways that have far-
reaching pharmacological outcomes. In a recent review, three pathways were
identified as central to the biological activity of curcumin.69 They are the
induction of Nrf2 signaling which switches on the antioxidant defense
mechanisms and phase 2 enzymes essential for chemoprevention, nuclear
factor kappa B (NF-ĸB) signaling cascade which is inhibited by curcumin and
contributes to its anti-inflammatory properties, and epigenetic regulation of
gene expression which may account in part for its anticancer properties.  Nrf2
is a redox sensitive transcription factor that regulates the gene expression of
antioxidant and Phase 2 enzymes. Under basal conditions, Nrf2 is bound to its
inhibitor Keap1 in the cytosol.  Activation of Nrf2 results in its translocation to
the nucleus where it binds as a heterodimer to the antioxidant response
element (ARE) in DNA to initiate gene expression. Curcumin induces Nrf2
translocation by reacting with the cysteine SH residues of Keap1 by Michael
addition, thereby releasing Nrf2 for nuclear translocation.
The NF-ĸB proteins are a family of DNA binding proteins that are commonly
upregulated in cancer and inflammatory diseases. NF-ĸB signaling is activated
by about 200 different stimuli (viruses, cytokines, stress, infection). These
lead to the activation of IĸB kinase (IKK) which proceeds to phosphorylate its
main substrate inhibitor of kappa-B α (IĸBα). In its unphosphorylated state,
IĸBα binds to NF-ĸB subunits, thus masking their DNA binding ability and
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transcriptional competence. When phosphorylated, IĸBα is diverted to the
proteasome for degradation and the liberated NF-ĸB subunits translocate to
the nucleus where it upregulates genes involve in cell proliferation, invasion
and apoptosis.  Curcumin inhibits NF-ĸB signaling at several nodal points,
namely inhibition of IKK and the proteasomal degradation of phosphorylated
IĸBα.  The inhibition of NF-ĸB signaling by curcumin contributes to its anti-
inflammatory and anti cancer properties.
Curcumin is a putative epigenetic regulator. It modulates DNA methylation
(through DNA methyltransferase), histone modification (through histone
deacetylases and histone acetyltransferases) and microRNAs.  Its modulatory
effects have significant consequences as it leads to the activation or
suppression of genes involved in inflammation and carcinogenesis.
Mention was made earlier of the ability of curcumin to sensitize APL cells to
UPR-induced apoptosis, essentially by inhibiting the proteasome (and very
likely, ubiquitin isopeptidase) and increasing the misfolded protein load in
cells.  Proteasomal inhibition also plays a decisive role in the NF-ĸB inhibitory
activity of curcumin as it restricts the degradation of phosphorylated IkBα
which in turn hinders nuclear translocation of the NF-ĸB subunits.
The pharmacological activity of curcumin is usually manifested at micromolar
concentrations. Curcumin inhibited ubiquitin isopeptidase activity of colon
cancer cells with an IC50 of approximately 50 µM.77 It induced Nrf2 activity of
murine fibroblast cells at 20 µM69 and inhibited proteasomal activity of APL
cells at 10 µM.19 The anti-proliferative effects of curcumin on cancer cell
panels are usually observed at 10-20 µM.  The modest pharmacodynamic
effects of curcumin on a range of druggable biological targets is one reason
for the on-going search of a “super curcumin” – an analog that would address
the shortcomings of curcumin (mediocre potency, poor bioavailability,
hydrolytic instability) while retaining its attractive safety profile and multi-
targeting potential.
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1.5.3. Structural modification of curcumin
Extensive structural modifications of curcumin have been reported. In a
comprehensive review, Anand et al68 classified these changes in three classes
– curcumin derivatives, metal complexes of curcumin and curcumin analogs.
Curcumin derivatives comprise a small class of compounds that retain the
core diphenylheptadienedione scaffold of curcumin but have substituents
derived from acylation or glycosidation of the existing phenolic OH groups.
Manganese, copper, vanadium, gallium and indium complexes of curcumin
have been prepared. The metal is chelated by the diketo groups and claims
have been made of improved biological activity.69
Curcumin analogs constitute by far the largest and most diverse category,
comprising compounds with “some perceived or claimed structural analogy
to curcumin.”68 The main categories are (I) analogs derived from partial or
complete reduction of double bonds in the central linker, (II) analogs with
symmetrically or asymmetrically substituted terminal phenyl or
heteroaromatic rings, (III) conformationally restricted analogs, (IV) analogs in
which the 1,3-diketone functionality is masked and rigidified, (V) analogs
derived from acetylacetones  and  (VI) C3, C5 or longer bridged analogs.
Examples are given in Figure 1-10.
Figure 1-9: Examples of curcumin analogs.
(I) Analogs derived from partial reduction of double bonds, (II) Analogs with
asymmetrically substituted terminal rings, (III) Conformationally restricted
analogs, (IV) Analogs in which the 1,3-diketone functionality is modified to a
pyrazole, (V) Analogs derived from acetylacetones  and  (VI) C5 and C7
bridged analogs.
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The C5 bridged analogs, also described as monocarbonyl cross-conjugated
dienone analogs of curcumin, are arguably the most widely investigated
curcumin analogs.  As shown in Figure 1-10, the monocarbonyl group may be
left as such or embedded in a carbocyclic or heterocyclic ring. Several of
these analogs demonstrated potent growth inhibitory activities on cancer
cells. 73, 79, 80
Figure 1-10: Monocarbonyl cross-conjugated dienone analogs ofcurcumin
One of best known C5 bridged analogs is EF24 (3E,5E-3,5-bis(2-
fluorobenzylidene)piperidin-4-one) which has shown exceptional anticancer
potency81, 82 and improved pharmacokinetics in mice.70 (Figure 1-11). Like
curcumin, EF24 inhibited NF-ĸB signaling83 and was reportedly a more potent
Michael acceptor than curcumin based on its strong reactivity with
glutathione and thioredoxin-1.84, 85 EF31 which is a closely related analog of
EF24, was reported to inhibit (> 40% at 5 µM) nearly half of 50 kinases that
were relevant to many forms of cancer.86 It had a marked preference for
serine/threonine kinases and the authors proposed that reversible Michael
acceptor reactivity for cysteine residues in kinases may again form the basis
of its widespread inhibitory activity.
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Figure 1-11: Selected examples of C5-Bridged analogs bearingpiperidinone ring
Another reason for the keen interest in C5 bridged analogs is their enhanced
stability to hydrolysis and enzymatic degradation. Liang and coworkers
compared the hydrolytic stabilities of analogs in which the monocarbonyl
dienone moiety existed as such (“acetones”) or were embedded in a five
membered (“cyclopentanones”) or six-membered (“cyclohexanones”) ring.73
The analogs were found to be more stable than curcumin, with the
cyclopentanones generally more stable than acetones and cyclohexanones.
Their hypothesis was that hydrolytic degradation of curcumin was initiated by
a nucleophilic attack by a hydroxide anion at the carbonyl carbon of the keto-
enol moiety.  In the absence of this moiety, hydrolytic stability should be
enhanced. Unfortunately, cyclopentanones are reputedly associated with
poorer biological activities compared to acetones and cyclohexanones.73, 87
Thus, the structural  “sweet spot” combining optimal activity and stability
remains elusive.   Replacing the β-diketone moiety will also reduce hydrolytic
susceptibility to hydrolases because this moiety is a specific substrate of
several hydrolases such as fumarylacetoacetate hydrolase, cyclohexane-1,3-
dione hydrolase, diketone-cleaving enzyme (Dke1) and 6-oxocamphor
hydrolase.88, 89
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Following the report on the proteasomal inhibitory activity of curcumin,90
there was considerable interest on curcumin analogs as proteasomal
inhibitors. AM114  [3,5-bis(4-boronic acid benzylidene)-1-methylpiperidin-4-
one] was one such analog and its activity was further improved by replacing
the boronic acid substitutents with dichloro substituent and tagging an
aromatic amino acid (phenylalanine) at the piperidinone N.91 (Figure 1-10)
The resulting compound inhibited proteasomal function in vitro and in living
cells, was cell permeable and inhibited all three proteolytic subunits in
purified proteasomes (IC50  5 µM). In silico docking studies suggested that
the α,β-unsaturated carbonyl system may the site of nucleophilic attack by
the N-terminal threonine residue in the catalytic sites of the proteasome.
Notwithstanding the importance of the latter, the choice of N-substituted
amino acid was equally important, as seen from the loss of proteasomal
inhibition in analogs bearing tyrosine or leucine at the piperidinone N.
1.6. Statement of Purpose
Curcumin is a remarkable molecule that is widely recognized for its
impressive safety profile, capacity to interact with diverse biochemical
pathways and its pleiotropic effects on multiple oncogenic genes and
signaling molecules.80, 81, 87, 92 For these reasons, curcumin is widely
employed as a starting lead for structural modification with the aim of
improving on the mediocre potency, poor pharmacokinetic profile and
hydrolytic instability which characterizes the compound. .68, 90, 93, 94 There is
certainly no lack of effort in this regard and the literature is replete with
reports on curcumin analogs and derivatives (curcuminoids) although not
many have complied with the desired endpoints of potency, stability and
drug-like character.
The investigations reported in this thesis were initiated by findings on the
role of the N-CoR in the pathogenesis of acute promyelocytic leukemia8, 16, 17
The prevailing view was that conformation of N-CoR in APL could be
manipulated to have a positive outcome on the course of the disease. Two
agents have been identified – genistein which restored N-CoR to its original
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non-misfolded conformation, and curcumin which promoted the misfolded
conformation by preventing its degradation.18 Of the two, curcumin was
selected for further investigations because the mechanistic basis of its
actions on APL19 - inducing accumulation of misfolded N-CoR by preventing
its degradation and activating ER-stress induced apoptosis – was better
defined and more suited as a screening platform in a medicinal chemistry
project.  As anticipated, curcumin intercepted viability of APL cells and
activated ER-stress induced apoptosis in the micromolar range (10-20 µM).
The working hypothesis of this thesis is that structurally modifying the
curcumin scaffold will not only identify analogs with greater growth inhibitory
activities on APL cells but also retain the mechanistic basis of activity.   UPR-
induced apoptosis is increasing recognized as a novel signaling target for anti-
cancer therapeutics.30, 37, 95 Other aspiring endpoints for these analogs are
greater stability and improved pharmacokinetics.  In keeping with the stated
hypothesis, the objectives of this project are (i) to design structurally novel
curcumin analogs which demonstrate greater growth inhibitory activities and
selectivities for APL cells, (ii) to determine if greater potency and selectivity is
linked to targeting of misfolded N-CoR in APL cells, and (iii) to investigate the
mechanistic basis underlying the growth inhibitory properties of potent
analogs on APL cells.
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Chapter 2: Design and Synthesis of Target Compounds
2.1. Introduction
This chapter describes the syntheses of curcumin analogs that were designed
with the following objectives: (i) To achieve greater growth inhibitory
activities on APL cells than the lead compound curcumin. Curcumin affected
viability of APL cells at an IC50 (concentration required to reduce viability by
50%) of 6-7 µM. The aim here was to obtain analogs with IC50 in the
submicromolar range; (ii) To address the hydrolytic instability (pH 7) and
metabolic susceptibility of curcumin.
In total, 77 analogs were synthesized, of which 23 were structurally novel (27
– 29, 40, 41, 201 – 205, 210, 217 – 220, 221 – 227) based on an exact
structure search of Scifinder Scholar (March 2013). Of the 77 compounds, 13
(7, 8, 11 – 14, 28, 29, 32, 33, 42, 43, 60, 61) were synthesized by an
undergraduate (Mr Koh Siang Boon) and 4 (2 – 4, 10) were obtained from a
previous graduate student (Dr Low Pay Chin). The rest were synthesized by
the author.
An iterative 2-cycle approach was adopted whereby 47 compounds were first
synthesized and evaluated for growth inhibitory activity on APL cells. Analysis
of structure activity relationship (SAR) directed the 2nd round of synthesis
which yielded 30 compounds. Round 1 compounds were identified by two
digits (1 – 47) while round 2 compounds had three digits (201 – 231).
Compound 39 was resynthesized in round 2 and numbered as 212. Promising
compounds from rounds 1 and 2 were carried forward for mechanistic
pathway analysis. Figure 2-1 describes the general workflow of this project.
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Figure 2-1: Workflow diagram of project
2.2. Rationale of compound design
2.2.1 Overview of design rationale
At the start of the project, only curcumin had been evaluated on APL cells.
Hence, there was no precedent or direction as to how it might be structurally
modified to improve potency. On the other hand, the motifs responsible for
the hydrolytic and metabolic susceptibility of curcumin were well established.
Thus, the design approach was to minimize the presence of these motifs in
the synthesized compounds. To this end, the heptadienedione linker of
curcumin was replaced by a monocarbonyl cross conjugated dienone moiety
in the synthesized analogs (Series I-IV) (Figure 2-2).
56
Figure 2-2: Chemical structures of 77 curcumin analogs; symmetrical andasymmetrical. a] Phenyl ring is replaced by pyridine in 24 – 26, 207 – 209.
[b] 3-pyridinyl ring is substituted with methoxy groups at 4- and 5-positions.
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The β-diketone moiety of curcumin is widely held to be responsible for its
hydrolytic and metabolic instabilities. It is the site of hydrolytic cleavage by
nucleophilic hydroxide ions and enzymatic hydrolysis by hydrolases.  Liang et
al showed that hydrolytic stability improved in compounds bearing the
monocarbonyl cross conjugated dienone moieties such as those present in
Series I, II and III.  Adopting this motif was also a means of improving polarity
since the carbonyl ketone would be embedded in polar heterocyclic rings
such as tetrahydrothiopyran (Series IV), tetrahydrothiopyran dioxide (Series
V) and piperidine (Series IV).
The metabolic hotspots in curcumin are the phenolic OH groups (sites of
Phase 2 conjugation reactions) and the double bonds in the central linker
(targeted by reductases). Unfortunately, the ortho methoxy-phenol motif in
curcumin is generally associated with good biological activity. Hence, only
conservative changes were made at the terminal phenyl rings and most of
the Series I-VI compounds retained the same substituents as curcumin.
Notwithstanding, the following substituent changes were made at the
terminal rings:
(i) Introduction of fluorine:  Fluorine, an isostere of hydrogen, has unique
properties such as high electronegativity, small size and exceptionally strong
bonding to carbon. As a result, fluorine is widely utilized in drug design as a
means of hindering phase I metabolic hydroxylation at susceptible sites.
(ii) Introduction of methoxy groups: Replacing the phenolic OH with methoxy
will result in the loss of a H bond donor and an increase in lipophilicity.
Intramolecular H bonding between the methoxy and OH groups in curcumin
would be abolished.
(iii) Replacement of the terminal phenyl rings with pyridine: Pyridine is a
weak base (pKa 5.3) and will not be protonated at pH 7.4. The azomethine
nitrogen will thus function as a H bond acceptor and a decrease in
lipophilicity (about two-fold magnitude compared to phenyl) could be
anticipated with this modification.
Asymmetrical substitution of the terminal rings was also explored as a means
of injecting structural novelty. Substituents associated with good activity in
58
round 1 were selected and incorporated in the asymmetrically substituted
analogs. Figure 2-3 summarizes the design options explored in this chapter. A
more detailed discussion of each series is provided in the following
paragraphs.
Figure 2-3: Summary of modifications made to the structure of curcumin
2.2.2. Series I
Series I comprise functionalized 1,5-diphenylpenta-1,4-diene-3-ones  (1-5) in
which the monocarbonyl functionality was not embedded in a ring system
(“free”). The choice of ring substituents (fluoro, methoxy, hydroxyl) on these
compounds were discussed in Section 2.2.1.  To assess the importance of the
carbonyl group for cell growth inhibitory activity, the carbonyl group was
derivatized to an oxime (27) or an O-methyloxime (28, 29).
The oxime and O-methyloxime moieties are electron withdrawing but have
weaker electron withdrawing effects than the keto carbonyl. σpara and σmeta
values for CH=NOH were reported to be 0.10 and 0.22 respectively,
compared to 0.42 and 0.35 for CHO respectively.96 Electrons delocalized on
the oxime nitrogen can experience repulsion by the lone pairs of electrons on
the adjacent oxygen (Figure 2-4). In the present context, it may imply weaker
Michael acceptor reactivity of the beta carbon atoms of 27-29 due to
impeded delocalization in the conjugated system.
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Figure 2-4: Electronic effects of the O-methyloxime functionality in
compound 28.
Oximes of series I are found to maintain the double bonds in the E (trans)
configuration. Determination of the vicinal coupling constants of these
compounds from their proton nuclear magnetic resonance (1H-NMR) spectra
confirmed the E stereochemistry. Briefly, the extent of vicinal coupling
depends on the magnitude of orbital overlap (Figure 2-5). When the vicinal C-
H bonds are 90˚ to each other, the vicinal coupling constant is zero. At this
angle, there is no overlap between the sp3 hybrid orbitals.  When the vicinal
C-H bonds are at 180˚, there is maximum overlap between the almost parallel
molecular orbitals and electrons can transfer spin information effectively
through the bonds. Vicinal coupling constant for E configuration is therefore
large, between 10 – 16 Hz. When the protons are Z (cis), only sideways orbital
overlap occurs. Communication through the bonds is less effective and the
vicinal coupling constant is distinctly smaller (between 6 to 11 Hz). The vicinal
coupling constants of 1-5 were found to be 16 Hz, thus confirming the E
stereochemistry of the C=C bonds.
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Figure 2-5: (A) Relationship between dihedral angle and orbital overlap.(B) Vicinal coupling constant of cis (Z) and trans (E) isomers
2.2.3. Series II and III
In order to rigidify the monocarbonyl cross conjugated dienone motif, the
carbonyl group was embedded in a 5-membered or 6-membered carbocyclic
ring, to give Series II (cyclopentanones) or Series III (cyclohexanones)
respectively.  A review of the literature showed that analogs with the
cyclopentanone linker were generally associated with poor growth inhibitory
activities.68, 73 Thus, only 6 compounds were synthesized in Series II and they
were distinguished by the terminal ring substitution: unsubstituted phenyl
(6), fluoro-substituted regioisomers (7 – 9) and methoxy/hydroxyl substituted
analogs (10 and 11).
In contrast, Series III was a larger series with 22 compounds which were again
distinguished by the terminal ring substitution (fluoro, methoxy/hydroxyl,
pyridine).  Evaluation of the 1st round compounds showed that 3-fluoro
substitution and phenyl-pyridine replacement improved potency whereas
hydroxyl and methoxy groups conferred selectivity for APL over non-APL cell
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lines. Hence in the 2nd round of synthesis, asymmetrically substituted analogs
bearing 3-fluoro on one ring and methoxy/hydroxyl substituents on another
ring were synthesized (202-205).
Also synthesized were symmetrically substituted analogs 201 and 206 which
had groups associated with potency (fluoro, pyridine) and selectivity
(methoxy, hydroxyl) on the same ring.
2.2.4. Series IV
In a 2011 study of 831 drugs,  200 compounds were found to contain at least
one sulfur atom in their structures.97 Sulfur-containing moieties are well-
established in the drug-like chemical space and molecules containing sulfur
have shown good biological and physiochemical properties.
In Series IV, the cyclohexanone ring of Series III was replaced by
tetrahydrothiopyranone.
Hence, differences in the biological profiles of the two series could essentially
be traced to the CH2 (methylene, Series III) versus S (sulfide, Series IV)
substitution in the central ring system.  In terms of electron withdrawing
effects, the sulfide is comparable to methylene.  Sulfur is a soft base with
available lone pair of electrons.  The sulfide sulfur is potentially oxidizable to
sulfoxide and sulfone and this may be viewed as a metabolic liability.  Noting
that bond dissociation energies are of the order C-S < C–C < C–O, the
weakness of the C-S bond may also render the Series IV thiopyranones more
susceptible to hydrolysis. On the positive side, estimated clogP values of
Series IV compounds were lower than that of their Series III counterparts
which may translate to a much needed improvement in aqueous solubility.
In addition, the scaffold has not been widely investigated in the literature.
2.2.5. Series V
Oxidation of the thiopyranone sulfide in Series IV to sulfone gave rise to
Series V (“thiopyranone dioxides”).  This modification serves to preempt
concerns over the propensity of the thiopyranone sulfide to undergo
metabolic oxidation.  Differences in the biological activities of Series IV and V
would logically stem from the sulfide to sulfone conversion. In terms of
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physicochemical properties, the thiopyranone dioxides of Series V were
anticipated to be less lipophilic, as seen from their lower clogP values (1.0 to
2.4). Dihydroxy substutition of the terminal phenyl rings or replacing the
latter with pyridine would reduce lipophilicity further (clogP 0.22 to -0.6) to
the point that permeability may be adversely affected. Thus, ring
substitutions in Series V were limited to fluoro, methoxy and mono hydroxyl.
An attractive feature of Series VI was its structural novelty. None of the 9
compounds synthesized were listed in SciFinder Scholar.
2.2.6. Series VI
Series VI comprise compounds bearing a central piperidinone ring.
Compound 42 in Series VI is EF24, which was reported to have outstanding
growth inhibitory properties, rivaling that of cisplatin, on a panel of cancer
cell lines.81 As this motif has been widely explored, the series lacked
structural novelty but were anticipated to have greater activity than their
Series III, IV and V counterparts. The basicity of the piperidinone NH in Sereis
VI was estimated to be 5.3 (ACD Labs). Experimentally, a higher value of 6.5
was reported. Thus, the NH is likely to exist in the predominant non-ionized
state at physiological pH 7.4. Both the NH and lone pair on N of piperidinone
NH would available for H bonding. Its role as a H bond donor would be
unique as it is not shared by the other scaffolds. As a HB acceptor, the lone
pair on N would be less available than the sulfonyl moiety in Series V, as
evidenced from the diminished pKa of the NH.
2.3. Syntheses of Series I-VI: Mechanistic considerations
2.3.1. Syntheses of symmetrical analogs of Series I, II and III, IV and V
by base-catalyzed aldol condensation
These compounds were prepared in a base-catalyzed aldol condensation of
the ketone (1 equivalent) and the functionalized aromatic aldehyde (2.1
equivalents) (Scheme 2-1)
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Scheme 2-1: Synthesis of selected series I – IV analogues. Reagents and
conditions: a) benzaldehyde (2.1 eq), NaOH (3 eq), EtOH, 25 ˚C.
Mechanistically, the reaction starts with the deprotonation of the acidic Cα-H
proton of the ketone in the presence of a base (NaOH) to give an enolate
(Scheme 2-2) The Cα-H protons are weakly acidic (pKa 25-27, Figure 2-6) but
more so that than C-H protons due to the proximity of the
electronwithdrawing carbonyl group.
Figure 2-6: Relative acidities of protons on α-carbon of acetone,cyclopentanone and cyclohexanone.
The enolate attacks the electron deficient carbonyl carbon of the aromatic
aldehyde to give the aldol product (Scheme 2-2). In this step, the carbonyl
oxygen of the aldehyde accepts a proton from water (or a protic solvent like
ethanol) to form an alcoholic OH which is eliminated as water in the presence
of base (E1 Elimination) to give the enone. The aldol condensation is
repeated on the other “side” of the symmetrical ketone to give the desired
cross conjugated dienone product.
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Scheme 2-2: Base-catalyzed aldol condensation reaction. (n = 0, 2, 3)
2.3.2. Syntheses of oximes
Scheme 2-3: Synthesis of oximes from series I. Reagents and conditions: a)
R’ = H: NH2OH.HCl (2 eq), Et3N (3 eq), EtOH, 25 ˚C; R’ = Me: NH2OMe.HCl (2
eq), NaOAc (1.05 eq), EtOH:H2O (8:1), 25 ˚C.
Compounds 2 and 3 of Series I are converted to the corresponding oxime and
O-methyloxime by a nucleophilic addition reaction by hydroxylamine or
methoxyamine on the electron deficient carbonyl carbon (Scheme 2-3).
When a strong nucleophile like hydroxylamine or methoxyamine is involved,
the initial addition does not require acid catalysis to activate the carbonyl
oxygen. Typically, oxime formation occurs at weakly acidic conditions (pH 5-
6).98, 99 The reaction of 2 and 3 with methoxyamine hydrochloride was carried
out in the presence of sodium acetate, a weak acid buffer with maximum
buffering capacity at pH 3.6-5.6. However, these conditions were not
conducive for the reaction of 3 with hydroxylamine which instead proceeded
only in the presence of the base triethylamine. The base-catalyzed addition
reaction between acetone and hydroxylamine was in fact reported in the
early literature.100, 101
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Scheme 2-4: Mechanism of oxime formation.
Scheme 2-4 depicts the mechanism of oxime formation. The presence of acid
will reduce the nucleophilicity of hydroxylamine/methoxyamine by
protonating the basic nitrogen (pKa 5.97 hydroxylamine; 4.66 methoxyamine)
but acidic conditions will increase the rate of dehydration. Basic conditions
will have the reverse effect.
2.3.3. Syntheses of symmetrical analogs of Series IV by acid catalyzed
aldol condensation
The thiopyranone analogs of Series IV were synthesized by a base-catalyzed
or acid-catalyzed aldol reaction. Base-catalyzed aldol reaction was described
in Section 2.4.1. The acid catalyzed reaction is outlined in Scheme 2-5. The
main difference between acid- and base-catalyzed aldol reaction is in the first
step. In the presence of acid, the carbonyl oxygen is protonated which then
facilitates deprotonation of the Cα-H proton to give the enol. Enols are less
nucleophilic than enolates but the reaction proceeds because the aldehyde
carbonyl is protonated. Dehydration is also acid catalyzed.  However, higher
temperatures (60 ˚C to reflux temperatures) are normally required for the
reaction to reach completion in contrast to the base-catalyzed reaction which
reach completion at room temperature conditions. For this reason, the base-
catalyzed aldol reaction was preferred and was employed for the syntheses
of Series IV compounds except when the reacting benzaldehydes were
substituted with phenolic OH groups.
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Scheme 2-5: Acid-catalyzed aldol condensation reaction (X = CH2, S)
Oxidation of the thiopyranone sulfide moiety in Series IV gave the
thiopyranone dioxides of Series V (Scheme 2-6).
Scheme 2-6: Synthesis of thiopyranone dioxides from series IV. Reagents
and conditions: a) 30 % H2O2, CH3CO2H, 60 ˚C.
Oxidation was effected by peracetic acid which was generated in situ from
acetic acid and hydrogen peroxide. Peracids are weaker acids than carboxylic
acid from which they are prepared because loss of proton gives a conjugate
base that lacks the resonance stabilization of the carboxylate. Moreover,
intramolecular H-bonding stabilizes the conjugate acid species. (Figure 2-7A)
The oxidizing property of peracids stems from the electrophilic peroxide
oxygen which when attacked by an nucleophile (in this case, sulfide),
displaces carboxylate as a leaving group (Figure 2-7B).
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Figure 2-7: (A) Acid-base character of peracids (B) Peracids as oxidizingagents
The thiopyranone sulfide underwent stepwise oxidization to a sulfoxide (not
isoloated) and finally a sulfone. The literature recommended temperatures as
high as 100 ˚C for the oxidation of thiopyranones by peracetic acid102, 103 but
degradation was observed under these conditions, possibly due to
epoxidation of the C=C bonds of the enone. The reaction temperature was
finally optimized at 60 ˚C and the product was obtained in reasonable yields
(20-73%). In general, the oxidizing capacity of a peracid is linked to its
strength as an acid. Thus m-chloroperoxybenzoic acid (m-CPBA) is a stronger
oxidizing agent than peracetic acid because the presence of the inductively
withdrawing chloro makes it a stronger acid. When the oxidation was
attempted with m-CPBA, the sulfone was obtaine in lower yields.  Thus,
peracetic acid was retained as the oxidizing agent of choice for the sulfide to
sulfone conversion (Scheme 2-7).
Scheme 2-7: Oxidation of thiopyranone analogs to thiopyranone dioxidein the presence of peracetic acid as oxidizing agent.
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2.3.4. Synthesis of asymmetrical analogs of series III using sequential
acid-catalyzed aldol condensation
The asymmetrically substituted cyclohexanone analogs of series III were
synthesized by a stepwise aldol reaction starting with an excess of
cyclohexanone (Scheme 2-8). The reaction was reportedly carried out in the
presence of NaOH with yields of 30 – 70 %.104, 105 However, these conditions
yielded the symmetrically substituted analog in our hands. When repeated
under acid-catalyzed conditions, the reaction proceeded smoothly. The first
aldol product from the reaction of cyclohexanone and 3-flurobenzaldehyde
(48) was isolated and purified (yield 35.8%), and then reacted with another
benzaldehyde in a 2nd acid-catalyzed aldol reaction to give the asymmetrically
substituted analogs 202-205 (Scheme 2-8).  The failure of the reaction to
proceed under basic conditions may be attributed to the milder room
temperature conditions employed which could have driven it quickly to
completion. Since higher temperatures were necessary for the acid catalyzed
reaction, stepwise reaction could be achieved by adjusting the temperature
to a less than optimal level, but at the expense of yield.
Scheme 2-8: Synthesis of asymmetrical series III and IV analogues, 202 –
205. Reagents and conditions: a) cyclohexanone (4 eq), 3-
fluorobenzaldehyde (1 eq), conc. HCl, EtOH, 60 ˚C; b) intermediate I (1 eq),
benzaldehyde (1 eq), conc. HCl, EtOH, 60 ˚C.
2.3.5. Synthesis of asymmetrical analogs of Series IV
The syntheses of the asymmetrically substituted thiopyranone analogs of
series IV proved to be more challenging.  The reaction of dihydro-2H-
thiopyran-4(3H)-one and 3-fluorbenzaldehyde did not give the aldol product
3-[(3-fluorobenzylidene)dihydro-2H-thiopyran-4(3H)-one (49) under acidic
conditions. Thus, base-catalyzed condensation was re-examined with
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different bases (NaOH, KOH, piperidine, tertiary butoxide), varying reaction
times and different temperatures. Attempts to control the reaction by
avoiding excessive ketone (equivalent amounts of reactants) or to carry out
the reaction at low temperatures with a strong base (tert-butoxide) was
employed were not successful. Finally, the reaction proceeded in the
presence of lithium diisopropylamide (LDA), a strong and sterically hindered
amide base. Typically, LDA is employed to provide kinetic control in the
deprotonation of asymmetrical ketones. Because of its steric character, LDA
deprotonates the less hindered proton in the asymmetric ketone to give the
lithium enolate. Low temperatures and THF are required to stabilize the
lithium enolate.
The reaction scheme for the synthesis of the asymmetrical analogs 217-220 is
presented in Scheme 2-9).  In step (a), tetrahydrothiopyranone was
deprotonated by LDA (in excess, 1.3 equivalent) at low temperatures (-78 ˚C)
to give the lithium enolate. In step (b), 3-fluorobenzaldehyde in dry THF was
added dropwise to the enolate at -78 ˚C to give the aldol product on aqueous
workup. The latter was dehydrated in the presence of catalytic amounts of p-
toluenesulfonic acid (PTSA) to give (49) in 21% yield after purification. The
crude yield was higher but was reduced on purification because the reactant
3-fluorobenzaldehyde co-eluted with the product in column chromatography.
However, 49 could be obtained on repeated column chromatography with
dichloromethane as the eluting solvent. The second aldol reaction (step d)
was carried out under acidic conditions and gave the desired products 217-
220 in reasonable yields.
70
Scheme 2-9: Synthesis of asymmetrical series III and IV analogues, 217 –
220. Reagents and conditions: a) LDA (2 M), dry THF, -78 ˚C, 1 h; b) 3-
fluorobenzaldehyde (1 eq), dry THF, -78 ˚C, 6 h; c) p-TsOH (5 mol%), toluene,
90 ˚C, 1.5 h; d) benzaldehyde (1 eq), conc. HCl, EtOH, 60 ˚C, 18 – 24 h.
Mechanistically, the formation of the 1st aldol product in the presence of LDA
proceeded via the formation of lithium enolate (Scheme 2-10A).  The
formation of the enolate begins with Li-O bond formation before the removal
of the CαH proton by the basic nitrogen of LDA.  On addition of the
benzaldehyde, a complex is formed with the same lithium atom and allows
the aldol reaction to occur by a cyclic mechanism within the coordination
sphere of the lithium atom. Dehydration of the aldol is facilitated by catalytic
amounts of p-toluenesulfonic acid to give the conjugated unsaturated
carbonyl compound 49 which was isolated and purified prior to the next aldol
reaction (Figure 2-10B). The 2nd aldol condensation was carried out under
acidic conditions as described in Section 2.4.2. Dehydration occurs with the
regeneration of PTSA to give the α,β-unsaturated intermediate 49. The 2nd
aldol reaction was carried out under acidic conditions as described earlier.
Scheme 2-10: Reaction mechanism of asymmetric thiopyranone analogsof series IV.
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2.3.6. Synthesis of piperidinone analogs of Series VI
The method of Adams et al81 was initially followed for the synthesis of the
Series VI compounds. The method required passing dry hydrogen chloride
(HCl) gas through a stirred solution of piperidinone and benzaldehyde in
glacial acetic acid.  HCl gas was generated from the reaction of concentrated
sulfuric acid and ammonium chloride but this procedure yielded the desired
product in low yields. The condensation was then attempted in the presence
of NaOH and gratifyingly, it yielded the desired product in good yields. More
importantly, the method was readily carried out without the need to
generate dry HCl gas.
2.3.7. Synthesis of analogs containing hydroxyl substituents on
phenyl ring
The presence of a phenolic hydroxyl (OH) group on the benzaldehyde would
interfere with the base-catalyzed aldol reaction due to its greater acidic
character (pKa  10) compared to that of the α-hydrogen atoms (pKa20) of
the reacting ketone (acetone, cyclopentantone, cyclohexanone). Thus the
phenolic OH would be preferentially deprotonated in the basic reaction
mixture, giving rise to unwanted side products. To avoid these reactions, the
phenolic OH was converted to the tetrahydropyranyl ether for the base-
catalyzed condensation and then removed by acid hydrolysis to give the

























n = 2, (-CH2CH2-)n = 3, (-CH2XCH2-)X = CH2, S, NH
Scheme 2-11: Synthesis of selected hydroxyl-substituted benzylideneanalogs, 4, 10, 22. Reagents and conditions: a) respective benzaldehyde (1
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eq), p-toluenesulfonic acid (1 mol%), CH2Cl2, 3,4-dihydro-α-pyran (1.5 eq), 4
h; b) respective ketone (1 eq), 18 – 24 h); c) HCl (4 M), 25 ˚C, 4 h.
Briefly, 3,4-dihydro-α-pyran is protonated at its β-carbon by p-
toluenesulfonic acid to give an electrophilic oxonium ion which is attacked by
the phenolic OH (Scheme 2-12). Proton loss gives the tetrahydropyranyl
ether. The initial protonation was reportedly carried out with silicon dioxide
and sulfuric acid with apparently higher yields and shorter reaction times.106
Removal of the tetrahydropyranyl group was effected in the presence of acid
and the reaction was essentially the reverse of those involved in its
formation.
Scheme 2-12: Protection of alcohols using tetrahydropyran.
Only 4, 10 and 22 were prepared under basic aldol conditions with
protection/deprotection of the phenolic OH groups in the reacting
benzaldehydes. The other compounds with phenolic OH groups were
prepared under acidic conditions without the need for the addition
protection/deprotection steps.
2.4. Materials and methods
2.4.1. General details
Reagents (synthetic grade or better) were obtained from commercial
suppliers (Sigma-Aldrich Chemical Company Inc, Singapore; Alfa Aesar, MA,
USA) and used without further purification. 1H and 13C NMR spectra were
recorded on a Bruker ACF (DPX 300 or 400 MHz). Chemical shifts were
reported in parts per million (ppm). The residual solvent peak was used as an
internal reference. Analytical thin layer chromatography (TLC) was performed
on Merck pre-coated TLC plates, silica gel 60F-254, layer thickness 0.25 mm.
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Flash chromatography separations were performed on Merck 60 (0.040-
0.063 mm) mesh silica gel. Nominal mass spectra were analyzed on LcQ
Finnigan MAT mass spectrometer with atmospheric pressure chemical
ionization (APCI) as probe. High resolution accurate mass spectra were
analyzed on Bruker micrOTOF-QII mass spectrometer with atmospheric
pressure chemical ionization (APCI) as probe. Spectroscopic data of final
compounds are given in Appendix 2-1. Purity of final compounds was verified
by combustion analysis (Perkin Elmer PRE-2400 Elemental Analyzer) or by
reverse phase HPLC on two different solvent systems (isocratic mode).
Details are given in Appendix 2-2. Unless otherwise stated, combustion
analyses for C and H were within 0.4% of theoretical values. Compounds
analyzed on HPLC were found to be of  98% purity on both solvent systems,
with the exception of compounds 4, 5, 11 and 18.
2.4.2. General procedure for syntheses of 1 – 3, 5 – 9, 11-15, 18 – 19,
21, 24 – 26, 31 – 33, 201, 206, 30, 36 – 37, 207 – 214, 42 – 44, 47, 228,
229 by aldol condensation under basic conditions.
A solution of the reacting ketone (cyclohexanone, tetrahydro-thiopyran-4-
one or piperidin-4-one) (1 mmol) in 0.3% (w/v) sodium hydroxide in aqueous
ethanol (50% v/v, 6 mL) was  stirred at room temperature (25 oC) in a round
bottom flask sealed with a rubber septum.  A solution of the substituted
benzaldehyde (2.1 mmol) in ethanol (1 mL) was added dropwise to the
stirred solution over 5 min, after which stirring was continued overnight at
room temperature.  The precipitated solids were removed by vacuum
filtration, washed with cold ethanol and dried under vacuum.  In most cases,
the product was purified by column chromatography with hexane/ethyl
acetate as eluting solvents. For 42 – 44, 47, 228 and 229, the free base was
dissolved in ethyl acetate and acidified with 6 M HCl to afford the
corresponding HCl salt which was removed by filtration under reduced
pressure and washed with ethyl acetate.
2.4.3. Syntheses of 4, 10 and 22
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The hydroxyl group on 3-hydroxy-4-methoxybenzaldehyde was protected by
reaction with 3,4-dihydro--pyran prior to reaction with the ketone.  Briefly,
to a stirred suspension of the benzaldehyde (28.8 mmol) and pyridinium p-
toluenesulfonate (0.32 mmol) in dichloromethane (80 mL) was added
dropwise a solution of 3,4-dihydro--pyran (44 mmol) in dichloromethane
(40 mL).  The mixture was stirred at room temperature for  4 h,  then  washed
with 1 M NaHCO3 solution (60 ml x 3) and brine (60 ml x 3), the organic layer
was dried over anhydrous Na2SO4, evaporated in vacuo and purified by
column chromatography (hexane / ethyl acetate as eluting solvents). 4-
Methoxy-3-(tetrahydro-pyran-2-yloxy)-benzaldehyde was obtained as a pale
yellow oil and reacted with the ketone as described in Section 2.5.2.  At the
end of the reaction, the tetrahydro-pyran-2-yloxy group was removed by
stirring in 4 M HCl for 4 h, room temperature. The reaction mixture was then
diluted with water, extracted with ethyl acetate (50 ml x 3), the combined
organic phase was washed with brine (50 ml x 3), dried over anhydrous
Na2SO4, evaporated in vacuo and the residue purified by column
chromatography with hexane / ethyl acetate as eluting solvents and/or re-
crystallization.
2.4.4. General procedure for syntheses of 16, 17, 20, 23, 34 – 35, 38,
215, 216, 230, 231, 45 – 46 by aldol condensation under acidic
conditions
A solution of the reacting ketone (acetone, cyclohexanone, tetrahydro-
thiopyran-4-one or piperidin-4-one) (0.5 mmol) in denatured ethanol (2 mL)
was stirred at room temperature (25 oC) in a round bottom flask sealed with
a rubber septum. 6 M HCl (25 µL) was added followed by the substituted
benzaldehyde (1 mmol).  The mixture was heated to 30 – 60 oC in an oil bath
and the progress of the reaction was periodically monitored by TLC over 18 –
24 h. Solids were removed by vacuum filtration, washed with ethanol. In
most cases, the product was further purified by column chromatography with
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hexane / ethyl acetate as eluting solvents followed by recrystallization with
suitable solvents.
2.4.5. 5-Bis-(4-fluoro-phenyl)-penta-1,4-dien-3-one oxime (27)
To a stirred solution of hydroxylamine hydrochloride (4.0 mmol) in denatured
ethanol (30 mL) was added triethylamine (4.0 mmol) and 1,5-bis(4-
fluorophenyl)penta-1,4-dien-3-one (3, 2.0 mmol). The reaction flask
containing the light yellow solution was sealed with a rubber septum and
stirred at room temperature for 15 hours. Progress of reaction was
monitored on TLC (hexane: ethyl acetate = 4:1). The resultant pale yellow
reaction mixture was evaporated to dryness in vacuo and extracted with
ethyl acetate / water. The organic layers were combined and dried over
anhydrous Na2SO4. Organic solvent was removed in vacuo to give a yellow oil
which was purified by column chromatography (progressive elution with
hexane : ethyl acetate 10:1 to 2:1). Fractions containing the desired
compound were combined and dried in vacuo to give a pale yellow solid
which on recrystallization with acetone / hexane provided a white solid
(23.3% yield).
2.4.6. Syntheses of O-methyloximes of 1,5-bis-(fluorophenyl)-penta-
1,4-dien-3-ones (28 and 29)
A solution of methoxylamine hydrodrochloride (2.5 mmol) in aqueous sodium
acetate (2M, 1 mL) was added dropwise to a stirred solution of the 1,5-bis(4-
fluorophenyl)penta-1,4-dien-3-one (2 or 3, 2.0 mmol) in ethanol (12 mL). The
mixture was stirred at 60 oC in a sealed flask and the course of reaction
monitored on TLC (hexane / ethyl acetate 4:1). Reaction was completed after
about 23 h. Solvent was removed from the light yellow reaction mixture
under reduced pressure, giving a yellow (28) or orange (29) oil which was
extracted with ethyl acetate / water, the organic phase was dried over
anhydrous Na2SO4. The organic extracts were combined and concentrated in
vacuo to give a yellow (28) or orange (29) solid. Both crude products were
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purified by column chromatography (progressive elution with hexane / ethyl
acetate 100:1 to 10:1) to give a white solid.
2.4.7. General procedure for syntheses of 40, 41, 221 – 227
To a clear and dry round bottom flask was added the 3,5-bis-(n-substituted-
benzylidene)-tetrahydro-thiopyran-4-one (0.5 mmol) in glacial acetic acid (3.5
mL) which was then warmed to 30 – 40 oC. 30% Hydrogen peroxide (320 µL)
was then added to the reaction mixture and allowed to stir at 60 ˚C. The
progress of the reaction was periodically monitored by TLC over 6 – 24 h. The
flask was cooled to room temperature and distilled water was added to
induce precipitation. The flask was further cooled over ice, the yellow solid
was filtered and washed with distilled water. The crude product was purified
by flash column chromatography with hexane / ethyl acetate as eluting
solvents followed by recrystallization in suitable solvents.
2.4.8. Synthesis of 2-(3-Fluoro-benzylidene)-cyclohexanone (48)
To a clear, dry round bottom flask was added an ethanolic solution (4 mL) of
cyclohexanone (4 mmol). 3-Fluorobenzaldehyde (1 mmol) was dissolved in
ethanol (1 mL) and added dropwise to the stirred solution over 5 min with
warming (65 ˚C). 6 M HCl (10 µL) was added and the reaction was monitored
for the disappearance of the benzaldehyde by TLC. The crude mixture was
dried in vacuo and extracted with brine / dichloromethane. The residue was
purified by flash column chromatography with hexane / ethyl acetate as
eluting solvents.
2.4.9. Synthesis of (3-[(3-fluorobenzylidene)dihydro-2H-thiopyran-
4(3H)-one) (49)
To a clear and dry 3-necked round bottom flask was added lithium
diisopropylamide (LDA) in tetrahydrofuran (THF) (2 M, 4 mmol). The mixture
was cooled to -78 ˚C in a dry ice- acetone mixture. The  flask was purged with
argon for 3 – 5 min afterwhich a solution of tetrahydro-thiopyran-4-one (2.0
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mmol) in anhydrous THF (1 mL) was added dropwise with stirring at -78 ˚C.
After 1 h, 3-fluorobenzaldehyde (2 mmol) in anhydrous THF (1 mL) was added
dropwise to the mixture over 10 min. The progress of the reaction was
periodically monitored by TLC over 6 h. THF was removed in vacuo followed
by extraction with brine/dichloromethane to give a yellow oil which was
dissolved in toluene (3 mL). Para-toluenesulfonic acid (p-TsOH) (0.1 mmol)
was added and the mixture was stirred at 90 ˚C for 1.5 h. The crude product
was purified by  flash column chromatography with hexane / ethyl acetate as
eluting solvents.
2.4.10. General procedure for syntheses of 202 – 205, 217 – 220
The procedure described in Section 2.5.3 was followed with minor changes. A
solution of the 2-(3-fluoro-benzylidene)-cyclohexanone or [3-[(3-
fluorobenzylidene)dihydro-2H-thiopyran-4(3H)-one] (0.5 mmol) in denatured
ethanol (2 mL) was stirred at room temperature (25 oC) in a round bottom
flask sealed with a rubber septum. 6 M HCl (25 µL) was added followed by
the substituted benzaldehyde (0.5 mmol).  The mixture was heated to 65 oC
in an oil bath and the progress of the reaction was periodically monitored by
TLC over 1 – 2 days, after which solvent was removed in vacuo and the
residue extracted with brine / dichloromethane for purification by column
chromatography with hexane / ethyl acetate as eluting solvents and
recrystallization with suitable solvents.
2.5. Summary
A focused library of 77 compounds in Series I-VI were successfully
synthesized and characterized by 1H and 13C NMR spectroscopy and APCI-
mass spectrometry.   All final compounds were at least 95 % pure based on
elemental analyses and reversed phase HPLC with two different mobile
phases. Of the 77 compounds, 23 were structurally novel based at the point
of writing.
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Chapter 3: Effects of synthesized compounds on viability of
leukemic and non-malignant cells.
3.1. Introduction
This chapter describes the growth inhibitory activities of the synthesized
compounds on a panel of leukemia and non-malignant cells.  The leukemia
panel comprises two APL (NB4, NB4-R1) and two non-APL (K562, HL60) cell
lines. The APL cells express PML-RARα and misfolded N-CoR. NB4 responds to
the growth inhibitory and differentiation effects of retinoic acid (RA) while
NB4-R1, a de novo line from parental NB4 cells,107 is resistant to retinoic acid.
The non-APL cells K562 (chronic myelogenous leukemia) and HL60 (acute
myeloblastic leukemia) do not express PML-RARα fusion protein or
accumulate misfolded N-CoR. Neither are they known to possess aberrant
proteases that cleave misfolded N-CoR in APL cells.17 Thus, it is hypothesized
that compounds that selectively induce APL cell death do so by targeting the
pro-survival misfolded N-CoR pathway that is characteristic of APL cells. In
order to identify these compounds, a phenotypic cell-based screen was
initiated whereby compounds were evaluated for their growth inhibitory
effects on both APL and non-APL cell lines.  Potent and APL selective
compounds were next evaluated for their effects on the viability of two
human non-malignant cell lines - lung fibroblast (IMR90) and mammary
epithelial (MCF10A) cells.  The purpose was to determine if the potent and
APL selective activity profiles of these compounds would be further
complemented by minimal growth inhibitory effects on non-malignant cells.
The investigations are reported in the following sequence: First, the
synthesized compounds were evaluated for growth inhibitory effects on APL
cells. Cell viability based on redox enzyme activity was quantified using 3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS, CellTitre 96® AQueous One Solution Assay). Next, they
were evaluated on non-APL cells to identify candidates that selectively
targeted APL cell viability. Finally, selected compounds were tested for their
effects on the viability of non-malignant cells. These investigations also
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yielded useful structure-activity relationships (SAR) with regards to potency
and selectivity for APL cells.
3.2. Materials and methods
3.2.1. Cell lines and culture medium















NB4-R1 Gift from Dr. Lanotte M.
(INSERM U-301, Centre


























All media contained penicillin/streptomycin (50U/10µg/mL) and heat-
inactivated fetal bovine serum (10%) at 37˚C.
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3.2.2. Medium and reagents for cell culture
Medium / Reagent Company Country
RPMI-1640 Gibco®, Invitrogen Life
Technologies CA, USADMEM
EMEM Sigma Aldrich MO, USA
Penicillin/streptomycin PAA Laboratories NJ, USA
Fetal bovine serum (FBS) Gibco®, Invitrogen Life
Technologies
CA, USA
Dimethylsulfoxide (DMSO) National University of
Singapore Medical
Institute (NUMI) store.
Curcumin Sigma Aldrich MO, USA
CellTitre 96® AQueous One
Solution Assay
Promega WI, USA
3.2.3. Cell viability assay
Cell viability was determined by the MTS assay (CellTitre 96® AQueous One
Solution Assay). Leukemia cells, IMR90 cells, MCF10A cells were seeded at
3,500 cells, 4,000 cells, 2,000 cells per well respectively. Stock solutions of
test compounds were prepared in DMSO and diluted with media to give a
final concentration of 0.5% v/v DMSO. Cells were treated with at least 6
concentrations of test compound that covered the dynamic range of the
inverted S-shaped cell viability curve. Incubation was for 72h at 37˚C in a
humidified 5% CO2 atmosphere. After this time, 10μL MTS labeling reagent
(CellTitre 96® AQueous One Solution Assay) was added to each well under
dim light, the plates were incubated in the dark at 37°C, 4 h after which
absorbance readings were taken at 490 nm on a microplate reader (Biorad
Ultramark  microplate imaging system).   Cell viability was determined from
the expression:
Cell viability (%) = (A – C) / (U – Z) x 100%
81
where A is the absorbance of wells containing cells and test compound, C is
the absorbance of test compound at 490 nm, U is the absorbance of
untreated cells in media and 0.5% DMSO, and Z is the absorbance of media
and 0.5% DMSO.  The IC50 of test compound (concentration required to
reduce cell viability to 50% of control values from untreated cells) was
determined using GraphPad Prism (Version 3.0, GraphPad Software, San
Diego, CA). Each concentration of test compound was evaluated in triplicate
for each run and the assay was carried out on at least three separate
occasions using two or more freshly prepared stock solutions.
3.3. Results
3.3.1. Anti-proliferative activity of curcumin and analogs on
leukemic APL cell lines
Compounds synthesized in round 1 (n = 47) were first screened at two
concentrations (5M, 20M) on NB4-R1. Curcumin at 5M was found to
reduce NB4-R1 viability to 4.5%. Thus an arbitrary threshold of less than 10%
viability ( twice that observed for curcumin) at 5M test compound was set
as the cut-off for identifying “actives”.  In this way, 13 of the 47 compounds
were omitted. They comprised oximes 27-29 (Series I) and several fluorinated
analogs in Series II (7-9) and III (13, 15) (Appendix 3-1).   The oximes had
negligible effects on cell viability even at 20M, pointing to the importance of
keeping the keto carbonyl in an underivatized state. The inactivity of the
oximes may stem from their hydrolytic instability or diminished reactivity as
Michael acceptors as described earlier (Section 2.2.2).
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Table 3-1. Mean growth inhibitory activity (IC50, µM)a of compounds onAPL cell lines NB4 and NB4 R1.
Linker NB4c NB4-R1d
- CUR 3-OCH3, 4-OH 6.0 ± 1.9 8.0 ± 1.0
2 3-F 3.5 ± 0.5 4.1 ± 0.6
4 3-OH, 4-OCH3 2.8 ± 0.7 3.7 ± 0.1
5 3-OCH3, 4-OCH3 1.8 ± 0.6 2.1 ± 0.2
Series II 11 3-OCH3, 4-OCH3 6.7 ± 1.2 6.2 ± 0.3
SubstituentsCompoundRef





12 H 4.5 ± 0.4 7.8 ± 1.1
14 3-F 1.7 ± 0.3 2.5 ± 0.1
16 3-OH 1.0 ± 0.1 1.7 ± 0.7
17 4-OH 2.5 ± 0.1 11.5 ± 0.3
18 3-OCH3 6.2 ± 0.5 10.3 ± 2.1
19  4-OCH3 19.6 ± 1.5 >20e
20 3-OH, 4-OH 2.8 ± 0.6 2.2 ± 0.2
21 3-OCH3, 4-OCH3 5.6 ± 2.0 5.9 ± 0.1
22 3-OH, 4-OCH3 1.5 ± 0.5 1.8 ± 0.3
23 3-OCH3, 4-OH 2.1 ± 0.3 3.0 ± 0.3
24 2-PY 0.19 ± 0.03 0.24 ± 0.02
25 3-PY 0.22 ± 0.02 0.43 ± 0.14
26 4-PY 0.27 ± 0.04 0.43 ± 0.08
201 3-PY-5-OCH3, 6-OCH3 1.1 ± 0.1 1.0 ± 0.2
206  3-F, 4-OCH3 5.4 ± 1.0 6.8 ± 1.1
202 R1 = 3-F, R2 = 3-OCH3, 4-OCH3 3.9 ± 1.0 3.9 ± 0.7
203 R1 = 3-F, R2 = 3-OH,4-OH 1.4 ± 0.2 1.2 ± 0.1
204 R1 = 3-F, R2 = 3-OH,4-OCH3 1.8 ± 0.4 1.9 ± 0.2
205 R1 = 3-F, R2 = 3-OH 1.4 ± 0.4 1.2 ± 0.2
Series III
SubstituentsCompoundRef
Mean IC50 (µM) ± SDb
83
Linker NB4c NB4-R1d
30 H 1.2 ± 0.2 2.4 ± 0.3
31 2-F 0.9 ± 0.2 1.1 ± 0.1
32 3-F 0.3 ± 0.1 0.66 ± 0.03
33 4-F 1.1 ± 0.2 1.5 ± 0.5
34 3-OH 0.5 ± 0.1 0.59 ± 0.34
35 4-OH 2.5 ± 0.2 2.5 ± 0.7
36 3-OCH3 2.5 ± 0.3 3.6 ± 1.2
37  4-OCH3 17 ± 4.5 >20e
38 3-OH, 4-OH 4.7 ± 0.3 8.4 ± 1.1
207 2-Py 0.17 ± 0.04 0.10 ± 0.02
208 3-Py 0.11 ± 0.02 0.11 ± 0.01
209 4-Py >40e >40e
210 3-PY-5-OCH3, 6-OCH3 0.17 ± 0.02 0.27 ± 0.09
211  3-F, 4-OCH3 5.4 ± 1.9 5.7 ± 1.2
212 3-OCH3, 4-OCH3 0.69 ± 0.13 0.52 ± 0.15
213 2-OCH3, 5-OCH3 3.2 ± 0.6 1.8 ± 0.4
214 3-OCH3, 4-OCH3, 5-OCH3 3.8 ± 1.4 0.16 ± 0.02
215 3-OH, 4-OCH3 0.38 ± 0.04 0.33 ± 0.09
216 3-OCH3, 4-OH 0.84 ± 0.27 0.58 ± 0.16
217 R1 = 3-F, R2 = 3-OCH3, 4-OCH3 0.94 ± 0.15 0.56 ± 0.24
218 R1 = 3-F, R2 = 3-OH,4-OH 0.90 ± 0.16 0.55 ± 0.13
219 R1 = 3-F, R2 = 3-OH,4-OCH3 0.48 ± 0.12 0.21 ± 0.07




Mean IC50 (µM) ± SDb
Linker NB4c NB4-R1d
40 2-F 0.08 ± 0.02 0.07 ± 0.00
41 3-F 0.06 ± 0.02 0.07 ± 0.01
221 4-F 0.05 ± 0.01 0.11 ± 0.04
222 3-OCH3, 4-OCH3 0.12 ± 0.02 0.10 ± 0.03
223 2-OCH3, 5-OCH3 0.29 ± 0.09 0.23 ± 0.07
224 3-OCH3, 4-OCH3, 5-OCH3 0.05 ± 0.01 0.04 ± 0.01
225 3-OH, 4-OCH3 0.17 ± 0.04 0.15 ± 0.04
226 3-OH 0.14 ± 0.02 0.16 ± 0.03




Mean IC50 (µM) ± SDbSubstituents
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aConcentration of compound required to inhibit cell growth by 50% relative
to control cells. bAnti-proliferative activity data from 3 independent
experiments, each experiment performed in triplicate. cAPL cell line. dAPL cell
line resistant to retinoic acid. eIC50 not determined above 20 µM or 40µM due
to insolubility at these concentrations.
The “actives” were evaluated for their half maximal growth inhibitory
concentrations (IC50) on NB4-R1 and NB4 cells. Most of the compounds had
better anti-proliferative activities than curcumin (IC50 NB4-R1 7.99 M, IC50 NB4
6.01 M) (Table 3-1), except for 11 (Series II cyclopentanones), 18, 19 (Series
III cyclohexanones), 37 (Series IV thiopyranones) and 46 (Series VI
piperidinones).  Interestingly, these poorly active compounds share in
common the presence of a mono-oxygenated substituent (methoxy OMe or
hydroxyl OH) on the terminal phenyl rings.
Of greater interest were actives that had submicromolar growth inhibitory
IC50 on both APL cell lines.  These compounds were found in Series III
(cyclohexanones), IV (thiopyranones), V (thiopyranone dioxides) and VI
(piperidinones) and had IC50 values that did not differ by more than 2-fold on
the two cell lines.  In Series III, submicromolar actives were the pyridinyl
regioisomers 24-26 in which terminal phenyl rings were replaced by pyridinyl.
In Series IV, the actives were the fluoro F (31, 32), OH (34) and di-OMe (212)
substituted analogs. The fluoro analogs in Series V (40, 41) and Series VI (42-
44) were also associated with outstanding growth inhibitory activities.
Another active in Series VI was the 3-OH analog 45.  Unusually, the 4-OH
regioisomer (46) had very poor activity on both cell lines.  Of the substituents
Linker NB4c NB4-R1d
42 2-F 0.29 ± 0.05 0.32 ± 0.05
43 3-F 0.16 ± 0.04 0.21 ± 0.00
44 4-F 0.25 ± 0.02 0.36 ± 0.08
45 3-OH 0.20 ± 0.08 0.44 ± 0.21
46 4-OH 10 ± 0.7 18 ± 0.2
47 3-OCH3, 4-OCH3 0.50 ± 0.02 0.80 ± 0.20
228 2-OCH3, 5-OCH3 0.34 ± 0.06 0.24 ± 0.03
229 3-OCH3, 4-OCH3, 5-OCH3 0.10 ± 0.03 0.10 ± 0.01
230 3-OH, 4-OCH3 0.39 ± 0.07 0.42 ± 0.08




Mean IC50 (µM) ± SDb
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present in the submicromolar actives (Figure 3-1), fluoro was unusually  well
represented across the various scaffolds (Series IV, V, VI), suggesting that its
presence favored submicropolar potencies.
Figure 3-1: Structures of submicromolar actives from round 1
To determine if there was a preferred central linker /scaffold for potency, a
comparison of IC50 values of compounds bearing the same terminal rings but
different scaffolds (ie belonging to different series) was made. In the case of
3-F substituted terminal rings, the rank order of activity was 41 (Series V,
thiopyranone dioxides, most active) > 43 (Series VI, piperidinones) > 32
(Series IV, thiopyranones) > 14 (Series III, cyclohexanones) > 2 (Series I,
acetones). The rank order for analogs bearing 3-OH and 3,4-OMe substituted
rings broadly reflected that observed for the 3-F analogs (Figure 3-2).
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Figure 3-2: Potency ranking of compounds bearing the same ringsubstituents but with different central scaffolds
Several instances depicting regioisomeric influence on activity were noted in
Table 3-1. The 3-OH and 4-OH phenyl substituted analogs of Series III (16, 17),
Series IV (34, 35) and Series IV (45, 46) were cases in point. Here, analogs
with 3-OH were consistently more active than their 4-OH counterparts,
regardless of series. Other examples were the 3-F versus 4-F analogs of Series
I, III and IV (3-F more potent than 4-F). These regioisomeric effects on activity
may reflect a dominant role for the substituent vis-à-vis the central linker
since only the substituents were modified in these compounds.
Figure 3-3. Examples of regioisomers with different growth inhibitoryactivities
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Thirty compounds were synthesized in round 2 and these were similarly
evaluated for growth inhibitory activity on APL cells. Based on the SAR
deduced from round 1, Series I and II were not pursued. Instead, round 2
focussed on the more promising Series IV (thiopyranones) and V
(thiopyranone dioxides). Additional compounds in Series III (cyclohexanones)
and IV (piperidinones) were also investigated primarily to facilitate SAR
comparisons with Series IV and V.  A deliberate effort was made to include
ring substituents (F, pyridinyl, OH, OMe) identified in round 1 to be causally
linked to good activity.
The most potent compounds to emerge from the 2nd round of screening were
the thiopyranone dioxides of Series V. As before, no significant difference
was observed in IC50 values from NB4 and NB4R1 cells. Hence, the following
discussion will be based on IC50 values from NB4 cells.  Potent nanomolar
activities (comparable to 41, the most potent round one compound in this
series) were found for the 4-F analog 221 (IC50 NB4 0.05 µM), tri-OMe analog
224 (IC50 0.05 µM) and the 3-F-4-OMe analog 227 (IC50 0.08 µM) (Figure 3-4)
Figure 3-4: Nanomolar actives in Series V from round 2 screening
When compared to Series III, IV and VI compounds with the same
substituents, the thiopyranone dioxide analog was again the scaffold of
choice. Like its 3-F analog 41, the 4-F 221 was more potent than its
piperidinone (44) and thiopyranone (33) counterparts. The tri-OMe analog
224 was about twice as potent as its piperidinone counterpart (229) and 70
times more active than the cyclohexanone analog 214.  Similarly, the growth
inhibitory activity of the 3-F-4-OMe analog 227 of Series V far exceeded that







































Figure 3-5: Potency ranking of compounds bearing the same ringsubstituents but different central scaffolds.
Several potent Series IV thiopyranones were identified in the 2nd round of
screening (Figure 3-6). These were 207 (IC50 0.17 µM) and 208 (IC50 0.11 µM),
both of which had pyridine rings in place of phenyl. Their growth inhibitory
activities surpassed that of 32 (IC50 0.29 µM) which was the most potent
thiopyranone from round 1.  Moreover, the IC50 values of 207 and 208 were
comparable to that of the potent cyclohexanones 24 (0.19 µM) and 25 (IC50
0.22 µM) which also have terminal pyridine rings. Unfortunately, phenyl-to-
pyridine conversions were not explored in Series V and VI because these
series were deemed to be sufficiently polar. A phenyl with pyridine
conversion would have caused polarity to be reduced to unacceptably low
levels. In retrospect, it may be worthwhile investigating the activity-
enhancing potential of the phenyl to pyridine conversion in Series V and VI.
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Figure 3-6: Structures of Series IV (32, 207, 208) and Series III (24, 25)
A comparison of the growth inhibitory activities of Series III cyclohexanones
and Series IV thiopyranones revealed interesting scaffold-dependent
differences in the SAR (Figure 3-7). Notably, a regioisomeric preference was
apparent among the pyridine-bearing thiopyranones (209 with 4-pyridinyl
rings was less active than 207, 208 which have 2- or 3-pyridinyl) that was not
evident among the cyclohexanones (24 – 26). Additionally, methoxy
substitution of the pyridine ring was better tolerated in the thiopyranone
analog 210 (IC50 0.17 µM versus unsubstituted 208 IC50 0.11 µM) than the
cyclohexanone analog 201 (IC50 1.06 µM versus unsubstituted 25 IC50 0.22
µM).
Figure 3-7. (A) Regioisomeric preferences are Series dependent (B)Substitutent effects are Series dependent
In spite of the wider range of hydroxyl/methoxy substituents explored in
Series IV thiopyranones, only incremental improvements in activity were
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evident. Notably, the most promising thiopyranone 215 (R = 3-OH, 4-OMe;
IC50 0.38 µM) was marginally more active than the original hits 34 (IC50 0.51
µM) and 39/212 (IC50 0.69 µM).  On the other hand, di-OMe and tri-OMe
substitution resulted in exceptionally poor activities as seen from 213 (3,4-
OMe, IC50 3.23 µM) and 214 (3,4,5-OMe, IC50 3.82 µM).  The contrasting
activities of 213 and its 2,5-OMe regioisomer 39 was striking, pointing to a
preference for certain substitution patterns on the terminal rings. Again,
scaffold-dependent SAR was apparent as piperidinones bearing the same
dimethoxy/trimethoxy (47, 228, 229) groups retained outstanding
submicromolar activities. In fact, the tri-OMe substituted piperidinone 229
(IC50 0.10 µM) was the most potent member identified.
Figure 3-8: Methoxy substituted analogs in Series IV and VI
Compounds with asymmetrically substituted terminal phenyl rings were
investigated in Series III and IV. The design approach was employ groups that
were commonly encountered in round 1 actives. Fluoro was one such group
and it was retained on one phenyl ring (3-F) while oxygenated groups (OMe,
OH, di-OH, OH/OMe) were introduced on the other ring. Sadly, no apparent
activity advantage was observed among the asymmetrically substituted
analogs in either series vis-à-vis their symmetrically substituted counterparts.
The activity advantage of asymmetrically substituted thiopyranones (217-
220) over their cyclohexanone counterparts (202-205) was observed yet
again.
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The submicromolar actives identified in round 2 were generally equipotent
on both NB4 and NB4-R1 cell lines, with no more than 2-fold difference in IC50
values.  SAR trends were broadly similar on both cell lines. However, mention
should be made of the tri-OMe thiopyranone 214 which was unusually more
potent on NB4-R1 (IC50 0.16 µM) than NB4 (IC50 3.82 µM).
3.3.2. Anti-proliferative activity of curcumin and analogs on
leukemic non-APL cell linesTable 3-2. Mean growth inhibitory activity (IC50, µM)a and selectivity ratio(activity on non-APL versus APL) of compounds on two human non-APLcancer cell lines (HL60, K562).
Linker HL60d K562e
- CUR 3-OCH3, 4-OH 20 ± 2.8 19.9 ± 1.4 2.8
2 3-F 8.1 ± 1.3 7.5 ± 1.3 2.1
4 3-OH, 4-OCH3 5.3 ± 0.9 4.7 ± 0.6 1.5
5 3-OCH3, 4-OCH3 4.3 ± 1.3 8.3 ± 2.8 3.2








12 H 14 ± 0.5 14 ± 0.8 2.6
14 3-F 5.5 ± 1.5 6.1 ± 0.6 2.7
16 3-OH 2.3 ± 0.2 2.3 ± 0.9 1.7
17 4-OH >20f >20f >2
18 3-OCH3 15 ± 2.8 15 ± 0.8 1.8
19  4-OCH3 >20g >20g -
20 3-OH, 4-OH 9.2 ± 0.7 9.5 ± 0.7 3.8
21 3-OCH3, 4-OCH3 >20f >20f >3
22 3-OH, 4-OCH3 >20f >20f >3
23 3-OCH3, 4-OH 7.9 ± 1.9 9.0 ± 0.8 3.3
24 2-PY 0.18 ± 0.0 0.24 ± 0.1 1.0
25 3-PY 0.19 ± 0.0 0.29 ± 0.2 0.7
26 4-PY 0.46 ± 0.4 0.32 ± 0.2 1.1
201 3-PY-5-OCH3, 6-OCH3
2.3 ± 0.4 1.9 ± 0.2 2.0
206  3-F, 4-OCH3 14 ± 4.8 24 ± 2.5 3.1
202 R1 = 3-F, R2 = 3-OCH3, 4-OCH3 4.9 ± 1.8 4.3 ± 0.2 1.2
203 R1 = 3-F, R2 = 3-OH,4-OH 3.7 ± 0.7 2.8 ± 0.3 2.5
204 R1 = 3-F, R2 = 3-OH,4-OCH3 3.3 ± 0.1 3.8 ± 0.3 1.9








30 H 2.7 ± 0.3 2.4 ± 0.1 1.4
31 2-F 1.9 ± 0.1 4.1 ± 0.4 3.0
32 3-F 0.9 ± 0.1 1.7 ± 0.1 2.7
33 4-F 2.0 ± 0.02 3.3 ± 1.2 2.0
34 3-OH 0.93 ± 0.01 0.79 ± 0.3 1.6
35 4-OH 5.9 ± 2 4.9 ± 0.9 2.2
36 3-OCH3 6.5 ± 1 5.6 ± 0.7 2.0
37  4-OCH3 27 ± 3 16 ± 5.0 -
38 3-OH, 4-OH 18 ± 3 28 ± 0.9 3.5
207 2-Py 0.62 ± 0.2 0.65 ± 0.2 4.7
208 3-Py 0.60 ± 0.2 0.50 ± 0.05 5.0
209 4-Py >40f >40f -
210 3-PY-5-OCH3, 6-OCH3
0.92 ± 0.2 0.63 ± 0.2 3.6
211  3-F, 4-OCH3 4.05 ± 0.7 4.35 ± 0.2 0.8
212 3-OCH3, 4-OCH3 1.8 ± 0.2 1.4 ± 0.4 2.6
213 2-OCH3, 5-OCH3 4.3 ± 0.7 4.1 ± 1 1.7
214 3-OCH3, 4-OCH3,5-OCH3
1.0 ± 0.3 0.74 ± 0.07 0.4
215 3-OH, 4-OCH3 1.4 ± 0.2 0.77 ± 0.2 3.1
216 3-OCH3, 4-OH 2.6 ± 0.3 1.8 ± 0.10 3.1
217 R1 = 3-F, R2 = 3-OCH3, 4-OCH3 1.5 ± 0.5 0.84 ± 0.3 1.6
218 R1 = 3-F, R2 = 3-OH,4-OH 3.3 ± 0.9 1.9 ± 0.4 3.5
219 R1 = 3-F, R2 = 3-OH,4-OCH3 2.2 ± 0.2 1.7 ± 0.4 5.7
220 R1 = 3-F, R2 = 3-OH 1.4 ± 0.4 0.8 ± 0.2 3.5
Ref Substituents
Series IV
Compound Mean IC50 (µM) ± SDb Selectivity
Ratioc
Linker HL60d K562e
40 2-F 0.12 ± 0.0 0.14 ± 0.0 1.7
41 3-F 0.22 ± 0.02 0.15 ± 0.05 2.8
221 4-F 0.69 ± 0.2 0.43 ± 0.2 6.8
222 3-OCH3, 4-OCH3 0.52 ± 0.2 0.41 ± 0.06 4.2
223 2-OCH3, 5-OCH3 0.99 ± 0.3 0.50 ± 0.08 2.8
224 3-OCH3, 4-OCH3,5-OCH3
0.26 ± 0.09 0.31 ± 0.1 6.2
225 3-OH, 4-OCH3 0.71 ± 0.2 0.41 ± 0.02 3.4
226 3-OH 0.55 ± 0.2 0.49 ± 0.1 3.4
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aConcentration of compound required to inhibit cell growth by 50% relative
to control cells. bAnti-proliferative activity data from 3 independent
experiments, each experiment performed in triplicate. cSelectivity ratios
derived from mean IC50 of non-APL cell/mean IC50 of APL cell. dAML cell line.eCML cell line. fIC50 not determined above 20 µM or 40 µM due to insolubility
at these concentrations
All the compounds in Table 3-1 were assessed for their growth inhibitory
activities on leukemic non APL cells, K562 and HL60. As mentioned in Section
3.1, the hypothesis was that compounds that were more potent on APL cells
than non-APL cells owed their selective activity to  intercepting the
prosurvival misfolded N-CoR mechanism that is uniquely present in APL cells.
The benchmark for selective targeting of APL cells was based on the growth
inhibitory activities (IC50) of curcumin. Curcumin had very similar IC50 values
( 20 µM) on K562 and HL60 (Table 3-2). Hence, these values were averaged
and compared to the IC50 of curcumin on NB4 and NB4-R1. The latter were
also averaged so that a single selectivity ratio (IC50 HL60,K562 / IC50 NB4,NB4R1) was
obtained (2.85 for curcumin).  Growth inhibitory IC50 values of round 1 and 2
test compounds on APL /nonAPL cell lines were also averaged since they
were generally of the same magnitude (Table 3-2). The criteria for APL
selectivity was arbitrarily set at a ratio of > 3 for these compounds.
Analysis of the results in Table 3-2 highlighted the following points. First, only
25 of the 65 compounds (38%) had selectivity ratios exceeding 3. These
compounds were distributed across different series but were more prevalent
in certain series than in others (Table 3-3). For instance, Series II had
excellent representation since the only active in that series (11) complied
Linker HL60d K562e
42 2-F 0.19 ± 0.03 0.19 ± 0.01 0.6
43 3-F 0.16 ± 0.02 0.16 ± 0.02 0.9
44 4-F 0.17 ± 0.01 0.17 ± 0.03 0.6
45 3-OH 0.74 ± 0.1 0.71 ± 0.09 2.3
46 4-OH 24 ± 3 29 ± 2 1.9
47 3-OCH3, 4-OCH3 0.86 ± 0.06 0.89 ± 0.1 1.3
228 2-OCH3, 5-OCH3 0.83 ± 0.05 0.78 ± 0.1 2.8
229 3-OCH3, 4-OCH3,5-OCH3
0.41 ± 0.09 0.30 ± 0.09 3.5
230 3-OH, 4-OCH3 1.6 ± 0.4 0.89 ± 0.06 3.1
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with the selectivity criteria. In contrast, Series VI was poorly represented as
only 3 of the 10 actives met the threshold for selectivity. Overall, Series V
(thiopyranone dioxides) had the highest number (67%: 6 of 9) of selective
compounds, followed by Series IV (39%: 9 of 23).

































































a n represents total number of compounds in Series and comprise actives
from round 1 screening and compounds synthesized in round 2. Structures
are given in Table 3-1 and 3-2. bPY = pyridine. *Compounds that possess
submicromolar potencies on APL cells.
The 2nd observation pertained to the type of substituents found in selective
compounds. Table 3-3 shows a strong representation of oxygenated groups
(di-OMe, OH/OMe, diOH, tri-OMe). A closer analysis showed that compounds
bearing 3-OMe-4-OH ring substituents were present in Series III (23), IV (216)
and V (231) and all three compounds met selectivity criteria (ie 100% hit rate
for selectivity). A high selectivity hit rate was also noted for it regioisomer (3-
OH-4-OMe): It was present in Series I, III, IV, V, VI and except for the member
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in one Series I (4), the rest complied with selectivity criteria. On the other
hand, fluoro substituents had a poor hit rate, with only one (221) out of 10
mono-fluoro compounds (Series III-IV) associated with good selectivity.
Pyridine and asymmetrically substituted analogs did not fare better either –
only those in Series IV and not Series III complied with selectivity criteria. It
would seem that symmetrically substituted oxygenated groups enjoyed a
selectivity advantage, regardless of the type of scaffold present.
The 3rd point related to compounds that were both selective and had
submicromolar potency.  Here, only compounds (identified by * in Table 3-3)
in Series IV, V and VI met the necessary criteria. Clearly, the thiopyranone
dioxide scaffold of Series V was outstanding as all 6 compounds that met the
selectivity criteria also had submicromolar potencies.  The Series IV
thiopyranones fared just as well. The sole attrition (38) was selective but not
sufficiently potent.  The Series VI piperidinones may seem to be as good as
Series V but it should be noted that although there was no attrition, only 3
out of 10 compounds investigated complied with the stated criteria. The
other 7 compounds were potent but not sufficiently selective.
3.3.3. Anti-proliferative activity of curcumin and analogs on human
non-malignant cell lines
Selective growth inhibitory activity on malignant vis-a-vis non-malignant cells
is a desirable endpoint for early lead compounds. For this reason, several
compounds in Table 3-1 were evaluated for their effects on the viability of
two non-malignant human cell lines, lung fibroblast IMR90 and mammary
epithelial MCF10A (Table 3-12).  30 compounds were evaluated on IMR90
and of these, a smaller number (16) were assessed on MCF10A.  Compounds
screened included the potent and not so potent members of the various
series, symmetrically and asymmetrically substituted analogs, and
compounds bearing different terminal ring groups.
In keeping with its reputation for low toxicity, curcumin was significantly less
potent on both non-malignant cells with selectivity ratios (IC50 non-malignant /
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IC50 NB4) of 3.2 (IMR90) and 6.7 (MCF10A).  Gratifyingly, most of the
compounds in Table 3-4 had selectivity ratios that exceeded or were
comparable to that of curcumin on both IMR90 and MCF10A. A conspicuous
outlier was the trimethoxy analog in Series IV (214) which had an unusually
small ratio (based on IMR90) of 0.34, although its selectivity rebounded when
tested on MCF10A (ratio >5).  This was traced to its exceptionally low potency
on MCF10A (IC50 > 20 µM).   Generally, compounds had higher IC50 values on
MCF10A than IMR90 and hence greater selectivities when assessed on
MCF10A.Table 3-4. Mean growth inhibitory activity (IC50, µM)a of compounds onnormal human lung fibroblast (IMR90), non-tumorigenic humanmammary epithelial (MCF-10A)  and Selectivity ratios of non-malignantversus APL cells.
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aConcentration required to inhibit cell growth by 50% relative to control cells.
bAnti-proliferative activity data from 3 independent experiments, each
experiment performed in triplicate. c Selectivity ratios derived from  IC50 on
non-malignant cells/IC50 on APL cells. d Normal lung fibroblast cell line. e
Normal mammary epithelial cell line. f IC50 not determined due to solubility
problems. g Not determined. (*) are compounds that were APL selective and
had submicromolar potencies on APL cells (From Table 3-11).
Linker IMR90d MCF10Ae IMR90/NB4
MCF10A
/NB4
- CUR 3-OCH3, 4-OH 19.05 ± 2.38 >40f 3.17 6.66
Series I 2 3-F 10.30 ± 1.46 N.D.g 6.15 -
Series II 11 3-OCH3, 4-OCH3 >20d N.D.g >3 -
16 3-OH 6.54 ± 0.58 N.D.g 7.2 -
17 4-OH >20d N.D.g >8 -
20 3-OH, 4-OH >20d N.D.g >7 -
21 3-OCH3, 4-OCH3 >20d N.D.g >5 -
22 3-OH, 4-OCH3 >20d N.D.g >13 -
23 3-OCH3, 4-OH >10d N.D.g >5 -
25 3-PY 2.77 ± 0.90 N.D.g 12.5 -
203 R1 = 3-F, R2 = 3-OH,4-OH 8.80 ± 1.22 12.12 ± 1.65 6.42 8.85
32 3-F 2.35 ± 0.35 N.D.g 8.07 -
34 3-OH 1.33 ± 0.12 N.D.g 3.10 -
208* 3-Py 0.96 ± 0.13 5.34 ± 0.30 8.56 47.76
214 3-OCH3, 4-OCH3,5-OCH3
1.31 ± 0.38 >20f 0.34 >5
215* 3-OH, 4-OCH3 1.66 ± 0.10 1.94 ± 0.11 4.37 5.12
216* 3-OCH3, 4-OH 3.10 ± 0.72 7.64 ± 0.77 3.71 9.13
212 3-OCH3, 4-OCH3 2.53 ± 0.12 N.D.g 3.70 -
217 R1 = 3-F, R2 = 3-OCH3, 4-OCH3 3.02 ± 0.88 8.05 ± 0.91 3.21 8.57
218* R1 = 3-F, R2 = 3-OH,4-OH 2.42 ± 0.57 8.28 ± 0.76 2.69 9.19
219* R1 = 3-F, R2 = 3-OH,4-OCH3 4.22 ± 0.29 2.58 ± 0.46 8.71 5.32
41 3-F 0.84 ± 0.16 1.16 ± 0.11 13.68 18.79
221* 4-F 1.63 ± 0.43 0.67 ± 0.03 31.76 13.16
222* 3-OCH3, 4-OCH3 0.72 ± 0.12 0.54 ± 0.03 5.95 4.45
224* 3-OCH3, 4-OCH3,5-OCH3
0.70 ± 0.18 >5f 12.96 >90
227*  3-F, 4-OCH3 0.61 ± 0.19 0.89 ± 0.05 7.66 11.05
43 3-F 0.54 ± 0.08 N.D.g 3.45 -
45 3-OH 0.62 ± 0.03 N.D.g 3.50 -
229* 3-OCH3, 4-OCH3,5-OCH3
0.55 ± 0.03 0.58 ± 0.04 5.48 5.76
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In Section 3.3.2, 17 compounds were identified to have submicromolar IC50
values and APL selectivities exceeding that of curcumin. Only 11 of these
compounds were assessed for growth inhibitory effects on IMR90 and
MCF10A. Based on a selectivity ratio threshold of 4 (IC50 IMR90/IC50 NB4) and 7
(IC50 MCF10A/IC50 NB4), these thresholds were met by only five compounds
(Figure 3-9). The strong representation of compounds from Series V
thiopyranone dioxides should be noted. In fact, of the 5 compounds in Series
V evaluated on IMR90 and MCF10A, all had selectivity ratios that exceeded
the set thresholds. However, only 4 are represented in Figure 3-9 because
the sole omission (41) was only comparable to in terms of APL versus non-
APL selectivity (Table 3-10).
Figure 3-9: Compounds with selectivity ratios (IC50 IMR90/IC50 NB4) > 4and (IC50 MCF10A/IC50 NB4) > 7, submicromolar IC50s on APL cells andAPL versus non-APL selectivities (selectivity ratios>3).
3.4. Discussion
The objective of this chapter was to identify compounds that were more
potent and had greater selective growth inhibitory activity (APL versus non
APL cells, APL versus non malignant cells) than curcumin. As described in
Results, this was achieved over two rounds of synthesis and screening, in the
course of which useful SAR was deduced for potency and selectivity.
With regards to growth inhibitory activity on APL cells, a high proportion of
the synthesized compounds (60 out of 65 or 92%, Table 3-1) were more
potent than curcumin. Features that were unfavorable for activity were a
functionalized ketone carbonyl (based on poor activities of oximes) and
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monocarbonyl (Series I) or cyclopentanone (Series II) as central
linkers/scaffolds.  Features that favored activity were duly identified for
terminal rings and central scaffolds. Substituents commonly found in
compounds with submicromolar activities were fluoro, pyridinyl (in place of
phenyl), OH/OMe, di-OMe, tri-OMe and 3-OH. Scaffolds strongly associated
with submicromolar activities were thiopyranone dioxide, piperidinone and
thiopyranone. Invariably, this raised the question as to which feature was
more important for activity – the terminal rings and their subsitutents, the
central scaffold or both? The present results point to a more decisive role for
the scaffold. The most compelling evidence to support this notion comes
from a comparison of scaffolds bearing similar ring substituents. Numerous
examples based on rings substituted with 3-F, 4-F, 3-OH, 3,4-diOMe, 3-OH-4-
OMe, 3-OMe-4-OH, 3-F-4-OMe, Tri-OMe and found in 3 or more series,
showed that activity was scaffold driven. A similar observation was evident
among compounds with asymmetrically substituted terminal rings but these
were represented by only two series (III and IV). Taken together, the
preferred scaffold was thiopyranone dioxide (Series V), followed by
piperidinone (Series VI) and thiopyranone (Series IV).  This evidence
notwithstanding, there were observations that point to an equal if not more
important role for the terminal rings. Compounds with terminal pyridine rings
were a case in point. These compounds were the most potent in both Series
III and IV, with closely matched IC50 values regardless of scaffold. Another
instance related to the different activities of regioisomers within the same
series. This was most frequently encountered in Series IV, and involved 3-OH
versus 4-OH, 2-and 3-pyridinyl versus 4-pyridinyl, 3-OMe versus 4-OMe, 3-F
versus 2- and 4-F. Curiously, the potencies of F regioisomers did not differ in
Series V and VI. It is tempting to speculate that both scaffold and terminal
ring substitution may contribute to activity in some series (like IV) but not in
others (like V).  The alternative view is that if more compounds were
investigated in each series, regioisomeric effects would probably be
observed. Notably, Series V was a small series with only 9 compounds
whereas Series IV had more than twice this number.
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Among the many curcuminoids investigated in the literature, the
piperidinone EF24 (Figure 1-11) stands out as the most promising pre-clinical
candidate70,81, 82 and was also investigated in this thesis as compound 42. It is
worth noting that thiopyranone dioxide 41 (IC50 0.06 µM) of series IV remains
three times more potent than 42 (EF24, IC50 0.29 µM).
Besides potency, another desired endpoint was APL selectivity. Here, an
interesting observation was that when benchmarked against curcumin, the
present series of compounds were more potent than APL selective. Of the 65
compounds listed in Table 3-2, only 25 (38%) were more APL selective than
curcumin. It is worth noting that 42 (EF24) was not one of the 25 compounds
that was more APL selective than curcumin. Of the 65 compounds evaluated,
60 (92%) were more potent than curcumin. Therefore, of the 34 compounds
with IC50 NB4/NB4R1 < 1 µM (submicromolar actives, Table 3-1), only 17
complied with the APL selectivity criteria (Table 3-11). Hence, a more cogent
SAR for potency and selectivity could be derived from these results and is
discussed as follows.
With regards to scaffold, the thiopyranone dioxide in Series V was highly
favored for both properties. Of the 9 compounds in this series, 6 complied
with the set thresholds for potency (submicromolar IC50) and selectivity (>3).
Of the 3 compounds that were not included (all of which had nanomolar
potencies), two (41, 223) were excluded because their selectivities were just
comparable to curcumin. In the case of the piperidinones of Series VI, 9 of 10
compounds had nanomolar potencies but only 3 compounds had the
required selectivity. Thus the “hit rate” for potency and selectivity in Series VI
was only 30% (3 out of 10).  Clearly, the piperidinone scaffold was more
strongly associated with potency than selectivity.  The thiopyranones of
Series IV had the largest number (8) of potent and selective analogs but
compared to the number of submicromolar actives in this series (13), the “hit
rate” (62%) was no better than that achieved in Series V (67%).
An analysis of substituents associated with APL selectivity revealed a
predominance of oxygenated substituents (Table 3-3) but when jointly
considered with potency, optimal substituents were not so readily identified
102
because of the overaching influence of the scaffold. Thus, fluoro was
uniquely favored in Series V, pyridine rings in Series IV, and oxygenated
substituents in Series IV and VI.
Based on the present results, growth inhibitory selectivity for APL versus non-
malignant cells could not be comprehensively discussed since it was
investigated for only selected compounds.  Notwithstanding, it was apparent
that the compounds had low toxicities on non-malignant cell lines that were
comparable or exceeded that of curcumin. More importantly, several of the
compounds shortlisted for submicromolar potencies and APL selectivities had
minimal growth inhibitory effects on the non-malignant cell lines.
3.5. Conclusions
The main findings from this chapter are summarized as follows:
(i)  A large proportion of compounds explored in this chapter had greater
growth inhibitory potencies than curcumin on APL cells  (92%) but a smaller
number (38%) were associated with selective APL (versus non-APL) growth
inhibitory potencies project.
(ii) Series V which had thiopyranone dioxide as the central scaffold was an
outstanding motif associated with submicromolar potencies and selective
activities on APL cells. These properties were largely scaffold dependent and
influenced to a lesser extent by the terminal ring substitution.
(iii) Series VI which had piperidinone as the central scaffold was more
strongly associated with submicromolar potencies than APL selective
activities.
(iv) Series IV which had thiopyranone as the central linker ranked lower than
Series V and VI in terms of potency but had a better selectivity profile than
Series VI. Differences in the activities of regioisomers were prevalent in this
Series which may imply that potency/selectivity profile was not only
determined by the scaffold but by the terminal rings as well.
(v) SAR for potency and selectivity is schematically depicted in the following
figure:
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Figure 3-10: Structure-activity relationship for potency andselectivity in Series I-IV compounds
(vi) Compounds with submicromolar potencies and APL selective growth
inhibitory activities (compared to non-APL and non-malignant cells) were
successfully identified. These compounds were 208 (Series IV), 221, 224, 227
(Series V) and 231 (Series VI).
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Chapter 4: Curcumin and analogs upregulate misfolded N-
CoR in APL
4.1. Introduction
In Chapter 3, the synthesized compounds were evaluated for their growth
inhibitory activities on APL cells (NB4, NB4-R1) and non-APL cells (K562,
HL60). Compounds that targeted APL cell growth were hypothesized to exert
their effects by intercepting the prosurvival misfolded N-CoR pathway.
Hence, these compounds were anticipated to increase levels of misfolded N-
CoR to the point that the pro-apoptotic UPR was triggered and APL cells
succumbed to apoptosis.  Curcumin was reported to promote accumulation
of misfolded N-CoR by blocking its degradation by N-CoR specific proteases
and the proteasome.19 Here, it is proposed that compounds with greater
potency and APL-selectivity than curcumin would require lower
concentrations to induce accumulation of misfolded N-CoR. To investigate
this hypothesis, the following experiments were carried out: (i)
Determination of N-CoR levels in NB4 cells exposed to APL selective and APL
non-selective compounds; (ii) Determination of the localization in N-CoR in
cellular compartments; (iii) Evaluation of the inhibition of OSGEP (a
glycoprotein endopeptidase that specifically cleaves N-CoR) and 26S
proteasome by selected compounds.  If APL selective compounds do indeed
intercept the misfolded N-CoR pathway, they would (i) increase the levels of
N-CoR in NB4 cells; (ii) promote cytoplasmic localization of N-CoR and (iii)
inhibit OSGEP and/or 26 proteasome.
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1X SDS Running buffer 25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS
1X Transfer buffer 48 mM Tris, 39 mM glycine, 0.037 % SDS, 10% methanol (added fresh)
4X SDS Sample buffer
250 mM Tris-HCl pH 6.8, 40 % glycerol, 9.2 %
SDS, 0.01 % bromophenol blue, 20 % β-
mercaptoethanol
PBS-T 1X PBS, 0.1 % (v/v) Tween-20
Milk blocking buffer 5 % (w/v) skim milk powder in PBS-T
Coomassie Blue staining
solution
0.25 % Coomassie Blue, 10 % (v/v) acetic acid,
50 % (v/v) methanol
Anti-N-CoR goat polyclonal
antibody 1:500 dilution in 2.5 % milk/PBS-T
Goat anti-rabbit IgG, HRP
conjugate 1:10 000 dilution in 2.5 % milk/PBS-T
4.2.2. Cell treatment and lysis using SDS sample buffer
NB4 cells were seeded in a T75 culture flask at 105 cells/mL in RPMI-1640
media containing a known concentration of test compound. Final
concentration of DMSO in the flask was maintained at 0.5% v/v. Treated cells
were incubated at 37 ˚C in a humidified 5 % CO2 atmosphere for 48 h after
which they were transferred to a 50 mL Falcon tube, pelleted by centrifuging
(200 g,  5 min) and washed once with ice-cold 1x PBS. The cells were
transferred to a microcentrifuge tube. 4 times the cell pellet volume of 2x
SDS sample buffer was added. The cells were sonicated on ice (Branson
Sonifier 150), with an output power of 5 W (3 x 10 sec). The protein samples
were denatured by heating at 50 ˚C, 10 min. Crude lysates were stored at -80
˚C.
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4.2.3. Sodium dodecyl sulfate - polyacrylamide gel electrophoresis
(SDS-PAGE)
SDS-PAGE resolving gels of various percentages and 5% of stacking gel were
prepared as stated below.
Resolving gel Stacking
gel
6 % 8 % 10 % 12 % 5 %
Autoclaved H2O
(mL)
5.3 4.6 4.0 3.3 6.8
30 % acrylamide
(mL)
2.0 2.7 3.3 4.0 1.71
1.5M Tris pH 8.8
(mL)
2.5 2.5 2.5 2.5 1.25
(pH 6.8)
10% APS (mL) 0.1 0.1 0.1 0.1 0.1
TEMED (µL) 8 6 4 4 10
Total volume (mL) 10 10 10 10 10
For the detection of N-CoR protein band at 270 kDa, protein lysates were
separated on a 6 % resolving gel at 4 ˚C. Electrophoresis was carried out at a
gradient current of 10 -15 mA for the 1st hour and at a constant current of 15
mA for the subsequent hours. After electrophoresis, the gel was used for
Coomassie staining or Western blotting.
4.2.4. Western blotting
Separated protein samples were  transferred to pre-wetted PVDF
membranes using a wet transelectroblotting system (Bio-Rad Inc., England) at
a constant current of 75 mA (120 min, 4˚C) using transfer buffer. Methanol
(10 % v/v) was added to the transfer buffer prior to use. The membrane was
blocked with 5 % milk in PBS-Tween (PBS-T) for 1 hr, 25 ˚C followed by
incubation with N-CoR (C-20) primary antibody in 2.5 % milk in PBS-T
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overnight, 25 ˚C. The membrane was washed with PBS-T (3x, 10 min per
wash) and incubated with horseradish peroxidase-conjugated secondary
antibody in 2.5 % milk in PBS-T (1 hr, 25 ˚C). The unbound secondary
antibodies were removed by washing with PBS-T (8x, 5 min per wash). The
immunoreactive bands were detected by Western Lightning
Chemiluminescence Reagent Plus (Perkin Elmer) using a Konica Minolta SRX-
101A film processor.
4.2.5. Coomassie blue staining
SDS-PAGE was carried out using the same lysate volume ratio used in
Western blot to monitor loading control. Resolving and stacking gels of 10 %
and 5 % respectively were prepared. Electrophoresis was carried out at a
constant current of 10 mA in cold 1x running buffer (4 ˚C) after which the gel
was stained with Coomassie Blue.
4.2.6. Immunofluoescence
Treated NB4 cells were incubated at 37˚C in a humidified 5 % CO2
atmosphere for 48 h. After incubation, the suspension cells were cytospun
onto glass slides (1000 rpm, 5 min, Shandon Cytospin 4). The cells were
washed with 1x PBS, fixed with 4 % paraformaldehyde in 1x PBS (freshly
prepared and pre-warmed to 37oC) for 20 min, 37oC, washed thrice with 1x
PBS and permeabilized using 0.2 % Triton X-100 in 1x PBS at 4 ºC, 5 min. The
fixed cells were washed thrice with 1x PBS, blocked with 5 % bovine serum
albumin (BSA) in 1x PBS for 30 min, 25 ˚C, incubated with N-CoR (C-20)
primary antibody in 2.5% BSA in 1x PBS (overnight, 25 ˚C) and then washed
with 1x PBS (3x, 5 min). Cells were then incubated (1 h, 25 ˚C) with Alexa
Fluor secondary antibodies (Molecular Probes, Eugene, OR) prepared at a
dilution of 1:200 in 2.5% BSA in 1x PBS. They were then washed thrice with 1x
PBS and stained with 6-diamidino-2-phenylindole (DAPI) (150 nM in 2.5% BSA
in 1x PBS) for 5 min, washed thrice with 1x PBS, mounted with SlowFade®
Gold antifade reagent (Molecular Probes, CA) and sealed with nail polish.
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Visualization was carried out with Axioplan 2 imaging fluorescence
microscope (Carl Zeiss).
4.2.7. Thermal shift assay
The assay was carried out on a Cycler iQ5 Real Time Detection System (Bio-
Rad, Hercules, CA) which contained a heating and cooling device for accurate
temperature control and a charge-coupled device detector for simultaneous
measurement of fluorescence intensity in a 96-well unskirted low profile PCR
plate.  Mixtures containing 10 mM Tris buffer pH 7.4, OSGEP (2µM), test
compounds at respective concentrations (0.5% DMSO) and Sypro® Orange
dye (final 5X) were prepared over ice. Freshly prepared Sypro Orange dye
was the last reagent to be added before the plate was heated (5 to 100˚C,
heating rate 0.5˚C/min). The fluorescence intensity was measured at
excitation and emission wavelengths of 490nm and 530nm respectively. The
melting temperature of each run was evaluated using Boltzmann sigmoidal
equation, GraphPad Prism (Version 3.0, GraphPad Software, San Diego, CA).
Each concentration of test compound was evaluated in triplicate for each run
and the assay was carried out on at least two separate occasions using two or
more freshly prepared stock solutions of test compound.
4.2.8. Surface plasmon resonance (SPR) assay
Biacore 3000 (Biacore, Uppsala, Sweden) was used for determination of real-
time protein-ligand interaction. OSGEP (100 µg/mL) in 10 mM NaOAc pH 4.5
was immobilized on a CM5 sensor chip by amine coupling, following
manufacturer’s instructions. Binding analysis was carried out using 10 mM
HEPES pH 7.4 containing 0.5% DMSO as running buffer at a flow rate of 10
µL/min. Compounds at 100 µM were injected at 20 µL/injection. Surface was
regenerated with 10mM NaOH, 5µL injection, 2 pulses of 10sec each, flow
rate of 30µL/min followed by stabilization with running buffer. In total, each
run comprises 2min contact time, 3.5min dissociation time, 2 times
regeneration and 4min stabilization time. In total each run lasted
approximately 10min. Analysis was carried out using BIAevaluation 3.1
software (Biacore).
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4.2.9. Determination of 20S proteasomal inhibition
The human 20S proteasome was tested at 2 nM, 0.5 nM and 1 nM for trypsin-
like, chymotrypsin-like and caspase -like activities respectively. Substrates were
Boc-Leu-Arg-Arg-AMC (4µM) for trypsin-like, Z-Gly-Gly-Leu-AMC (20µM) for
chymotrypsin-like and Z-Leu-Leu-Glu-AMC (10µM) for caspase-like activity.
Assay buffer comprised Tris-HCl buffer (20mM, pH 8.0), EDTA (0.5mM) and
SDS (0.03%v/v).  Reactions were initiated by substrate addition (40µL) made
immediately (0h) or after 2 or 4h incubation of proteasome (50µL) and test
compound (10µM, 0.5% DMSO) at 37˚C. The release of the fluorescent tag
AMC on hydrolysis of substrate was monitored for 15 min at λex 360nm and
λem 460nm (25˚C) on an Infinite® 200 microplate reader (Tecan). Inhibition of
proteasomal activity was determined from the reaction velocities (gradients)
of treated and control/untreated proteasome activities between 0 and
15min. % = ( ) ( )( ) 100 %
The assay was carried out on three or more separate occasions using at least
two freshly prepared stock solutions of test compound.
4.2.10. Inhibition of 26S proteasome activity in NB4 cells
NB4 cells were seeded at 105 cells/mL and treated with a known
concentration of test compound (final concentration of DMSO, 0.1 %).  After
incubation (37 ˚C, humidified 5 % CO2, 48 h), the cells were transferred to a
50 mL Falcon tube, pelleted by centrifuging (200 g,  5 min) and washed twice
with ice-cold 1x PBS. The cells were then transferred to a microcentrifuge
tube and 4 times the cell pellet volume of cell lysis buffer (Sigma Aldrich
C2978) was added. The cells were subjected to gentle homogenization using
27G needle and syringe and allowed to stand over ice with frequent agitation
for 30 min. The lysates were centrifuged at 10,000 rpm, 5min, 4˚C. Protein
concentration in the supernatant was determined and normalized using BCA
protein assay kit (Pierce Laboratories, IL, USA).
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The same AMC-tagged substrates (Section 4.2.8) were used and at
concentrations corresponding to their Km values, 60 µM for trypsin-like, 50
µM for chymotrypsin-like and 30 µM for caspase-like activities.  Km for each
subunit was determined by measuring the rate of hydrolysis of substrate over
the concentration range 4µM to 200µM with 2µg (10µL) of protein lysate.
The Km and Vmax of each substrate was calculated using the Michaelis-
Menten equation. Proteasomal activity was determined using freshly
prepared cell lysates (2 µg in 10µL per well). Reactions were initiated by
substrate addition (90 µL) and the release of the fluorescent tag on substrate
hydrolysis was monitored for 1h at λex 360nm and λem 460nm (25˚C) on an
Infinite® 200 microplate reader (Tecan). Inhibition of proteasomal activity
was determined from the reaction velocities (gradients) of treated and
untreated proteasome activities as described in Section 4.2.8. The assay was
carried out on at least three separate occasions using two or more freshly
prepared stock solutions of test compound.
4.2.11. High content screening of NF-κB translocation in NB4 cells
NB4 cells were seeded in 384-well plate (Costar 3712) at 5 x 104 cells/well
and incubated at 37˚C in a humidified 5% CO2 atmosphere overnight.
Compounds at their respective concentrations (0.5µL) were added followed
by 30min incubation. TNF-α (BD Biosciences, Bedford, MA) (50ng/mL) was
added to stimulate NF-κB cell signaling pathway followed by incubation for
30min. The 384-well plate was centrifuged at 800rpm, 5min before careful
removal of media. Cells were fixed with 4 % paraformaldehyde in 1X PBS at
25˚C for 30min. Cells were rinsed with 1X PBS (3 x 5min) and the plate was
centrifuged in between washing steps to reduce loss of cells. Cells were
permeabilized with 0.1% Triton-X-100 in 1X PBS at 25˚C for 30 min and rinsed
with 1X PBS (3 x 5 min). NF-κB primary antibody was added (25 µL, 1:250
dilution in 1 % BSA/PBS, Santa Cruz SC-372, rabbit) and the plate was
incubated overnight with gentle orbital shaking at 4 ˚C. The cells were rinsed
with 1X PBS (3 x 5min) followed by addition of secondary antibody (25 µL,
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1:500, goat anti-Rabbit IgG conjugated to Alexa Fluor 488) with Hoechst dye
(1µg/mL) in 1% BSA in 1X PBS for 1 h at 25 ˚C. Cells were rinsed with 1X PBS
(3 x 5 min) followed by addition of 1X PBS (60 µL / well). The 384-well plate
was centrifuged at 800 rpm, 5 min before it was sealed and imaged using an
automated imaging system, ImageXpress5000A (Molecular Devices).
Fluorescence of Hoescht dye was measured at λex 358nm and λem 461nm
respectively while the corresponding wavelengths for measuring the
fluorescence of Alexa Fluor 488 were λex 495nm and λem 519nm.
Fluorescence intensities of Alexa Fluor 488 which corresponded to NF-ĸB
levels were measured from cells (nuclei) in four wells per treatment condition
to give the mean value which was used for the determination of % NF-ĸB
translocation by the following expression:
% NF-ĸB translocation = ( [FI Test compound + TNFα - FI background]  /  [FI TNFα – FI
background] ) x 100
The extent of NF-κB translocation was expressed as a % of the fluorescence
intensity (FI) of NF-ĸB in treated cells (FI test compound + TNFα) relative to FI of NF-
ĸB in cells treated with TNFα only (FI TNFα). Measurements were normalized
against control cells not exposed to TNFα (FI background). % NF-ĸB translocation
values were plotted against concentration of test compound to give a
sigmoidal curve for the derivation of IC50. IC50 was reported as mean ± SD of
at least 3 independent determinations.
4.3. Results
4.3.1. Determination of N-CoR levels in NB4 cells exposed to APL selective
and APL non-selective compounds
These experiments were carried out early in the author’s candidature. Hence
only round 1 compounds were selected based on their growth inhibitory IC50
on NB4 cells and APL versus non-APL growth inhibitory selectivities. The
chosen compounds (11, 22, 25, 41 and 42) covered a range of APL
selectivities and potencies (Figure 4-1). In terms of growth inhibitory
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potencies, all the compounds (except 11) were more potent than curcumin.
They were also APL selective, except 25 and 42.
Figure 4-1: Structures of APL selective (11, 22, 41) and APL non-selective(25, 42) compounds. Selectivity ratio = IC50 APL /IC50 non-APL (Table 3-2).
IC50 NB4 and selectivity ratio of curcumin: 6.01 µM and 2.85 respectively
As stated in Section 1.2.2. and 1.2.3., full length (intact) N-CoR was either
natively folded (detergent soluble) or misfolded (detergent insoluble). In NB4
cells, N-CoR existed predominantly as cleaved fragments (detergent soluble),
with some in the natively folded state and very little in the misfolded state.17
When treated with curcumin,  the levels of cleaved N-CoR was dramatically
reduced and N-CoR was found predominantly in its intact misfolded state.19
Here, levels of full length N-CoR in NB4 cells were probed by western blotting
with anti-N-CoR antibody.
As seen in Figure 4-2, control/untreated cells accumulated negligible
amounts of full length N-CoR.  Unfortunately, fragmented N-CoR could not be
detected in these experiments. When treated with curcumin (1 to 10 µM),
full length N-CoR bands were observed at 2 M and 5 M but not at 10 µM
(Figure 4-2A, B), possibly due to curcumin-induced cell death at this
concentration (IC50 of curcumin: 6.01 µM). These findings confirmed that
curcumin stabilized full length N-CoR at concentrations close to its IC50, in
keeping with earlier reports.19
When NB4 cells treated with 11, 22 and 41 were probed for N-CoR, full length
N-CoR bands were observed at concentrations that were significantly lower
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than the growth inhibitory IC50 of the test compounds. As seen from Figure 4-
2C, discernible N-CoR bands were observed in blots obtained from cells
treated with 11 at 0.5 µM, 1 µM and 2 µM, but not at 4 µM which was close
to its IC50 (6.76 ± 1.15 µM). In the case of cyclohexanone 22 (IC50 1.53 µM), N-
CoR bands were detected at 37.5 nM, 75 nM and 150 nM, with diminishing
intensities. (Figure 4-2D). As for cells treated with thiopyranone dioxide 41
(IC50 60 nM), the N-CoR band was most intense at 5 nM and diminished
steadily at 25 nM and 50 nM. Thus, the APL selective compounds (curcumin,
11, 22, 41) increased levels of full length N-CoR in NB4 cells at concentrations
that were at least 10 x lower than their IC50s.
When NB4 cells were treated with non-APL selective compounds (25, 42), the
presence of full length N-CoR was not detected at concentrations
approximating to the IC50 of test compound. Piperidinone 42 (IC50 0.29 µM)
was tested over a range of concentrations (0.15 µM – 0.60 µM) (Figure 4-2F)
while the cyclohexanone 25 (IC50 0.19 µM) was tested at 0.1 µM and 0.2 µM
(Figure 4-2B).  In both instances, N-CoR levels could not be detected.  Thus,
there is support for the notion that accumulation of full length N-CoR was
associated only with analogs that selectivity targeted APL cells.
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Figure 4-2. Curcumin and APL selective test compounds 11, 22 and 41caused a dose-dependent increase in full length N-CoR (MW 270 kDa)levels in NB4 cells. Non-APL selective compounds 25, 42 did not increaseN-CoR levels under similar conditions. NB4 cells were treated with vehicle
(DMSO) or respective concentrations of drug over 48 hours. Level of N-CoR
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was determined with anti-N-CoR antibody and level total protein was
relatively quantified by Coomassie staining.
4.3.2. N-CoR accumulated is in the misfolded state
It is known that natively folded N-CoR localizes in the nucleus unlike
misfolded N-CoR which is found in the cytosol.17 The localization of N-CoR in
the nuclear/cytosolic compartments is readily visualized by in vitro
immunofluorescence imaging. This method is more sensitive than the
western blot method of monitoring N-CoR levels (Section 4.3.1.). A non-
selective polyclonal anti-N-CoR antibody was used to probe N-CoR in western
blotting and this gave rise to blots with high background intensities and
poorly resolved N-CoR bands. In the imaging method, N-CoR was tagged to a
primary anti-N-CoR antibody which was then linked to a secondary antibody
carrying a red fluorescent probe. The location of N-CoR was then tracked by
monitoring the fluorescence probe.  At the same time, the cells were stained
by DAPI which strongly binds to nuclear DNA, imparting a bluish fluorescence.
If N-CoR was localized in the nucleus, its red fluorescence would overlap with
the blue DAPI fluorescence to give a purplish appearance to the cells. If N-
CoR was localized in the cytosol, a ring of red fluorescence would be
observed around the DAPI-stained nuclei.
Figure 4-3 shows muted red fluorescence in control NB4 cells in keeping with
low basal levels of intact N-CoR. The merged panel showed cells with weak
bluish purple fluorescence, suggesting that the N-CoR was retained in the
nucleus. When treated with curcumin at 5 µM and 10 µM, the red N-CoR
fluorescence intensified signifying an increase in N-CoR levels (middle panel,
Figure 4-3A). The expressed N-CoR was also increasingly localized in the
cytosol as seen from the red rings that appeared around the DAPI-stained
nuclei (merged panel). Cells treated with 11, 22 and 41 showed similar results
(Figure 4-3B–D) but at different concentrations which interestingly,
corresponded closely to those used to increase N-CoR levels in the western
blots (Figure 4-2). Thus, the results supported the notion that APL-selective
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compounds promoted the accumulation of misfolded N-CoR in the cytosolic
compartment of NB4 cells.
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Figure 4-3. Curcumin and APL selective test compounds 11, 22 and 41induced the localization of N-CoR in the cytosol of NB4 cells in a dose-dependent manner. NB4 cells were treated with vehicle (DMSO) or
respective concentrations of drug over 48 hours. Cells were cytospun on glass
slides, fixed and stained with N-CoR antibody (red). DNA was stained with
DAPI (blue).
4.3.3. Investigations on the interaction of curcumin and APL
selective compounds 11, 22 and 41 with O-Sialoglycoprotein
endopeptidase (OSGEP).
OSGEP is a protease that is selectively expressed in APL cells to cleave
misfolded N-CoR.17 It was reported that the activity of N-CoR cleaving
proteases were significantly reduced in curcumin-treated NB4 cells19 and
although not mentioned specifically, one of these proteases would include
OSGEP. In this section, the APL selective compounds were investigated for
OSGEP inhibition by two biophysical techniques - thermal shift assay and
surface plasmon resonance.
The thermal shift assay monitors the change in melting temperature
(unfolding transition temperature, Tm) of a protein in the presence of a
ligand Sypro Orange. Sypro Orange is strongly fluorescent in environments
with low dielectric constant. When the protein is normally folded, Sypro
Orange is enclosed in a polar (high dielectric constant) environment and does
not fluoresce. When the protein is at its melting temperature, it unfolds to
expose its hydrophobic core and in this non-polar environment, the
fluorescence of Sypro Orange increases. If a compound binds to the protein,
the protein is stabilized and will melt at a higher temperature. This
temperature (Tm) can be determined by monitoring the fluorescence of
Sypro Orange.
Figure 4-4 shows the change in Sypro Orange fluorescence when OSGEP was
progressively heated. Fluorescence peaked at two temperatures indicating
that OSGEP had two unfolding transition states (33˚C and 63˚C), a
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phenomenon also observed for several other proteins.108 When the melt
curve of OSGEP was repeated in the presence of different concentrations of
curcumin (5, 10, 20, 50 µM), OSGEP now had only one Tm which shifted to
higher temperatures with increasing concentrations of curcumin (Figure 4-
5A). The increase in Tm with concentration was linear (Figure 4-5B).  When
the experiment was repeated in the presence of 41 (1-50 µM), no significant
shift in the melt curve of OSGEP was observed even at the highest
concentration (Figure 4-5C, D). Similar results were obtained with 11 and 22
(data not shown).  These findings indicated a stabilizing binding interaction
between OSGEP and curcumin as shown from the concentration dependent
increase in Tm. Such an interaction may lead to inhibition of OSGEP by
curcumin. On the other hand, the APL selective compounds did not cause a
change in the Tm of OSGEP and were unlikely to bind to OSGEP.
Figure 4-4. Melt curve of OSGEP showing two-phase unfolding transition
states. Mean and SD for three independent experiments.
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Figure 4-5. Melt curves of OSGEP in the presence of curcumin (5-50 µM) and
41 (1-50 µM). Average of two determinations.
The thermal shift assay is not without limitations. First, the shift in Tm (ΔTm),
the magnitude of which indicates the extent of ligand-protein interaction,
does not actually correlate to binding affinity if the binding enthalpy of the
ligand is not known (as in the present case). Second, it is assumed that the
ligand binds only to the folded state and not the unfolded state of the
protein. If it binds to both folded and unfolded states, the observed ΔTm will
be small, and the ligand wrongly dismissed as a non-binder (ie false negative).
In view of these limitations, a 2nd method was used to investigate the
interaction of test compounds with OSGEP. Surface plasmon resonance (SPR)
was selected because of its success in investigating protein-small molecule
binding. It is based on the change in refractive index of the solution at the
surface of a sensor chip. Monochromatic plane polarized light is reflected at
the gold-coated chip surface at an angle called the SPR angle. The SPR angle
changes with the refractive index of the solution bathing the surface of the
sensor chip. The protein under investigation is immobilized onto the surface
of the chip and exposed to a solution of the test compound. If the compound
binds to the immobilized protein, there will be a change in the refractive
index and the SPR angle (reported in resonance units, RU).109 The limitations
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of the SPR are that immobilization of the protein to the sensor chip may alter
or mask the active site and render it inaccessible to the ligand. The protein
may also undergo changes during the course of the assay due to the need to
regenerate the protein surface after each determination. This process
involves exposing the surface to harsh chemicals like strong bases which may
destroy the integrity of the protein.
In this assay, OSGEP was immobilized on a CM5 sensor chip by amine
coupling followed by injection of test compound. Interactions with the
immobilized protein were monitored in real-time by a sensogram which
provides information on the association and dissociation of the protein-ligand
complex. Consistent with the findings from the thermal shift assay, curcumin
was found to bind to OSGEP with a slow association and slow dissociation
profile (Figure 4-6). On analysis, the binding profile fitted a 1:1 Langmuir
model. However, high concentrations of curcumin (at least 100 µM) were
required for binding to OSGEP. The sensograms of the APL selective
compounds (11, 22, 41) did not show evidence of binding to OSGEP (data not
shown). Taken together, these findings support the view that curcumin but
not the APL selective compounds interacted with OSGEP.
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Figure 4-6. Sensogram depicting association and dissociation of curcumin
(100 µM) to OSGEP
4.4. Investigations on the inhibition of 20S proteasome by
curcumin and APL selective compounds 11, 22 and 41.
Having shown that the APL selective compounds did not interact with OSGEP,
investigations on their ability to inhibit the purified human 20S proteasome
was initiated. The 20S subunit is the catalytic core of the 26S proteasome and
comprises four heptameric rings stacked together in a cylindrical structure.
The three catalytic subunits of the proteasome are located in the two inner
rings, namely β1 (caspase-like), β2 (trypsin-like) and β5 (chymotrypsin-like).
The assay was carried out on substrates that were specifically cleaved by
each of the catalytic subunit. Each substrate was tagged with a fluorogenic
probe (7-amino-4-methylcoumarin, AMC) which was released when the
substrate was hydrolyzed by the catalytic unit.90, 110 Briefly, the 20S
proteasome was exposed to test compound (10 µM) followed by addition of
substrate immediately (0 h), or after an incubation period of 2h or 4h.
Hydrolysis of the substrate was accompanied by an increase in fluorescence
which was monitored for 15 min.  As this increase was almost linear, the
gradient was determined and compared to that of the control to give a ratio
which provided a measure of the residual activity of the catalytic subunit. The
results are presented in Figure 4-7.  Figure 4-7A1 – C1 show fluorescence
versus time plots for the hydrolyses of substrates by the various proteasomal
catalytic subunits after 2 hours incubation with test compound. Figure 4-7A2
– C2 summarize the % inhibition of each subunit by test compounds after
different incubation periods.
Broadly, inhibition by test compounds was affected by the incubation period
(0, 2, 4 h) and the catalytic subunit investigated. The inhibition by curcumin
showed little variation over time for trypsin and caspase-like subunits but
diminished somewhat with time for the chymotrypsin-like subunit. For the
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same incubation period, curcumin inhibited the trypsin subunit least, as
reported in the literature.19, 90, 94, 111 The cyclohexanone 22 weakly inhibited
all three catalytic subunits ( 25 % inhibition) while the cyclopentanone 11
failed to inhibit the trypsin-like subunit altogether but showed modest
inhibition of the other two (chymotrypsin-like > caspase-like). The
thiopyranone dioxide 41 was unusual in that it exhibited time-dependent
increases in inhibition for all three subunits, with the chymotrypsin-like
subunit inhibited to the greatest extent.
Figure 4-7: Inhibition of human 20S Proteasome catalytic sites  by 10 µMCurcumin, 11, 22 and 41. A1, B1, C1: After 2 hours incubation of testcompound with 20S proteasome. A2, B2, C2: % Inhibition of varioussubunits by test compounds (10 µM) at 0h , 2h and 4h incubation.
In view of the promising inhibitory profile of 41, its IC50 was determined for
each subunit. Similar determinations were made for curcumin. As shown in
Table 4-1, inhibitory activities of 41 were of the order trypsin-like > caspase-
like > chymotrypsin-like. In contrast, curcumin inhibited caspase-like and
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chymotrypsin-like activities to the same extent and trypsin-like activity to a
lesser degree (caspase-like  chymotrypsin-like > trypsin-like). 41 was a more
potent inhibitor of trypsin-like activity than curcumin (3x more potent). It was
equipotent to curcumin with respect to caspase-like activity and a weaker
inhibitor of chymotrypsin-like. If determined at a longer time point (4 h), the
inhibition of the chymotrypsin-like site by 41 is likely to exceed that of






Trypsin-like 32.85 ± 4.72 10.40 ± 0.25
Caspase-like 13.88 ± 1.55 13.00 ± 0.34
Chymotrypsin-like 14.81 ± 0.79 23.38 ± 3.62
aConcentration to inhibit 50% of catalytic activity after 2 h incubation. Mean
± SD of n= 3 experiments. Dose-response curves are given in Appendix 4-1
4.5. Investigations on the inhibition of 26S proteasome in NB4
cells by APL selective compounds (41, 206, 219, 220, 221, 227)
and curcumin
In the preceding section, proteasomal inhibition was assessed on purified
human 20S proteasome. In order to demonstrate the relevance of inhibition
to APL cells, the experiments were repeated on NB4 cell lysates. As these
experiments were carried out in the latter stages of the author’s candidature,
round 2 compounds were also evaluated. They were 206 (Series III), 211, 219,
220 (Series IV) and 221, 227 (Series V). 41 and curcumin were included as
well. Except for 211, the other compounds were APL selective (Figure 4-8).
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Figure 4-8. Structures of compounds evaluated for 26S proteasomalinhibitory activity in NB4 cells.
The assay protocol was adapted from the method used in Section 4.4. Briefly,
NB4 cells were incubated with for 48 h, after which cells were lysed and
protein concentration was determined. An aliquot of protein (2µg) was
added to each well containing the AMC-tagged site-specific substrate.
Substrate hydrolysis released the AMC tag whose fluorescence was
monitored for 1 hour. By varying the substrate concentration, the Km
(concentration of substrate at ½ maximal hydrolytic rate Vmax) of the
trypsin-like, caspase-like and chymotrypsin-like subunits were found to be 66
µM, 27 µM and 58 µM respectively (Appendix 4-2). Substrate concentrations
were therefore set near the Km values for subsequent assays.
The test compounds were first evaluated at a fixed concentration of 1µM.
The results showed that only the Series V thiopyranone dioxides (41, 221,
227) inhibited proteasomal activity (Figure 4-9).  All 3 subunits were inhibited
to the same extent and inhibitory potencies exceeded that of curcumin.
Consistent with the earlier findings, curcumin inhibited caspase-like activity
to a greater extent.
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Figure 4-9. Inhibition of 26S proteasomal subunits by test compounds andcurcumin at  1 µM concentration.
The experiments were repeated at 2 other concentrations to investigate
dose-dependency (Figure 4-10). Of the 4 compounds that failed to
demonstrate inhibition at 1 µM, two of them (206, 219) showed inhibition at
higher concentrations. In contrast, inhibition was not observed for Series IV
thiopyranones 220, 211 even when tested at concentrations approximating 5
x IC50NB4 (data not shown). The Series V thiopyranone dioxides 41, 221, 227
showed dose-dependent inhibition of all three catalytic subunits of the
proteasome, with near complete inhibition at the highest test concentration
(1 µM). A similar profile was observed for 219 which was the only one of the
Series IV thiopyranones to demonstrate proteasome inhibition at a
concentration (2.4 µM) close to its IC50 NB4 (0.46 µM). Cyclohexanone 206
exhibited modest proteasomal inhibition, with markedly weaker inhibition of
trypsin-like activity. Tentatively, the results pointed to the following rank
order of inhibition: 227 (most potent, inhibition at 0.1 µM) > 41, 221 > 219 >
curcumin > 206 > 211, 220 (no inhibition at 5x IC50). This sequence broadly
reflected the cell based (NB4) growth inhibitory activities, except for 220
which failed to inhibit the proteasome in spite of its potent growth inhibitory
activity (IC50NB4 0.41 µM) and more importantly, its APL selectivity (ratio =
3.5). On the other hand, the inactivity of 211 was consistent with its lack of
APL selectivity (ratio = 0.76).
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Figure 4-10:  Dose-dependent inhibition of the trypsin-like, caspase-likeand chymotrypsin-like subunits of 26Sproteasome in NB4 cells by testcompounds after 48 h of incubation.  Trypsin-like activity ■ Caspase-like
activity■ Chymotrypsin-like activity
4.6. Curcuminoids that are proteasome inhibitors similarly
inhibit TNFα-induced activation of NF-κB
In the preceding section, proteasomal inhibition was demonstrated in an
assay that employed non-physiological peptide substrates.  This raises the
question as to whether the results were functionally relevant in the cellular
context.  If they were, signaling pathways that were dependent on a
functional proteasome would be affected. Hence, the pro-survival nuclear
factor kappa B (NF-ĸB) signalling pathway was selected for investigation. In
the canonical pathway, inactivated NF-ĸB dimers of p65 and p50 are
sequestered in the cytosol by IĸBα (inhibitor of kappa -Bα). Phosphorylation
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of IĸBα marks it for proteasomal degradation, and when this occurs, the p65 -
p50 dimer is liberated and translocates to the nucleus where it up-regulates
transcription of target genes. When the proteasome is inhibited, levels of
IĸBα increase as its degradation is halted and the p65-p50 dimer remains in
the cytosol.  The increase in IĸBα levels prevents the translocation of p65-p50
to the nucleus and this event was monitored.
Briefly,  NB4 cells were sequentially treated with test compound and the NF-
ĸB activator TNFα, after which the cytoplasmic/nuclear localization of p65
was monitored by immunofluorescence imaging on a high content screening
platform.112 NB4 cell nuclei were stained blue by Hoechst dye while p65 was
stained green by Alexa Fluor. The merged panel in Figure 4-11A shows that
p65 was predominantly localized in the cytosol of control cells as seen from
the Hoechst-stained blue nuclei surrounded by peripheral rings of green
fluorescence. When TNFα was added, activated p65 translocated to the
nucleus and the merged panel now shows predominantly aquamarine nuclei
due to overlapping green and blue fluorescence of the two dyes.  The
addition of 41 impeded the TNFα-induced translocation of p65 to the nucleus
which took on an increasingly blue appearance due to the cytosolic
localization of p65.
Quantification of signal intensities of p65 assigned an IC50 of 0.069 µM to 41.
Table 4-2 lists the IC50of other compounds evaluated for inhibition of nuclear
translocation of p65 in NB4 cells under similar conditions.  Strikingly, Series IV
thiopyranones 211 and 220 which failed to inhibit the 26S proteasome, did
not impede p65 nuclear translocation. This was also true of cyclohexanone
206 which was previously found to be a weak proteasomal inhibitor. The
thiopyranone dioxides 41, 221 and 227 retained good inhibitory potencies
although not in the same rank order as their inhibition of the proteasome.
Curcumin was unusually potent in inhibiting p65 translocation (IC50 0.045
µM) when compared to its observed level of proteasomal inhibition. One
reason may be that curcumin intercepted other signalling pathways that
regulated nuclear localization of p65.  For example, it is known to inhibit the
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kinase (inhibitor of ĸB kinase, IKK) responsible for phosphorylation of IĸBα83,
113 and the synergy between inhibition of IKK and proteasome may have led
to its potent effects on p65 nuclear translocation. Taken together, the results
supported the view that proteasomal inhibition by APL selective compounds
was functionally relevant in the cellular context as it contributed to inhibition
of nuclear translocation of p65 in NB4 cells.
Figure 4-11. Inhibition of TNFα-induced activation of NF-κB by 41. (A)
Representative images of TNFa induced NF-kB p65 localization in NB4 cells.
NB4 cells were treated with vehicle (DMSO) or respective concentrations of
41 over 30min followed by TNFa for an additional 30min. Cells were fixed and
stained with NF-kB antibody (green) and Hoescht (blue). (B) Dose-response
curve of the inhibitory effect of 41 on TNFα-induced activation of NF-κB. The
inhibitory effect was expressed as a % of the fluorescence intensity (FI) of
treated cells (41+ TNFα) relative to FI of cells treated with TNFα only. FI
readings were corrected for background fluorescence of untreated cells. IC50
was obtained from 3 or more independent experiments.
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% Proteasome Inhibition at 1 µM Cpd ± SDb
Trypsin-like Caspase-like Chymotrypsin-like
Cur 0.045 ± 0.021 3.62 ± 1.75 48.1 ± 16.8 11.3 ± 1.9
41 0.069 ± 0.017 94.53 ± 0.40 100.00 ± 4.68 92.31 ± 4.20
206 >20c 0 0 0
211 >20c 0 0 0
219 1.68 ± 0.54 0 0 0
220 >20c 0 0 0
221 1.08 ± 0.80 59.6 ± 1.3 57.9 ± 1.0 29.1 ± 1.7
227 0.57 ± 0.40 100.9 ± 0.6 100.00 ± 0.7 96.0 ± 0.2
aConcentration required to reduce TNFα-induced NF-ĸB activation to 50 % of
vehicle control treated cells. b Percent inhibition of 26S proteasome after 1
µM compound treatment of NB4 cells relative to vehicle control treated NB4
cells. From Table 3-2. c IC50 not determined above 100 µM.
4.7. Discussion
The objective of this chapter was to determine if APL-selective compounds
induced the accumulation of misfolded N-CoR to a greater extent than APL
non-selective compounds.  Investigations on selected round 1 compounds
showed that there was a causal link between compounds that selectively
targeted NB4 cells and N-CoR accumulation. Notably, the highly APL-selective
candidates 11, 22 and 41 increased levels of full length N-CoR in NB4 cells
when probed by western blotting. In contrast, compounds that were not APL
selective (25, 42) failed to do so.  Interestingly, the APL selective compounds
increased N-CoR levels at concentrations that were at least 10 x lower than
their IC50s on NB4 cells. The Series V thiopyranone dioxide 41 was the most
potent, increasing N-CoR levels at 5 nM compared to its IC50 NB4 of 60 nM. It
was further established by immunofluroescence imaging that in NB4 cells
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treated with APL-selective compounds 11, 22 and 41, most of the N-CoR was
localized in the cytosol, which would be the case if it was misfolded. Taken
together, these findings notionally supported the hypothesis that APL-
selective analogs promoted buildup of misfolded N-CoR.
In the light of these findings, it was of interest to investigate the mechanisms
leading to the accumulation of misfolded N-CoR.  Curcumin was reported to
induce accumulation by inhibiting the degradation of misfolded N-CoR by
APL-specific proteases and the proteasome.19 Thus, the logical approach was
to investigate APL selective compounds on these two targets. Here, the
interactions of APL selective compounds with a known APL selective
protease, OSGEP, were investigated by thermal shift and SPR.  Both methods
failed to detect interactions between the APL selective compounds and
OSGEP, although they succeeded in identifying an interaction between
curcumin and OSGEP. The limitations of these methods notwithstanding, it
would seem that the APL selective compounds do not interact with OSGEP to
bring about inhibition.
More promising results were obtained when the APL selective compounds
(11, 22, 41) were investigated for proteasomal inhibition. A preliminary
investigation on purified human 20S proteasome revealed time dependent
and subunit-specific inhibition by the test compounds at 10 µM.114
Proteasomal inhibition was further confirmed in a cell based assay (NB4 cells)
with 41, curcumin and several round 2 compounds. 41 and two other Series V
thiopyranone dioxides 221, 227 stood out for their outstanding inhibitory
effects, with near complete inhibition of all three proteasomal subunits at 1
µM, as compared to 30 µM for curcumin. Gratifyingly, there was a broad
alignment between proteasomal inhibition and the APL selectivity status of
the compounds. Notably, the non-APL selective thiopyranone 22 failed to
inhibit the proteasome while all but one APL selective compounds
demonstrated proteasomal inhibitory activity. The outlier was the
thiopyranone 220 and its deviation may be due to the following factors. First,
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misfolded proteins have to be ubiquitinated before proteasomal degradation
and this process involves E1-E3 ligases.60 Ubiquitin isopeptidases responsible
for maintaining the pool of available ubiquitin also play a decisive role59
(Section 1.4.1.) Although 220 did not inhibit the proteasome, it may interfere
with these enzymes to intercept the degradation process.  In fact, the α,β-
unsaturated dienone motif present in curcumin and several monocarbonyl
dienones had been identified as the necessary pharmacophore for ubiquitin
isopeptidase inhibition.77 Second, the limitations of the selectivity ratio used
to distinguish APL selective from APL non selective compounds should be
recognized. It is derived from cell based assays and there could be other
differences between APL and non-APL cells besides N-CoR and PML-RARα,
that could have accounted for variations in the ratio.  While it provides a
convenient back of the envelope assessment, false positives and negatives
should be anticipated.
That proteasomal inhibition was functionally relevant in the cellular context
was demonstrated by the ability of the same round 2 compounds to inhibit
the prosurvival signaling NF-ĸB signaling pathway.  Compounds highly ranked
for proteasomal inhibition (41, 227, 221, 219) were also potent inhibitors of
the nuclear translocation of p65 while those that failed to inhibit the
proteasome (206, 211, 220) were conspicuous in not intercepting the
translocation process.
4.8. Conclusions
The findings of this chapter have provided proof-of-concept that APL
selective compounds induced the accumulation of misfolded N-CoR by
inhibiting its proteasomal degradation.  The most promising compounds
identified were the thiopyranone dioxides 41, 221 and 227 of Series V.
Detailed investigations on 41 showed that it increased full length N-CoR
levels,   promoted its localization in the cytosol of NB4 cells, inhibited the
proteasomal activity of the human 20S proteasome and that of NB4-derived
cell lysates. 41, 221 and 227 were pan-inhibitors of proteasomal activity in
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NB4 cells with near complete inhibition observed at 1 µM. The functional
relevance of proteasomal inhibition was further confirmed by the ability of
these compounds to inhibit nuclear translocation of the NFkB subunit p65.
The outstanding feature of 41, not seen with APL selective compounds from
other series, was its potency as reflected by the exceptionally low
concentrations ( 1 µM, twice that of its IC50 NB4) required to elicit the various
responses. Tentatively, this suggests that other mechanisms may be involved
for the APL selectivity of those compounds, but for 41, the involvement of N-
CoR may be central to its APL selectivity.
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Chapter 5: Mode of action studies on the APL selective
compound 41.
5.1. Introduction
In the preceding chapters, 41 was identified as a potent and APL selective
compound that promoted the accumulation of misfolded N-CoR by
intercepting its degradation by the proteasome. In view of its favorable
activity profile, detailed investigations were carried out on 41 to provide a
better understanding of its mode of action in NB4 cells. Two questions were
posed in this chapter. First, it was necessary to ascertain the extent to which
inhibition of proteasome contributed to the growth inhibitory profile of 41.
The structural similarity of 41 to curcumin may predispose it to a pleiotropic
profile in which myriad pathways (including proteasomal inhibition) are
intercepted to the same degree. This would diminish the standing of
proteasome inhibition and the involvement of misfolded N-CoR in NB4 cell
death. Second, if the present hypothesis holds, the accumulation of
misfolded N-CoR would ultimately trigger UPR-induced apoptosis. It is thus
important to determine the effects of 41 on ER stress markers and the
canonical signaling arms of the UPR.
To this end, the following experiments were planned. First, the gene
expression profile of NB4 cells treated with 41 was determined by microarray
analysis. This would identify the major cellular pathways modulated by 41
and provide insight to the 1st question. Second, NB4 cells were treated with
41 and levels of ER stress chaperone proteins and ER stress sensors involved
in UPR signaling were probed by western blotting.
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Promega WI, USAMurine Reverse Transcriptase (MMLV)
RNase Inhibitor
Qiagen RNeasy Plus Mini Kit Qiagen Hilden,Germany
TaqMan Gene Expression Assay
MasterMix ABI systems CA, USA
5.2.2. NB4 cell treatment and harvest
NB4 cells were seeded in a T75 culture flask at 105 cells/mL followed by
addition of 41 (50 nM) or curcumin (5 uM). Final concentration of DMSO in
the flask was maintained at 0.1% v/v. Treated cells were incubated at 37 ˚C, 5
% CO2 for 48 h after which they were transferred to a 50 mL Falcon tube,
pelleted by centrifuging (200 g,  5 min) and washed twice with ice-cold 1x
PBS.
5.2.3. Isolation and purification of mRNA
Total RNA was isolated from treated cells using the RNeasy Plus Mini kit
(Qiagen GmBH, Hilden, Germany) following manufacturers’ protocol. mRNA
concentrations were measured using the Nanodrop 1000 (Thermo Scientific)
and only samples with OD260nm/OD280nm between 1.9 – 2.1 were used.
5.2.4. Determination of mRNA integrity
RNA samples containing 1µg total RNA and 1X loading dye in a total volume
of 12µL were separated on a 1% agaose-TBE gel containing 1.25mM ethidium
bromide. 1Kb DNA ladder was used instead of RNA ladder and the gel was
subjected to electrophoresis in 1X TBE running buffer at 100V for 1.5hr.
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Visualization of distinct 18S and 28S ribosomal RNAs were carried out on the
Gel Doc System (Bio-Rad, CA, USA).
5.2.5. Microarray chip hybridization and pathway analysis
6 total RNA samples (2 replicates of vehicle, curcumin-treated and 41-treated
samples) were submitted to Origin Labs for processing according to
Affymetric and NuGEN recommended protocols (Project reference number
OL-2012-1214-AFGE). All 6 samples passed assay quality control and were
hybridized to GeneChip® Human Gene 1.0 ST arrays. Expression analysis of 6
samples was carried out by Sciencewerke Pte Ltd according to recommended
protocols. Data was pre-processed to calibrate background levels and
intensities of probes were normalized and transformed. To assess differential
expression, a Bioconductor package, Limma, was used followed by
application of the Benjamini & Hochberg multiple testing adjustment method
to p-values to sieve out false positive rates.  Genes significantly affected
(compared to vehicle control, adjusted p-values < 0.05) were short-listed and
pathway analysis was carried out using the KEGG Mapper software
(http://www.genome.jp/kegg/mapper.html).
5.2.6. Validation by real-time PCR
RNase-free water was added to 2µg RNA, 3 pmoles oligo-dT (18-mer) to give
a final volume of 21µl. The mixture was incubated at 65°C, 15 min and
immediately quenched on ice thereafter.  A mastermix of 10µL 5X RT buffer,
1µl 25mM dNTPs, 0.5µL RNasin inhibitor, 1µL murine reverse transcriptase
and sterile water was prepared to  a total volume of 29µL for each sample.
The mastermix was added to the RNA and mixed. The sample was incubated
at 42°C, 1 h for the generation of cDNA.  PCR amplification was carried out in
50µL volumes containing 1µL of 10 X template, 1X PCR reaction buffer,
200nM of each dNTP, 0.8µM of each primer and 1.5units of DNA polymerase.
Real-time PCR of selected genes was carried out using the TaqMan® Gene
Expression Assay System (Applied Biosystems, CA, USA) and recorded using
the ABI 7500 Fast PCR System (Applied Biosystems, CA, USA). The qRT -PCR
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reaction conditions and list of TaqMan primers are given in Appendix 5-1 and
5-2.




Cell Signaling MA, USA
anti-Caspase 3 (rabbit, 1:1000)




anti-phospho ASK1 (rabbit, 1:2000)











anti-phosphor PERK (rabbit, 1:2000)
HRP goat anti-mouse, (1:10 000)
Zymed Laboratories CA, USAHRP goat anti-rabbit, (1:10 000)
HRP mouse-antigoat, (1:10 000)
Annexin V-FITC Apoptosis Detection
Kit (Catalog no. APOAF) Sigma Aldrich MO, USA





Propidium iodide (Catalog no. P4170) Sigma Aldrich MO, USA
5.2.7.2. Western blot
NB4 cells were treated at respective concentrations, harvest and lysed
according to method described in Section 5.2.1.2. All lysates are normalized
to 1µg/µL based on protein concentration determination by BCA assay.
Protein lysates were separated on SDS-PAGE gel (Section 4.2.2).
5.2.7.3. Detection of apoptosis through flow cytometry
NB4 cells were treated at respective concentrations and harvested according
to method described in Section 5.2.1.2. The cell pellet was de-clumped
thoroughly and resuspended in 1X binding buffer at density of 106 cells/mL.
Annexin V-FITC conjugate protein (5 µL) and propidium iodide solution (1 µL)
were added to cell suspension (500 µL) and incubated at RT for 10 min in the
dark. Flow cytometric analysis was carried out on the Cytomation Cyan LX
instrument (Dako, Fort Collins, Co, USA) using Summit software. Unstained
treated cells, treated cells single stained with Annexin V-FITC or propidium
iodide only were used for calibration and compensation. 20 000 cells were
read for each sample determination.  Each compound was evaluated in at
least three independent experiments using two or more freshly prepared
stock solutions of test compound.
5.3. Results
5.3.1. Gene expression profile of NB4 cells treated with compound 41
and curcumin
Microarray analysis was carried out on cells treated with vehicle control (0.1
% DMSO), 41 (50 nM) and curcumin (5 µM). Duplicate determinations were
made for each case. Non-lethal concentrations of 41 and curcumin were
employed and incubation periods were reduced to 48 h to ensure cell
viability was not adversely affected by compound treatment. Analysis was
carried out on the Affymetrix GeneChip Human Gene 1.0 ST Array which
covered 28,689 genes. PCA clustering analysis of the results showed that the
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duplicate samples of 41 (41-1, 41-2) but not curcumin (Cur-1, Cur-2) and
control (V-1, V-2), were reproducible.  Cross over comparisons identified
vehicle control V-2 and curcumin sample Cur-2 to be more reliable, in that
more pathways were identified with this combination than with others. As
this was more in line with the multi-targeting character of curcumin, the Cur-
2 versus V-2 results were retained. The duplicate 41 samples were averaged
and compared separately to V-1 and V-2. Broadly similar results were
obtained from either comparison but the results from 41 versus V-2 were
used here to maintain compatibility with the curcumin results.
Figure 5-1. Effect of 41 on multiple biological signaling pathways in NB4cells. Representative target genes with log fold change>1.5 or <1.5, p-value
<0.05. The complete list of genes involved in DNA replication, cell cycle,
apoptosis and proteasomal structure that were significantly regulated by
both curcumin and 41 are given in Appendix 5-3.
Analysis of the results revealed that 599 genes were significantly up- or
down-regulated (adjusted p value < 0.05) in 41-treated NB4 cells compared
to control cells. The extent of change ranged from 48-fold (up-regulation) to
negative 50-fold (down-regulation). An overwhelming majority of genes (581)
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were up-regulated.  KEGG pathway analysis of the microarray profiles
identified several pathways that were affected by 41 (Figure 5-2). Pathways
that harboured the largest number of up-regulated genes were those
involved in metabolism (26 genes), protein processing in the ER (22 genes)
and RNA transport (21 genes) (Table 5-3).
In the case of curcumin, the expression of 611 genes were significantly
modified in NB4 cells, with 599 genes up-regulated and 12 genes down-
regulated. The variation ranged from 66-fold (up-regulation) to negative 60-
fold (down-regulation), which closely mirrored that of 41.  Interestingly, the
major pathways affected by curcumin were also those identified for 41
(Figure 5-1). Thus, 41 and curcumin regulated very similar genes and affected
similar pathways in NB4 cells. However, 41 was clearly more potent than
curcumin as it was employed at a 100-fold lower concentration (5 nM) than
curcumin (50 µM).
Table 5-2: Biological pathways in NB4 cells that were significantly affectedby 41 (50 nM) and curcumin (5 µM), as analysed by KEGG pathwaydatabase analysis. Numbers of affected genes are listed for each pathway.
Pathways Total no. of genes regulated41 Cur
Metabolic pathways 26 29
Protein processing in the ER 22 23
RNA transport 21 22
Pathways in cancer 13 16
Ubiquitin mediated proteolysis 15 13
Cell cycle 10 10
PI3K-Akt signaling pathway 9 10
Wnt signaling pathway 9 9
MAPK signaling pathway 6 9
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Hungtington's disease 8 8
HIF-1 signaling pathway 7 7
mTOR signaling pathway 6 7
Renal cell carcinoma 5 6
Ribosomes 9 5
Non-small cell lung cancer 5 5
Proteasome 5 5
DNA replication 4 5
Apoptosis 4 5
VEGF signaling pathway 4 4
NFkB signaling 2 3
Pathway analysis identified protein processing in the ER as one of three top
networks affected by 41 and curcumin. A total of 21 genes in this pathway
were up-regulated by both curcumin and 41 (Table 5-2). None were
downregulated. Further analysis showed that these genes regulated protein
transport (SEC62/63, STT3A/B, SAR1A/B, LMAN1), protein folding
(DNAJC10/3, PDIA6, HSP90AB1), attachment of ubiquitin to other proteins
(UBE2D1, UBE2E1) and protein synthesis (EIF2AK2, EIF2S1). SEC63, which has
a role in post-translational protein translocation in ER, was up-regulated to
the greatest extent by both 41 and curcumin (Table 5-3). The significant up-
regulation of protein processing in the ER as seen from the microarray results
with curcumin has not been reported before but could be indirectly inferred
from the UPR-induced apoptosis of NB4 cells by curcumin since an increase in
protein processing would amplify ER stress and shift the UPR from a pro-
survival to pro-death mode. The same mechanism may apply to 41.
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Table 5-3: List of genes in the ER protein processing pathway that weresignificantly up-regulated by 41 and curcumin. The extent of upregulation
is reported as the Log2FC which is the logarithm (base 2) of the fold change in









translocation in and out of the ER.
5.60 6.05
SEC62 2.79 3.12
STT3A Forms a complex with Sec61 to




SAR1B Involved in protein transport from





facilitates the translocation of









LMAN1-MCFD2 complex forms a
specific cargo receptor for the ER-to-
Golgi transport of proteins.
2.51 2.93
SEC24B Implicated in the shaping of thevesicle and cargo selection. 2.05 2.49
Protein
folding
DNAJC10 Protein disulfide isomerase (PDI)
family - ER resident proteins that
catalyze formation, reduction, and




HSP90 Fold newly synthesized proteins or 2.78 3.06
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ATXN3 Deubiquitinating enzyme involved inprotein homeostasis maintenance. 2.45 2.34
CUL1 Core component of E3 ubiquitin-protein ligase complexes. 3.11 3.27
UBE2E1 Accepts ubiquitin from the E1
complex and catalyzes its covalent
attachment to other proteins.
2.97 3.06
UBE2D1 2.42 3.01




The translation initiation factor EIF2




The activated form of the encoded
protein can phosphorylate
translation initiation factor EIF2S1,
which in turn inhibits protein
synthesis.
2.58 2.78
Only a handful of genes were down-regulated by 41 (18) and curcumin (12).
Of these, 6 genes were down-regulated by both compounds (Table 5-4) and
they were involved in cell development and proliferation (OCM, RGL2, CFB),
protein translation (NXF2, MRPL36) and DNA-binding transcriptional
repression (THAP5).115, 116
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Table 5-4 List of commonly downregulated genes by both curcumin and
41









binding protein found in





involved in cell division in













NXF2 Nuclear export of bulk RNAs -3.099 -2.927
MRPL36
Structural constituent of
mitochondrial ribosome L36. -3.080 -2.660
a Log fold change of gene expression in treated cells relative to vehicle control
5.3.2. Validation of selected genes identified in microarray analysis
Having shown that certain genes were upregulated or downregulated in NB4
cells treated with 41 or curcumin, the next step was to confirm these findings
by determining the expression levels of these genes in treated NB4 cells.
Genes that were up-regulated should have higher expression levels in treated
cells relative to control cells and vice versa. Validation was carried out using
real-time polymerase chain reaction (PCR). In view of the high cost of the
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primers, only 6 genes were chosen for validation. These are genes found to
be up-regulated in the protein processing pathway – UBE2E1, EIF2AK2,
SEC62, LMAN1 and one down-regulated gene THAP5. Figure 5-2 shows that
41 and curcumin affected the expression of these genes as predicted from
the microarray data. The UPR genes were up-regulated by 2-3 fold by 41 and
1.4 -2.0 fold by curcumin. Both 41 and curcumin reduced the expression of
THAP5 by 5 fold. Although the fold-changes induced by 41 and curcumin
were broadly comparable, they were elicited at significantly different
concentrations (50 nM 41 versus 5 µM curcumin).  Thus, the present results
point to 41 as an exceptionally potent activator of protein processing
pathways in the ER of NB4 cells.
Notwithstanding the successful validation of selected genes reported here,
caveats that apply to gene expression analysis by microarray should be
noted. First, gene expression levels were quantified at the DNA level, not
protein level. It is not known if regulated gene expression is reliably
translated to the protein level. Second, gene expression analysis does not
provide information on the inhibitory activity of 41 and curcumin on proteins
involved in different signaling pathways. Third, the results were obtained at
one concentration of compound and at a single time point. The global gene
expression profile may vary significantly when repeated at different assay
conditions.
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Figure 5-2: Validation of selected genes that were up- or down-regulatedin NB4 cells treated with 41 (50 nM) or curcumin (0.5 µM) byquantitative real-time PCR analysis.
Vehicle control contains 0.1 % DMSO. Changes in gene expression levels were
compared to levels in control cells (normalized to 1) and presented as mean fold
change relative to control. Mean and SD of 3 independent experiments.
5.3.3. Effects of 41, 219 and 227 on ER stress markers in NB4 cells
Up-regulation of genes in the protein processing pathway of the ER will
exacerbate stress in NB4 cells and trigger the unfolded protein response
(UPR). The UPR signalling pathway is mediated by ER stress sensors which are
maintained in their inactive states under non-stressed conditions by ER stress
markers/chaperone proteins. In the presence of ER stress, these chaperones
are diverted from the ER stress sensors for binding to misfolded proteins. The
liberated ER stress sensors then trigger UPR signalling pathways.  Here, three
compounds were investigated for their effects on the UPR: Series IV
thiopyranone 219 and Series V thiopyranone dioxides 41 and 227 (Figure 5-3)Figure 5-3: Structures of 41, 219 and 220.
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The compounds were first evaluated for their effects on the levels of ER
stress chaperone proteins - protein disulfide isomerase (PDI), glucose-
regulated protein 78 (GRP78) and heat shock protein 60 (HSP60). Figure 5-4
shows that these chaperone proteins were not detected in control cells when
probed by western blotting but were discernible in cells treated with test
compound. Based on the lowest concentration required to elicit expression
of the protein, 41 was deemed the most potent as nanomolar
concentrations of 41 were required to increase levels of PD1 (50 nM), GRP78
(250nM) and HSP60 (250nM). Although 227 was almost as potent as 41 in
terms of its IC50(NB4), higher concentrations of 227 were required to increase
chaperone protein levels (PDI 0.4µM, GRP78 1.0µM, HSP60 0.4µM). As for
thiopyranone 219 which had the highest IC50 NB4 of the three compounds, it
elicited increases in chaperone proteins at concentrations that were 1-5x its
IC50 NB4. Thus all three compounds increased ER stress chaperone proteins in
NB4 cells and at concentrations that were no more than 10 x their growth
inhibitory IC50 on NB4 cells.
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Figure 5-4: Compounds 41, 219 and 227 induce ER stress in NB4 cells.
Cells were treated with vehicle control or test compounds at the stated
concentrations for 48 h after which ER stress markers PDI, GRP78 and HSP60 were
probed by western blotting, with β-actin as loading control. *indicates IC50(NB4)of test
compound.
5.3.4. Effects of 41, 219 and 227 on the ER stress sensors PERK and
IRE2
The preceding section has shown that 41, 219 and 227 increased ER stress
chaperone proteins and hence ER stress levels in the cells. Thus, it was timely
to investigate their effects on UPR signaling.  UPR signaling is mediated by ER
stress sensors - protein kinase RNA-like ER kinase (PERK), inositol-requiring
enzyme 1 (IRE1) and activating transcription factor 6 (ATF6). These sensors
are activated sequentially, with PERK activated early in the UPR, followed by
ATF6 and then IRE1. Each sensor also recruits additional proteins to execute
their pro-survival or pro-apoptotic functions. Here, only two ER sensors were
investigated –PERK and IRE1. NB4 cells were treated with 41, 219 or 227 for
24 and 48 hours at a concentration close to their IC50NB4, after which protein
levels were probed by western blotting.
PERK recruits elF2α and ATF4 to carry out its signaling function. The PERK-
elF2α-ATF4 signaling arm initially blocks protein synthesis and promotes
protein folding to reduce ER stress levels.  If ER stress is resolved, PERK
signaling will stop but if ER stress persists, PERK signaling will switch over to a
pro-apoptotic mode. Figure 5-5 shows levels of PERK, elF2α and GADD34
from cells treated with test compound over time. Increases in
phosphorylated PERK and elF2α levels would signify activation of the PERK-
elF2α-ATF4 signaling axis and this was duly observed for 41 and curcumin.
Increases in phosphorylated PERK and elF2α were time-dependent. The
persistence of pPERK up to 48 hours was considered unusual as PERK
signaling is normally an early event (within 4-8 hours). It may signify
sustained ER stress in the cells that could not be handled by early UPR
signaling.  Indeed, levels of GADD34 were increased. GADD34 is one of the
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pro-apoptotic proteins recruited when the PERK signaling switches to a pro-
apoptotic mode. GADD34 is reported to contribute to the pro-apoptotic
effects of CHOP which is more commonly monitored in PERK signaling.
Figure 5.5: 41, 219 and 227 activate PERK signaling in NB4 cells. Cells
were treated 41 (50 nM), 219 (0.5 µM), 227 (0.1 µM) for 24 h and 48 h. Control cells
were harvested at 0 h. Up-regulation of proteins involved in the PERK cascade (p-
PERK, p-eIF2α, GADD34) were monitored by western blot. β-actin is shown as the
loading control.
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Figure 5-6: 41, 219 and 227 activate the IRE pathway in NB4 cells. Cells
were treated 41 (50 nM), 219 (0.5 µM), 227 (0.1 µM) for 24 h and 48 h. Control cells
were harvested at 0 h. (Up-regulation of proteins involved in the IRE cascade (p-
ASK1, p-JNK) were monitored by western blot. β-actin is shown as the loading
control.
The IRE1 pathway is the final arm to be activated in the UPR signaling
cascade.  Initially, IRE1 assists the pro-survival UPR by upregulating the
expression of ER stress chaperone proteins and genes involved in protein
degradation. If ER stress persists, IRE1 recruits ASK1 and JNK which are
sequentially phosphorylated. ASK1-induced phosphorylation of JNK
contributes to UPR apoptosis. Figure 5-6 shows basal levels of
phosphorylated ASK1 and JNK in untreated NB4 cells, an indication that NB4
cells were under ER stress. Phosphorylated ASK1 and JNK levels were further
increased in the presence of test compound after 48 hours.  Compared to
219 and 227, the increase in phosphorylated Jun in the presence of 41 was
less prominent.
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Taken together, the results presented in this section showed that 41, 219 and
227 increased levels of activated ER chaperone proteins, which led to
sustained signaling through the PERK and IRE1 arms of the UPR and
subsequent activation of downstream molecules (GADD34, ASK1, JNK) which
relay the pro-apoptotic signals to the final execution phase.
5.3.5. Effects of 41, 219 and 227 on apoptotic markers caspases 3, 9
and PARP.
To examine whether the elevated levels of GADD34, pASK1 and pJNK
detected in the presence of 41, 219 and 227 would result in apoptosis,
caspase activation and poly ADP-ribose polymerase (PARP) cleavage were
monitored. The compounds were incubated with NB4 cells for 48 hours after
which levels of cleaved caspases 3,9 and PARP were probed by western
blotting (Figure 5-7). 41 and 219 induced a dose dependent increase in
cleaved caspase 9 at concentrations equivalent to their IC50 NB4.  In contrast,
227 did not activate caspase 9 even at concentrations that approached 10 x
its IC50.  Cleavage of caspase 9 is initiated by the release of cytochrome c from
the mitochondria in the intrinsic apoptotic pathway. Notionally, this pathway
may not be involved in the apoptotic cascade for 227.  If this is indeed so, it
shows that minor changes in structure, as in the case of 41 and 227, do have
a marked effect on mechanistic pathways.  All three compounds promoted
the cleavage of the downstream executioner caspase 3 which is common to
both intrinsic and extrinsic apoptotic pathways. Levels of cleaved PARP were
also elevated. Some differences were observed in the concentrations
required to upregulate protein levels, but these variations were no more than
5x IC50(NB4) of test compound.
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Figure 5-7: Compounds 41, 219 and 227 induce caspase-dependent apoptosis
in NB4 cells. Cells were treated with test compounds at stated concentrations
or 0.1% DMSO (control) for 48 h.  Cell lysates were prepared and caspases 9,
3 and PARP and their cleaved states were examined by western blot. β-actin
was used as the loading control.
Apoptosis was also investigated by flow cytometry using the Annexin V-FITC
Apoptosis Detection Kit which contains Annexin V tagged to a fluorescent
probe (FITC) and propidium iodide (PI). Briefly, phosphatidylserine which is a
component of cell membranes translocates from the inner to outer surface of
the membrane during apoptosis. The exposed phosphatidylserine molecules
bind to Annexin V and are detected by the fluorescence imparted by FITC.  PI
intercalates cellular DNA but cannot permeate the intact membranes of live
cells for binding. Thus only dead cells or those in late apoptosis are stained by
PI. Dual staining by Annexin-V FITC and PI serves to distinguish cells into 3
categories: normal cells (not stained by Annexin –V or PI), cells in early
apoptosis (stained by Annexin V but not PI) and cells in late apoptosis
(stained by both Annexin V and PI). Data from flow cytometry is represented
by four quadrants (Figure 5-8). Normal live cells are located in quadrant R3
while early and late apoptotic cells are located in R4 and R5 respectively.
Cells located in R1 are commonly referred to as necrotic or cells in an
undetermined state.
153
Only 41 and 219 were investigated. As seen from Figure 5-8, onset of
apoptosis was observed at 100 nM 41 and 0.5 µM 219. Both compounds
caused dose dependent increases in the proportion of apoptotic cells.
Figure 5-8: Compounds 41 and 219 increased the proportion of apoptoticells in a dose-related manner. Cells were incubated with NB4 for 48 hours
and double stained with propidium iodide and Annexin V for the detection of
necrotic and apoptotic cells by cell cytometry. Representative FACS analysis
diagrams and mean ( SD) viable and apoptotic cell population after treated
with curcumin, 41 and 219 at respective concentrations.
Test Compound % Normal Cellsa % Total ApoptoticCellsb
Vehicle control - 97.2 ± 1.7 3.77 ± 0.31
41
25 nM 94.0 ± 4.1 3.53 ± 0.81
50 nM 92.9 ± 5.0 4.40 ± 1.15
100 nM 85.3 ± 5.8 14.4 ± 4.7
250 nM 53.6 ± 9.8 43.4 ± 7.0
219
0.5 µM 89.2 ± 0.9 10.1 ± 0.8
1.0 µM 27.2 ± 3.7 69.9 ± 3.0
2.5 µM 5.9 ± 0.3 88.4 ± 0.5
aProportion of normal cells deduced from the FACS analysis of cell
populations in the lower left quadrant R2. b Proportion of apoptotic cells
were deduced from the FACS analysis of cell populations in the lower right
(early apoptosis)R4 and upper right (late apoptosis) R5 quadrants. Values
represent the mean ± SD for n ≥ 3 determinations.
5.4. Discussion
The broad picture to emerge from the microarray analysis was that 41
increased protein processing activities in the ER of NB4 cells, with more
proteins being transported to the ER for folding and post translational
ubiquitination. 41 upregulated two genes involved in protein synthesis
(EIF2S1, EIF2AK2) but paradoxically, the net outcome was not more but less
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protein synthesis. This is because the protein encoded by EIF1AK2
phosphorylates EIF2 (the protein product of EIF2S1) which would in turn
inhibit protein synthesis.
The revelation that 41 heightened levels of protein processing in the ER is
significant for at least two reasons.  First, it provides a causal link to the
proteasomal inhibitory activity of 41.  Inhibition of the proteasome would
lead to a buildup in proteins, including misfolded proteins like N-CoR.  In
order to blunt the mounting protein levels, the cellular response would be to
upregulate genes involved in protein processing in the ER. Second, NB4 cells
like other hemapoietic cells are constitutively under ER stress due to their
secretory nature and the presence of misfolded proteins (including N-CoR).
The heightened levels of folding, ubiquintination and transport within the ER
would invariably aggravate ER stress to the point that it cannot be
neutralized by the UPR. The pro-apoptotic signaling pathway would be
activated leading to cell death. This was duly observed for 41 (and 219, 227)
from the upregulated levels of ER stress chaperone proteins (GRP78, PDI,
HSP60) and proteins associated with PERK and IRE1 signaling.  Apoptotic cell
death was also confirmed for 41. Thus, the increase in protein processing
activities in the ER is both a response to proteasomal inhibition, as well as an
impetus to the pro-apoptotic UPR response and ensuing cell death.
Pathway analyses based on the gene expression profiles of NB4 cells treated
with 41 or curcumin pointed to significant overlaps in the signaling pathways
affected by both compounds. Curcumin is a known multi-targeting compound
affecting diverse signaling pathways and this may be true of 41 as well.
However, 41 is distinguished from curcumin by its potency which was clearly
evident from the range of in vitro assays (growth inhibitory, proteasomal
inhibition, N-CoR accumulation, microarray analysis) carried out in this thesis.
Tentatively, 41 is about 100 times more potent than curcumin in intercepting
pathways that were germane to APL pathology. If this level of potency is




Two objectives were stated for this chapter, namely to assess the extent to
which inhibition of proteasome contributed to the growth inhibitory profile
of 41 and to determine if the accumulation of N-CoR due to proteasomal
inhibition would trigger UPR-induced apoptosis. The findings in this chapter
have shown that proteasomal inhibition is not an inconsequential component
in the mechanistic pathways affected by 41. In fact, it played a key role in
sensitizing NB4 cells to UPR-induced apoptotic cell death.
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Chapter 6: Evaluation of the hydrolytic stability and
Michael acceptor reactivity of selected Series V
thiopyranones and Series V thiopyranone dioxides
6.1. Introduction
The design of Series I-VI compounds was based on the desired endpoints of
achieving greater potency and greater hydrolytic /metabolic stability
compared to curcumin. The discovery of the Series V thiopyranone dioxides
has fulfilled the first objective but the hydrolytic stability of these compounds
has yet to be investigated. Hence, this aspect was explored in the present
Chapter on two Series V compounds (41, 227) and a potent Series IV
compound 219.  The in vitro metabolic stabilities of 41 and 227 were also
reported based on investigations carried out by an undergraduate student
supervised by the candidate. Another aspect that was investigated was the
Michael acceptor reactivities of 41 and 227. The Michael acceptor reactivity
of curcumin has been implicated in the induction of Nrf2 signaling and
inhibition of ubiquitin isopeptidases.77 Brown et al proposed that curcumin
analogs with electrophilic enone moieties reacted with cysteine residues in
the vicinity of the substrate binding site of kinases to bring about inhibition.86
Thus there was a compelling reason to determine if potent members like 41
and 227 were as reactive Michael acceptors as curcumin.
6.2. Materials and methods
6.2.1. Determination of hydrolytic stability of 41, 219, 227 and
curcumin
The method described by Liang et al73was followed with some modifications.
Test compound (1 mg) was dissolved in 0.5 mL PBS (1X, pH 7.4) comprising
DMSO (50 %) and sodium carboxymethylcellulose (0.3%) and kept in the dark
at 25 ˚C. Aliquots were withdrawn at the stated time period (0 h, 24 h, 48 h,
75 h), diluted 100x with methanol and analyzed  by HPLC on a  Shimadzu SPD-
20A HPLC system. Samples were separated on a Poroshell 120 EC-C18 column
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(Agilent Technologies) at 80 % methanol, 20 % H2O; flow rate 0.6 mL/min. %
Degradation was assessed from a comparison of peak areas of signals
attributed to test compound at the start of experiment and after x = 24, 48
and 75 h.
% Degradation = ([Peak Area at 0 h – Peak Area at x hour] / [Peak Area at 0
h]) x 100
The determinations were made on two freshly prepared solutions of test
compound. Results were analyzed for statistical significance using one-way
ANOVA with post-Bonferroni Multiple Comparison test (GraphPad Prism 3.0).
6.2.2. Determination of Michael acceptor reactivity by NMR
The method described by Avonto et al117 was followed with some
modifications. Test compound (4 mg) was dissolved in 0.5 mL DMSO-d6 and
the 1H NMR spectrum was recorded immediately on a 400 mHz Bruker ACF
NMR instrument. Cysteamine (6 mg) was added and the mixture vortexed for
5 min after which the 1H NMR spectrum was recorded. The residual solvent
peak was used as an internal reference. NMR spectrums were analyzed using
MestRec Research Software (Bajo, Spain).
6.3. Results
6.3.1. Hydrolytic stabilities of 41, 219 and 227
Replacing the conjugated β-diketone moiety of curcumin with a
monocarbonyl dienone moiety has been employed as a means of reducing
the hydrolytic instability of curcumin.  Liang and co-workers compared the 75
h hydrolytic stabilities of curcumin analogs in which the monocarbonyl
dienone moiety was either left intact (as in Series 1) or embedded in a
cyclopentane (Series II cyclopentanone) or cyclohexane (Series III
cyclohexanones) ring.73 While all compounds were indeed more stable than
curcumin, their hydrolytic stabilities varied. Broadly, for the same
substitution on the terminal phenyl rings, stabilities were of order
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cyclopentanones (most stable) > cyclohexanones > monocarbonyls (least
stable).
A related HPLC method was used to monitor the hydrolytic stabilities of
Series IV thiopyranone 219 and Series V thiopyranone dioxide 41 and 227.
Determinations were made in PBS buffer, pH 7.4 containing sodium CMC
(0.3%) and DMSO (50%). The high level of DMSO was necessary to dissolve
the test compounds. % Degradation was assessed by comparing peak areas
of signals attributed to the test compound at the start of experiment and
after 24, 48 and 75 h.  The hydrolytic stability of curcumin was determined
under similar conditions.
As shown in Figure 6-1, curcumin showed substantial time dependent
degradation (>90% after 75 h) which was consistent with literature reports.73
The test compounds also showed time-dependent degradation but retained
greater stability than curcumin. Compound 227 was initially resistant to
hydrolysis but after 75 hours, it was degraded to the same extent as 41 and
219 (60-68%). All three compounds were significantly more stable than
curcumin except at the 24 h time point for 41 and 219.
Figure 6-1: Hydrolytic stability of curcumin, 41, 219 and 227 in phosphatebuffer (1X) pH7.4 containing 0.3% sodium CMC and 50% DMSO.
Compounds were incubated in the dark at 25 ˚C and analyzed by HPLC. # No
significant difference between compounds when analyzed by 1-way ANOVA, post-
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Bonferroni Multiple comparison test.  Significant difference (p < 0.05) was detected
for the remaining comparisons.
6.3.2. Michael acceptor reactivities of 41 and 227.
The Michael acceptor reactivities of 41 and 227 were evaluated by an NMR
method using cysteamine as the nucleophilic species. The same method was
applied to assess the reactivity of curcumin. Briefly, curcumin (1 equivalent)
and cysteamine (2 equivalents) were dissolved in deuterated DMSO. The
NMR spectrum which was taken immediately (within 5 min) revealed loss of
the Hα and Hβ olefinic proton signals which were taken as evidence of
Michael adduct formation (Figure 6-2). Michael additions are known to be
highly sensitive to solvent polarity and the polar, aprotic nature of DMSO
presumably favored the intermolecular proton-transfer activation
mechanism of the addition reaction or stabilized the zwitterionic form of
cysteamine. 115
Figure 6-2: Reaction between the Michael acceptor moiety of curcuminand nucleophilic cysteamine to give the proposed curcumin-cysteamineadduct.
In agreement with an earlier report, 115 curcumin reacted rapidly with
cysteamine with loss of the olefinic protons Hα, Hβ (Figure 6-3A). Multiple
peaks were observed in the region 6.50 ppm-7.50 ppm which were attributed
to the curcumin-cysteamine adducts. These adducts have two chiral centres
and the overlapping chemical shifts of the diastereomers would result in
multiple peaks.  The reactions of 41 and 227 with cysteamine were
investigated under similar conditions and adduct formation was again
evident from the NMR spectra (Figure 6-3B). Due to the symmetrical
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chemical structures of 41 and 219, both olefinic protons Hα were
represented by one peak; 7.85 ppm in 41 and 7.80 ppm in 227. Reaction with
cysteamine resulted in a significant reduction in their intensities and a change
in their chemical shifts. Multiple peaks (6.90-8.00 ppm) due to the adduct
were observed in the resulting spectra. The reaction of 219 with cysteamine
was not attempted because the chemical shift of its Hα protons was not
readily distinguished from the aromatic protons in deuterated DMSO. Based
on their rapid reaction with cysteamine, it was concluded that the Michael
acceptor reactivities of 41 and 227 were comparable to curcumin.
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Figure 6-3: Reaction of (A) curcumin  (B) 41 and (C) 227 with cysteamine.
(Top) Aromatic region of 1H NMR spectrum of pure compound in DMSO-d6
and after 5 min upon addition of cysteamine (bottom). Spectra were
recorded on a 400 MHz  NMR instrument.
The NMR method for evaluating Michael reactivity also provides a means of
evaluating the reversibility of the cysteamine-test compound adduct. 115
Failure to regenerate the olefinic proton signals on dilution of the DMSO
solution with deuterated chloroform was interpreted to mean that adduct
formation was not readily reversible.117 Michael additions are known to be
highly sensitive to solvent polarity and the polar, aprotic nature of DMSO
presumably favored adduct formation, either by activating intermolecular
proton-transfer which is necessary for Michael addition or by promoting the
nucleophilicity of cysteamine by stabilizing its zwitterionic form. Michael
additions do not occur in the less polar solvent chloroform. If adduct
formation was readily reversible, dilution of the DMSO solution comprising
in-situ generated Michael adducts with chloroform would cause a change in
polarity and disrupt the equilibrium between the free and adducted states of
the compound in favor of the free state. This would result in the
reappearance of the olefin resonance(s) in the NMR spectra. The reversibility
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of adduct formation by addition of deuterated chloroform was not followed
up for 41 and 227.  One reason was that the authors who reported that the
curcumin-cysteamine adduct was irreversible used a rather stringent criteria
for irreversible adduct formation, namely that the adduct should be isolated
from the reaction medium.117 This view is not widely accepted.118
Furthermore, curcumin and some analogs were reported to react by a
reversible Michael addition with glutathione. 85
6.4. Discussion
Investigations on hydrolytic stability and Michael acceptor reactivity were
carried out on the more promising compounds 41, 227 and 219. It was
heartening to note that these compounds were hydrolytically more stable
than curcumin. Notably, nearly 50–66 % of these compounds were detected
after 24 hours as compared to 37 % curcumin. Although stability declined
with time, the compounds were still more stable than curcumin after 75
hours, with 32-40% detected as compared to only 5% for curcumin.  It has
been proposed that the hydrolytic instability of curcumin was linked to the
susceptibility of carbonyl carbon in conjugated β-diketone linker to
nucleophilic attack by hydroxide ions.73 If so, the thiopyranone dioxide
scaffold of 41 and 227 would in fact be a liability as the strong electron
withdrawing sulfone would enhance the electrophilicity of monocarbonyl
carbon and increase its susceptibility to nucleophilic attack. By the same
token, the weaker electron withdrawing sulfide in the thiopyranone 219
would be more resistant to hydrolysis.   Since this was not observed, there is
still much to understand of the mechanism of hydrolysis.
Liang et al noted that the hydrolytic stabilities of monocarbonyl dienone
analogs of curcumin varied widely from 50 % to 90 % depending on the
terminal ring substitution.73 Ring substituent effects may have influenced the
hydrolytic stabilities of 41 and 227 as well. 227 (3-F-4-OMe) was more stable
than 41 (3-F) at the earlier time points (24h, 48h) but this difference was
minimal after 75 hours. Possibly, a careful selection of ring substituents may
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result in thiopyranone dioxides with greater time-dependent hydrolytic
stabilities than 41 and 227.
Only 41 and 227 were evaluated for their Michael acceptor reactivities by the
NMR method. Both compounds, like curcumin, reacted with cysteamine
within 5 min, confirming their reactivities as Michael acceptors.
Unfortunately, cysteamine is not a physiological nucleophile. Reaction with
glutathione, an abundant physiological nucleophile, would have been more
meaningful but is not accessible by the NMR method which was designed to
provide a quick means of identifying Michael acceptors and assessing their
reversible nature. As mentioned earlier, the relevance of the method for
evaluating reversibility has been raised. 118
The general consensus is that the presence of a Michael acceptor moiety in a
molecule is a liability since its reactivity as a covalent modifier would
outweigh and preclude any selectivity. There is a growing realization that
Michael acceptor functionalities could be chemically tuned to favor reversible
covalent adduct formation, thus overriding some of the limitations and risks
of irreversible inhibitors while still retaining the desired biological
responses.118 However, since factors governing the extent of reversible
Michael addition and the position of the reaction equilibrium have not been
fully determined118, design approaches remain largely empirical. It is
tempting to speculate that 41 and 227 react as reversible Michael acceptors
based on their structural similarity to EF24 and EF23 (Figure 6-4) which were
reported to be react reversibly with glutathione.85
Figure 6-4: Chemical structures of EF23 and EF24
The in-vitro metabolic stabilities of 41, 227 and other related compounds
were evaluated on human liver microsomes by quantifying the percentage of
unmetabolized compound remaining over a period of 45 minutes.119
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Quantification was carried out by LC-MS-MS to give a plot of %
unmetabolized compound versus time. From the plot, the time required for a
50% reduction in unmetabolized compound was estimated and used as a
marker for metabolic stability.  A compound that took a longer time to
achieve 50% reduction was deemed to be metabolically more stable than a
compound that took a shorter time to reach the same level. The results are
given in Table 6-1 and depicted for selected compounds in Figure 6-6.Table 6-1: In vitro metabolic stabilities of test compounds in human livermicrosomes (pH 7.4, 37oC)*


































*Experiment carried out by Ms. Chung Yue Ling (final year undergraduate
student) and Ms. Yap Siew Qi.
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Figure 6-5: Metabolic stability of Curcumin, 41 and 204 using human livermicrosomes
The Series V thiopyranone dioxides (41, 227) were found to be metabolically
unstable under the experimental conditions. A comparison of 206, 211 and
227 which have similar ring substituents showed that metabolic stability was
of the order 219 (thiopyranone) ≥ 206 (cyclohexanone) > 227 (thiopyranone
dioxide). It would seem that the poor stability of 227 was due more to the
thiopyranone dioxide scaffold rather than the ring substituents.  It was
proposed that the strongly electron withdrawing sulfone in the thiopyranone
dioxide scaffold may render the α-carbon atoms of the scaffold more
susceptible to attack by activated oxygen radicals (notably the FeO3+ species)
that are involved in CYP450 mediated C-H oxidation.119 If so, one approach to
enhance stability would be to replace the reactive Cα-H with appropriate
substituents like C-F or C-D. Introducing ortho-substituents on the terminal
rings to sterically hinder the approach of the activated oxygen radicals to
these vulnerable positions is another approach.
Notwithstanding the contribution of the central scaffold, the differing
metabolic stabilities of 204 and 206 suggested some role for the ring
substituents as well.  Thus there is a possibility that the metabolic stability of
the thiapyranone dioxide scaffold may be enhanced by varying the
substitution on the terminal rings. The same may be true for the
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thiopyranones 211 and 219 which were comparable to curcumin in terms of
metabolic stability. If these modifications also improve growth inhibitory
potency, it could elevate the status of thiopyranone as a lead scaffold.
6.5. Conclusion
The Series V thiopyranone dioxides 41 and 227 were found to be
hydrolytically more stable than curcumin. The cross conjugated dienone
motif in 41 and 227 were reactive Michael acceptors, comparable to
curcumin. It is tempting to speculate that the closely aligned activity profiles
of 41 and curcumin, as evident from gene expression analysis, stemmed from
their shared reactivities as Michael acceptors. Disappointingly, both 41 and
227 were rapidly metabolized when incubated with human liver microsomes.
Future structural modification of the thiopyranone dioxide scaffold should
focus on addressing this pharmacokinetic liability.
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Chapter 7: Conclusions and Future work
Investigations on misfolded N-CoR, a protein linked to the pathogenesis of
APL, have led to the hypothesis that it could be therapeutically manipulated
to induce APL cell death.  This would be a novel approach that could lead to
alternative treatment options for APL. Curcumin has been shown to target
misfolded N-CoR by inducing its accumulation thereby increasing ER stress
and sensitizing APL cells to UPR-induced apoptosis. Curcumin is undoubtedly
a remarkable molecule endowed with an impressive safety profile and
activity against a broad spectrum of biological targets. But its limitations
(mediocre potency, hydrolytic instability, poor bioavailability, metabolic
instability) have largely hindered its progress as a mainstream drug
candidate. The aim of this thesis was to test the hypothesis that compounds
derived from structural modifications of curcumin would possess the
desirable attributes not found in curcumin, namely potent growth inhibitory
activity on APL cells and improved hydrolytic/metabolic stability, while
retaining the novel targeting of misfolded N-CoR as the mechanistic basis
underpinning their improved activities.  The structural features of curcumin
have been extensively exploited in the search for improved curcumin
analogs. The design approach (Figure 7-1) adopted here was not entirely
novel but the assessment of such modifications on APL cells and their unique
pathophysiology had not been considered before. Hence, it formed the focus
of the current study.
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Figure 7-1: Summary of modifications made to the structure of curcuminthat were undertaken in the present study
The 1st goal was to identify compounds that surpassed curcumin in three
areas: growth inhibitory activity on APL cells, selective growth inhibition of
APL cells vis-à-vis non-APL leukemic cells and growth inhibitory effects on
non-malignant cells. These compounds were identified in Series IV
(thiopyranones), V (thiopyranone dioxides) and VI (piperidinones), with Series
V having the largest number of members that complied with the stated
criteria (Figure 7-2).   The nature of the scaffold played a decisive role in SAR.
It influenced potency, selectivity and the type of substituents to be
introduced at the terminal rings. In this regard, the thiopyranone dioxide
scaffold was clearly superior, surpassing that of its thiopyranone and
piperidinone counterparts.
Figure 7-2: Series IV, V and VI
The next step was to provide proof-of-concept that that APL selectivity was
causally linked to the accumulation of misfolded N-CoR. Investigations on
compounds with varying APL selectivities showed that only APL-selective
compounds increased levels of misfolded N-CoR. Furthermore, several APL-
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selective compounds inhibited proteasomal activity of APL cells.  The potent
Series V compounds 41, 221 and 227 were pan-inhibitors of proteasomal
activity with near complete inhibition of all three proteasomal subunits
observed at 1 µM. 41 was outstanding in that exceptionally low
concentrations ( 1 µM, twice that of its IC50 NB4) were required to elicit
responses that were linked to the present hypothesis, namely the
accumulation of full length / misfolded N-CoR, its cytosolic localization in NB4
cells, proteasomal inhibition, increased levels of ER stress proteins (reflecting
an increase in ER stress), ER stress sensors involved in UPR apoptotic
signaling, and apoptotic markers (caspases 3, 9 and cleaved PARP).  A survey
of the gene expression profile of NB4 cells identified protein processing in the
ER as a key pathway that was up-regulated by 41.  The increase in protein
processing in the ER was deemed to be a response to proteasomal inhibition
by 41. To order to restore homeostasis in the ER, protein processing -
transport, ubiquitinitation, folding - were up-regulated to handle the increase
load arising from proteasomal inhibition. Paradoxically, these same events
were a potent impetus to the pro-apoptotic UPR response and the ensuing
cell death.  Clearly, 41 targeted APL cells by a mechanistic pathway that
closely resembled that of curcumin. It was however distinguished by its
greatly improved potency and selectivity.
Another objective was to evaluate the hydrolytic and metabolic stabilities of
the more promising compounds identified in this thesis. There was indeed
greater hydrolytic stability for selected members of Series IV (219) and V (41,
227) when compared to curcumin.  Both the thiopyranone and thiopyranone
dioxide scaffolds were fairly resilient to hydrolytic breakdown when
incubated in phosphate buffer (pH 7.4) for up to 75 hours. The metabolic
stability of these compounds was less promising when assessed in vitro with
human microsomes. In particular, the Series V thiopyranone dioxides 41 and
227 were highly prone to metabolic breakdown while the Series IV
thiopyranones 211 and 219 were comparable to curcumin. Metabolic liability
was determined largely by the nature of the scaffold and less so by the ring
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substituents. The susceptibility of the Series V compounds may be due to the
strongly electron withdrawing sulfone in the thiopyranone dioxide ring which
activated the Cα positions to phase I oxidation.  Thus, the metabolic liability
of this highly promising series should be addressed in future work.
In conclusion, the findings of this thesis supported the hypothesis that
structural modifications of curcumin was a means of yielding potent
compounds that selectively induced APL growth inhibitory activity via the
novel misfolded N-CoR pathway. Structural requirements for activity and APL
selectivity were established and a potent analog 41 was identified as a potent
proteasomal inhibitor that blocked the breakdown of misfolded N-CoR and
triggered the cascade of events in the UPR, ultimately leading to apoptotic
cell death.
Future work would necessarily focus on addressing the metabolic liability of
the thiopyranone dioxide scaffold. If this is due to hydroxylation at the
electrophilic Cα positions, it may be averted by substitution at these positions
or at the ortho positions of the terminal rings to block or reduce access of the
reactive oxygen species. Another approach is to inhibit the cytochrome P450
enzyme(s) responsible for metabolism. The metabolic liability of the anti-HIV
drug lopinavir was overcome by formulating it with a CYP3A inhibitor
ritonavir in a combined pill.
Quite understandably, disproportionate attention was paid to Series V in this
thesis. In retrospect, more Series IV thiopyranones should have been closely
examined. The only analog that was investigated in detail (219) had a very
similar mechanistic profile as 41 and 227 (Chapter 5) and a more favorable in
vitro metabolic profile as well.  Hence, lead optimization of Series IV may yet
uncover more promising candidates.
It is highly likely that the synthesized compounds are Michael acceptors. This
was demonstrated for 41 and 227 but several pertinent questions remain.
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How do reactivities vary across the different series or within a series? Are the
reactions reversible or irreversible? Michael acceptor reactivity of curcumin
analogs (structurally similar to those investigated in the thesis) has been
shown to contribute to the inhibition of ubiquitin isopeptidase and serine-
threonine kinases.77, 86 Proteasomal inhibition may involve a nucleophilic
attack from the N-terminal threonine residue of the β subunit to the carbonyl
group of the Michael acceptor motif.75 Reactivity of the Michael acceptor
and reversibility of the resulting adduct are aspects that would have a
profound effect on the mechanistic profile of the compound. Spectulatively, a
reactive Michael acceptor would inhibit the proteasome/ubiquitin
isopeptidase to a greater extent, resulting in greater accumulation of
misfolded proteins, and robust activation of UPR apoptosis and cell death.
Future medicinal chemistry efforts should be directed towards fine-tuning
the chemical reactivity of the Michael acceptor motif in Series IV and V.
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1,5-Diphenyl-penta-1,4-dien-3-one (1)120
Yellow crystals. Yield: 28%. 1H-NMR (300 MHz, CDCl3) δ: 7.75 (d, J = 16 Hz,
2H), 7.60-7.63 (m, 4H), 7.26-7.42 (m, 6H), 7.09 (d, J= 16 Hz, 2H); 13C-NMR (75
MHz, CDCl3) δ: 125.327, 128.310, 128.872, 130.411, 134.964, 143.206,
188.805; MS-APCI [M+H]+ 235.3 (234.10).
1,5-bis(3-fluorophenyl)penta-1,4-dien-3-one (2)87
Yellow solid. Yield: 99%. 1H NMR (300 MHz, CDCl3, ppm): δ, 7.53 – 7.59 (d, 2H,
J = 16 Hz), 7.14 – 7.28 (m, 6H), 6.89 – 7.02 (m, 4H); 13C NMR (75 MHz, CDCl3,
ppm): δ 114.26 – 114.54 (d), 117.22 – 117.52 (d), 124.44, 126.27, 130.52,
136.83 – 136.93 (d), 142.12, 161.34 – 164.61 (d), 188.25; MS-APCI [M+H]+
271.2 (271.09). Found (calcd. for C17H12F2O): C 75.37 % (75.55), H 4.46 %
(4.48).
1,5-bis(4-fluorophenyl)penta-1,4-dien-3-one (3)87
Yellow solid. Yield: 85%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.11 – 7.28 (m,
4H), 7.73 – 7.87 (m, 4H); 13C NMR (75 MHz, CDCl3, ppm): δ 114.94, 115.22,
124.00, 129.16, 129.28, 129.95, 141.02, 161.32 – 164.66 (d), 187.40; MS-APCI
[M+H]+ 271.2 (271.09). Found (calcd. for C17H12F2O): C 75.78 % (75.55), H 4.44
% (4.48, 0.9 % of calcd. values).
1,5-Bis-(3-hydroxy-4-methoxy-phenyl)-penta-1,4-dien-3-one (4)121
Yellow solid. Yield: 33%. 1H-NMR (300 MHz, DMSO-d6, ppm) δ: 7.57 (d, 2H, J =
16 Hz), 7.14-7.17 (m, 4H), 7.03 (d, 2H, J = 16 Hz), 6.93 (d, 2H, J = 8 Hz), 3.77 (s,
6H). 13C-NMR (75 MHz, DMSO-d6, ppm) δ: 189.454, 150.906, 147.087,
143.757, 128.057, 123.919, 122.818, 114.706, 112.592, 56.0; MS-APCI [M+H]+
327.0 (326.3).
1,5-Bis-(3,4-dimethoxy-phenyl)-penta-1,4-dien-3-one (5)121
Orange-yellow solid. Yield: 52%. 1H-NMR (300 MHz, CDCl3, ppm) δ: 7.69 (d,
2H, J = 16 Hz), 7.14 – 7.21 (m, 4H), 6.96 (d, 2H, J = 16 Hz), 6.89 (d, 2H, J =8.1
Hz), 3.95 (s, 6H), 3.93 (s, 6H). 13C-NMR (75 MHz, CDCl3, ppm) δ: 188.629,
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151.252, 149.156, 142.984, 127.763, 123.530, 123.033, 111.035, 109.840,
55.892, 55.845; MS-APCI [M+H]+ 355.0 (354.4).
2,5-Dibenzylidene-cyclopentanone (6)120
Yellow solid. Yield: 64%. 1H-NMR (300 MHz, CDCl3, ppm) δ: 7.56 – 7.58 (m,
6H), 7.35 – 7.44 (m, 6H), 3.07 (s, 4H). 13C-NMR (75 MHz, CDCl3, ppm) δ:
196.220, 137.212, 135.717, 133.722, 130.652, 129.286, 128.675, 26.434; MS-
APCI [M+H]+ 261.0 (260.3).
2,5-Bis-(2-fluoro-benzylidene)-cyclopentanone (7)87
Yellow solid. Yield: quantitative. 1H NMR (300 MHz, CDCl3, ppm): δ 7.81 (s,
2H), 7.60 – 7.55 (t, 2H, J = 7.5 Hz), 7.40 – 7.33 (m, 2H), 7.22 – 7.10 (m, 4H),
3.05 (s, 4H); 13C NMR (75 MHz, CDCl3, ppm): δ 195.11, 159.63, 138.50, 130.70
– 130.58 (d), 129.74, 125.33 – 125.27 (d), 123.66 – 123.61 (d), 123.35,
115.67, 26.08; MS-APCI [M+H]+ 297.1 (296.31). Found (calcd. for C19H14F2O):
C 77.47 % (77.01, 0.6 % of calcd. values), H 4.71 % (4.76, 1.1 % of calcd.
values).
2,5-Bis-(3-fluoro-benzylidene)-cyclopentanone (8)87
Yellow solid. Yield: quantitative. 1H NMR (300 MHz, CDCl3, ppm): δ 7.43 (s,
2H), 7.33 – 7.11 (m, 6H), 7.00 – 6.95 (m, 2H), 3.00 (s, 4H); 13C NMR (75 MHz,
CDCl3, ppm): δ 195.91, 161.15, 138.04 – 137.81 (d), 132.77, 130.28, 126.74,
116.88, 116.60, 116.19, 26.34; MS-APCI [M+H]+ 297.1 (296.31). Found (calcd.
for C19H14F2O): C 77.11 % (77.01), H 4.85 % (4.76, 1.9 % of calcd. values).
2,5-Bis-(4-fluoro-benzylidene)-cyclopentanone (9)87
Yellow solid. Yield: quantitative. 1H NMR (300 MHz, CDCl3, ppm): δ 7.31 –
7.26 (m, 6H), 6.80 – 6.72 (m, 4H), 2.79 (s, 4H); 13C NMR (75 MHz, CDCl3, ppm):
δ 196.04, 164.82 – 161.49 (d), 132.72 – 132.66 (d), 132.55, 132.04 – 132.00
(d), 116.10 – 115.81 (d), 26.32; MS-APCI [M+H]+ 297.1 (296.31). Found (calcd.
for C19H14F2O): C 77.10 % (77.01), H 4.90 % (4.76, 2.9 % of calcd. values).
2,5-Bis-(3-hydroxy-4-methoxy-benzylidene)-cyclopentanone (10)122
184
Dark yellow solid. Yield: 27%. 1H-NMR (300 MHz, DMSO-d6, ppm) δ : 9.28 (s,
2H), 7.28 (s, 2H), 7.12 – 7.14 (m, 4H), 7.02 (d, 2H, J= 8 Hz), 3.82 (s, 6H), 3.02
(s, 4H). 13C-NMR (75 MHz, DMSO-d6, ppm) δ: 194.795, 149.148, 146.481,
135.260, 132.410, 128.334, 123.566, 116.836, 112.095, 55.534, 25.846; MS-
APCI [M+H]+ 353.0 (352.4).
2,5-Bis-(3,4-dimethoxy-benzylidene)-cyclopentanone (11)123
Yellow solid. Yield: 44.0%. 1H-NMR (300 MHz, CDCl3, ppm) δ : 7.53 (s, 2H),
7.12-7.27 (m, 4H), 6.93 (d, 2H, J= 8 Hz), 3.93 (s, 12H), 3.10 (s, 4H). 13C-NMR
(75 MHz, DMSO-d6, ppm) δ: 195.946, 150.223, 148.856, 135.319, 133.622,
128.946, 124.534, 113.409, 111.112, 55.899, 55.822, 26.387. MS-APCI [M+H]+
381.0 (380.4). HRMS (APCI) calcd for C23H25O5: [M+H]+ = 381.1697. Found:
381.1711.
2,6-Dibenzylidene-cyclohexanone (12)120
Yellow crystals. Yield: 59.5%. 1H-NMR (300 MHz, CDCl3, ppm) δ: δ: 7.80 (s,
2H), 7.25 – 7.48 (m, 10H), 2.93 (t, 4H, J=5 Hz), 1.79 ( t, 2H, J=6 Hz); 13C-NMR
(75 MHz, DMSO-d6, ppm) δ: 190.373, 136.916, 136.175, 135.963, 130.340,
128.556, 128.356, 100.686, 77.002, 76.579, 28.429, 22.994; MS-APCI [M+H]+
275.1 (274.4).
2,6-bis(2-fluorobenzylidene)-cyclohexanone (13)87
Yellow solid. Yield: 98%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.82 (s, 2H), 7.29 –
7.39 (m, 4H), 7.07 – 7.19 (m, 4H), 2.79 – 2.83 (t, 4H, J = 6 Hz), 1.73 – 1.81 (q,
2H, J = 6 Hz); 13C NMR (75 MHz, CDCl3, ppm): δ 189.53, 162.49, 159.17,
138.20, 130.71, 130.27 – 130.37 (d), 129.70, 123.94, 123.67, 115.56 – 115.86
(d), 28.51, 22.94; MS-APCI [M+H]+ 311.1 (311.12)




Yellow solid. Yield: 99%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.73 (s, 2H), 7.33 –
7.40 (m, 4H), 7.01 – 7.23 (m, 4H), 2.89 – 2.93 (t, 4H, J = 5 Hz), 1.75 – 1.83 (q,
2H, J = 6 Hz); 13C NMR (75 MHz, CDCl3, ppm): δ 189.68, 160.85 – 160.11,
137.93, 136.86,  135.63, 129.76, 126.13, 116.44 – 116.74 (d), 115.28 – 115.57
(d), 28.22, 22.62; MS-APCI [M+H]+ 311.1 (311.12). Found (calcd. for
C20H16F2O): C 77.44 % (77.44), H 5.10 % (5.20, 1.9 % of calcd. values).
2,6-bis(4-fluorobenzylidene)-cyclohexanone (15)87
Yellow solid. Yield: 99%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.75 (s, 2H), 7.42 –
7.47 (m, 4H), 7.07 – 7.12 (m, 4H), 2.88 – 2.91 (t, 4H, J = 5 Hz), 1.79 – 1.82 (t,
2H, J = 6Hz); 13C NMR (75 MHz, CDCl3, ppm): δ 190.00, 160.99 – 164.30 (d),
135.84, 135.69, 132.28, 132.17, 132.02, 115.64, 115.34, 28.31, 22.87; MS-
APCI [M+H]+ 311.1 (311.12). Found (calcd. for C20H16F2O): C 77.56 % (77.44),
H 5.10 % (5.20, 1.9 % of calcd. values).
2,6-Bis-(3-hydroxy-benzylidene)-cyclohexanone (16)122
Recrystallized with ethanol. Brown solid. Yield: 34%. 1H NMR (300 MHz,
DMSO, ppm): δ 9.73 (s, 1H), 7.50 (s, 1H), 7.24 (t, 2H), 6.90 – 6.95 (m, 2H),
6.77 – 6.80 (d, 1H, J = 9 Hz), 2.85 (s, 1H), 1.67 – 1.70 (m, 1H); 13C NMR (75
MHz, DMSO, ppm): δ 165.26, 139.30, 122.55, 122.33, 122.09, 117.02, 110.35,
106.53, 106.03, 34.65, 30.18; MS-APCI [M+H]+ 307.0 (306.36). Found (calcd.
for C20H18O3): C 78.0 % (78.41, 0.5 % of calcd. values), H 5.92 % (5.92).
2,6-Bis-(4-hydroxy-benzylidene)-cyclohexanone (17)87
Brownish-yellow solid. Yield: 25%. 1H-NMR (300 MHz, DMSO-d6, ppm): δ 9.96
(br s, 2H), 7.53 (s, 2H), 7.40 (d, 4H, J = 4 Hz), 6.84 (d, 4H, J = 4 Hz), 2.85 (t, 4H,
J = 5 Hz), 1.71 (t, 2H, J = 6 Hz). 13C-NMR (75 MHz, DMSO-d6, ppm): δ 188.443,
158.250, 135.731, 133.242, 132.390, 126.393, 115.464, 27.912, 22.476; MS-
APCI [M+H]+ 307.0 (306.13).
2,6-Bis-(3-methoxy-benzylidene)-cyclohexanone (18)122
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Yellow crystals. Yield: 41%. 1H-NMR (300 MHz, CDCl3, ppm): δ 7.60 (s, 2H),
7.32 - 7.38 (m, 2H), 7.05 - 7.10 (m, 4H), 6.96 (d, 2H, J = 8 Hz), 3.835 (s, 6H),
2.86 (s, 4H), 1.68 (t, 2H, J = 5 Hz). 13C-NMR (75 MHz, DMSO-d6, ppm): δ
188.80, 159.109, 136.404, 135.636, 129.459, 122.449, 115.474, 114.502,
55.023, 27.780, 22.287. MS-APCI [M+H]+ 335.0 (334.16).
2,6-Bis-(4-methoxy-benzylidene)-cyclohexanone (19)122
Recrystallized with dichloromethane and ethanol. Yellow crystals. Yield: 58%.
1H NMR (300 MHz, CDCl3, ppm): δ 7.76 (s, 1H), 7.44 – 7.47 (d, 2H, J = 9 Hz),
6.92 – 6.95 (d, 2H, J = 9 Hz), 3.84 (s, 3H), 2.90 – 2.93 (m, 2H), 1.76 – 1.84 (m,
1H); 13C NMR (75 MHz, CDCl3, ppm): δ 190.24, 159.89, 136.51, 134.31,
132.21, 128.72, 113.87, 55.30, 28.49, 23.01; MS-APCI [M+H]+ 335.2 (334.41).
Found (calcd. for C22H22O13): C 79.20% (79.02), H 6.59 % (6.63, 0.6 % of calcd.
values).
2,6-Bis-(3,4-dihydroxy-benzylidene)-cyclohexanone (20)122
Recrystallized with methanol and hexane. Brownish green solid. Yield: 29%.
1H NMR (300 MHz, CD3OD, ppm): δ 7.60 (s, 1H), 7.01 (s, 1H), 6.92 – 6.94 (d,
1H, J = 6 Hz ), 6.81 – 6.84 (d, 1H, J = 9 Hz), 2.92 – 2.95 (m, 2H), 1.79 – 1.832
(m, 1H); 13C NMR (75 MHz, CD3OD, ppm): δ 191.62, 147.26, 145.45, 138.02,
134.03, 128.35, 124.22, 117.83, 115.58, 28.75, 23.33; MS-APCI [M+H]+ 339.0
(338.35).
2,6-Bis-(3,4-dimethoxy-benzylidene)-cyclohexanone (21)122
Yellow crystals. Yield: 47.7%. 1H-NMR (300 MHz, CDCl3, ppm) δ: 7.753 (s,
2H), 7.114 (d, 2H, J=4.2Hz), 7.023 (s, 2H), 6.911 (d, 2H, J=8.4Hz), 3.924 (s, 6H),
3.914 (s, 6H), 2.95 (t, 4H, J=5Hz), 1.830 (m, 2H, J= 6Hz); 13C-NMR (75 MHz,
CDCl3, ppm) δ: 189.929, 149.603, 148.640,  136.774, 134.490, 128.961,
123.936, 113.714, 110.897, 77.754, 77.150, 76.725, 55.909, 28.503, 23.022;
MS-APCI [M+H]+ 395.1 (394.5).
2,6-Bis-(3-hydroxy-4-methoxy-benzylidene)-cyclohexanone (22)122
187
Recrystallized with methanol and hexane. Brownish-yellow solid. Yield: 31%.
1H-NMR (300 MHz, DMSO-d6, ppm) δ: 9.18 (br s, 2H), 7.48 (s, 2H), 6.99-
7.01(m, 6H), 3.81 (s, 6H), 2.86 (s, 4H), 1.72 (t, 2H,  J =5Hz); 13C-NMR (75 MHz,
DMSO-d6, ppm) δ: 188.514, 148.483, 146.173, 135.691, 133.957, 129.172,
122.884, 117.060, 111.911, 55.504, 27.847, 22.237; MS-APCI [M+H]+ 367.3
(366.4). Found (calcd. for C22H22O5): C 72.57 % (72.12, 0.6 % of calcd values),
H 5.90 % (6.05, 2.5 % of calcd. values). HRMS (APCI) calcd for C22H23O5:
[M+H]+ = 367.1540. Found: 367.1538.
2,6-Bis-(4-hydroxy-3-methoxy-benzylidene)-cyclohexanone (23)87
Recrystallized with chloroform and hexane. Yellow solid. Yield: 30%. 1H NMR
(300 MHz, DMSO, ppm): δ 9.53 (s, 1H), 7.57 (s, 1H), 7.12 (s, 1H), 7.02 – 7.05
(d, 1H, J = 9 Hz), 6.84 – 6.87 (d, 1H, J = 9 Hz), 3.82 (s, 3H), 2.90 (s, 2H), 1.71 –
1.75 (m, 1H); 13C NMR (75 MHz, DMSO, ppm): δ 189.53, 148.87, 148.48,
137.19, 134.55, 127.97, 125.27, 116.59, 115.85, 56.69, 29.01, 23.63; MS-APCI
[M+H]+ 367.0 (366.41). Found (calcd. for C22H22O5): C 72.16 % (72.12), H 5.80
% (6.05, 4.1 % of calcd. values).
2,6-Bis-pyridin-2-ylmethylene-cyclohexanone (24)120
A yellow solid was obtained from the orange colored reaction mixture. It was
removed by vacuum filtration and purified by column chromatography
(hexane :ethyl acetate = 1:2) Yield: 14%. 1H NMR (300 MHz, CDCl3, ppm): δ
8.29 (s, 2H), 7.32 – 7.26 (m, 4H), 7.04 – 7.01 (m, 2H), 6.85 – 6.76 (m, 2H), 2.90
– 2.86 (m, 4H), 1.46 – 1.40 (q, 2H, J = 6 Hz); 13C NMR (75 MHz, CDCl3, ppm): δ
191.38, 155.50, 149.50, 140.09, 136.13, 134.02, 127.08, 122.44, 28.45, 22.22;
MS-APCI [M+H]+ 277.2 (276.33). Found (calcd. for C18H16N2O): C 78.32 %
(78.24), H 6.15 % (5.84, 5.3 % of calcd. values).
2,6-Bis-pyridin-3-ylmethylene-cyclohexanone (25)120
A yellow solid was obtained from the orange colored reaction mixture. It was
removed by vacuum filtration. The filtrate was evaporated to dryness in
vacuo and orange-colored residue was recrystalized from ethyl acetate
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/hexane. Both solids were then combined and purified by column
chromatography (ethyl acetate). The resulting yellow solid from the column
was recrystallize with acetone / hexane. Yield: 27%. 1H NMR (300 MHz, CDCl3,
ppm): δ 8.23, (s, 2H), 8.09 – 8.07 (d, 2H, J = 4 Hz), 7.29 – 7.26 (m, 4H), 6.89 –
6.84 (m, 2H), 2.47 – 2.43 (m, 4H), 1.39 – 1.30 (q, 2H, J = 6 Hz); 13C NMR (75
MHz, CDCl3, ppm): δ 189.18, 151.07, 149.24, 139.64, 137.65, 136.95, 133.53,
131.60, 123.25, 28.28, 22.67; MS-APCI [M+H]+ 277.0 (276.33). Found (calcd.
for C18H16N2O): C 78.58 % (78.24, 0.4 % of calcd. values), H 5.67 % (5.84, 2.9 %
of calcd. values). HRMS (APCI) calcd for C18H17N2O: [M+H]+ = 277.1335.
Found: 277.1339.
2,6-Bis-pyridin-4-ylmethylene-cyclohexanone (26)120
The yellow-brown reaction mixture was evaporated in vacuo to give orange
oil which was washed with hexane and purified by column chromatography
(ethyl acetate). The yellow solid from the column was recrystallized with
acetone / hexane. Yield: 32%. 1H NMR (300 MHz, CDCl3, ppm): δ 8.27 – 8.25
(d, 4H, J = 4 Hz), 7.26 (s, 2H), 6.90 – 6.86 (m, 4H), 2.53 – 2.50 (m, 4H), 1.46 –
1.38 (q, 2H, J = 6 Hz); 13C NMR (75 MHz, CDCl3, ppm): δ 189.25, 149.98,
143.10, 139.13, 134.34, 124.03, 28.19, 22.40; MS-APCI [M+H]+ 277.4 (276.33).
Found (calcd. for C18H16N2O): C 78.68 % (78.24, 0.6 % of calcd. values), H 5.74
% (5.84, 1.7 % of calcd. values).
1,5-Bis-(4-fluoro-phenyl)-penta-1,4-dien-3-one oxime (27)
Recrystallized with acetone and hexane. White solid. Yield: 23%. 1H NMR (300
MHz, CD3OD, ppm): δ 7.51 – 7.49 (m, 4H), 7.40 – 7.36 (m, 4H), 7.04 – 7.01 (m,
4H), 4.36 (s, 1H), 3.98 (s, 1H), 3.00 – 2.88 (m, 2H); 13C NMR (75 MHz, CD3OD,
ppm): δ 165.12 – 161.78 (d), 157.53, 138.20, 137.62, 131.14, 115.90, 115.62;
MS-APCI [M+H]+ 286.1 (285.29). Found (calcd. for C13H12F2NO·2H2O): C 64.82
% (63.55, 2.0 % of calcd. values), H 5.57 % (5.33, 4.5 % of calcd. values).
1,5-Bis-(3-fluoro-phenyl)-penta-1,4-dien-3-one O-methyl-oxime (28)
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White solid. Yield: 79%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.38 – 7.26 (m,
7H), 7.15 – 6.87 (m, 5H), 4.08 (s, 3H); 13C NMR (75 MHz, CDCl3, ppm): δ
164.70, 161.45, 153.24, 138.78 – 138.68 (d), 138.51 – 138.41 (d), 135.80,
133.52, 130.27 – 130.17 (d), 130.20 – 130.10 (d), 123.44, 123.26 – 123.23 (d),
122.92 – 122.88 (d), 118.42, 116.00 – 115.67 (d), 115.41 – 115.11 (d), 113.64
– 113.39 (d), 113.39 – 113.11 (d), 62.46; MS-APCI [M+H]+ 300.2 (299.31).
Found (calcd. for C18H15F2NO): C 72.41 % (72.23), H 5.24 % (5.05, 3.8 % of
calcd. values).
1,5-Bis-(4-fluoro-phenyl)-penta-1,4-dien-3-one O-methyl-oxime (29)
White solid. Yield: 84%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.75 – 7.67 (m,
4H), 7.44 – 7.20 (m, 7H), 7.03 – 6.98 (d, 1H, J = 16 Hz), 4.25 (s, 3H); 13C NMR
(75 MHz, CDCl3, ppm): δ 164.77 – 164.43 (d), 161.46 – 161.14 (d), 153.76,
135.81, 133.56 132.68 – 132.64 (d), 132.39 – 132.34 (d), 128.98 – 128.88 (d),
128.61 – 128.49 (d), 121.94, 117.06, 115.93 – 115.84 (d), 115.64 – 115.55 (d),
62.31; MS-APCI [M+H]+ 300.1 (299.31). Found (calcd. for C18H15F2NO): C 72.69
% (72.23, 0.6 % of calcd. value), H 5.13 % (5.05, 1.6 % of calcd. value).
3,5-Dibenzylidene-tetrahydro-thiopyran-4one (30)102
Recrystallized with dichloromethane and ethanol. Yellow crystals. Yield: 56%.
1H NMR (300 MHz, CDCl3, ppm): δ 7.79 (s, 1H), 7.26 – 7.45 (m, 5H), 3.92 (s,
2H); 13C NMR (75 MHz, CDCl3, ppm): δ 189.06, 136.91, 135.12, 133.89,
130.02, 128.94, 128.59, 30.05; MS-APCI [M+H]+ 293.0 (292.39). Found (calcd.
for C19H16OS): C 78.27 % (78.05), H 5.43 % (5.52, 1.6 % of calcd. value).
3,5-Bis-(2-fluoro-benzylidene)-tetrahydro-thiopyran-4-one (31)
7 h reflux. Recrystallized with chloroform and ethanol. Yellow solid. Yield:
53%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.77 (s, 2H), 7.39 – 7.29 (m, 4H), 7.18
– 7.10 (m, 4H), 3.78 (s, 4H); 13C NMR (75 MHz, CDCl3, ppm): δ 187.98, 162.13
– 158.81 (d), 135.72, 130.87, 130.75, 129.85, 124.01 – 123.97 (d), 123.04 –
122.85 (d), 116.09 – 115.80 (d), 30.28; MS-APCI [M+H]+ 329.1 (328.07). Found
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(calcd. for C19H14F2OS): C 69.33 % (69.49), H 4.52 % (4.30, 5.2 % of calcd.
value).
3,5-Bis-(3-fluoro-benzylidene)-tetrahydro-thiopyran-4-one (32)
Overnight reflux. Recrystallized with chloroform and ethanol. Yellow solid.
Yield: 55%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.90 (s, 2H), 7.62 – 7.57 (m,
2H), 7.45 – 7.23 (m, 6H), 4.07 (s, 4H); 13C NMR (75 MHz, CDCl3, ppm): δ
188.43, 164.21 – 160.94 (d), 137.09 – 136.98 (d), 135.52, 134.55, 130.20 –
130.10 (d), 125.76 – 125.72 (d), 116.64 – 116.35 (d), 116.02 – 115.74 (d),
29.92; MS-APCI [M+H]+ 329.0 (328.07). Found (calcd. for C19H14F2OS): C 69.45
% (69.49), H 4.36 % (4.30, 1.4 % of calcd. value).
3,5-Bis-(4-fluoro-benzylidene)-tetrahydro-thiopyran-4-one (33)
3.5 h reflux. Recrystallized with chloroform and ethanol. Yellow solid. Yield:
57%. 1H NMR (300 MHz, CDCl3, ppm): δ 7.88 (s, 2H), 7.56 – 7.51 (m, 4H), 7.29
– 7.23 (m, 4H), 4.03 (s, 4H); 13C NMR (75 MHz, CDCl3, ppm): δ 188.65, 164.49
– 161.17 (d), 135.81, 133.52, 132.01, 131.16, 115.92 – 115.63 (d), 29.95; MS-
APCI [M+H]+ 329.0 (328.07). Found (calcd. for C19H14F2OS): C 69.77 % (69.49),
H 4.25 % (4.30, 1.2 % of calcd. value).
3,5-Bis-(3-hydroxy-benzylidene)-tetrahydro-thiopyran-4one (34)
Recrystallized with ethanol. Brown crystals. Yield: 22%. 1H NMR (300 MHz,
DMSO, ppm): δ 9.77 (s, 1H), 7.49 (s, 1H), 7.23 – 7.28 (t, 1H, J = 15 Hz), 6.79 –
6.93 (m, 3H), 3.93 (s, 2H); 13C NMR (75 MHz, DMSO, ppm): δ 189.39, 158.37,
136.80, 136.48, 135.22, 130.89, 122.19, 117.62, 117.39, 30.36; MS-APCI
[M+H]+ 325.3 (324.39). Found (calcd. for C19H16O3S): C 70.18 % (70.35), H 4.97
% (4.97, 6.4 % of calcd. value).
3,5-Bis-(4-hydroxy-benzylidene)-tetrahydro-thiopyran-4one (35)
Recrystallized with ethanol. Green solid. Yield: 20%. 1H NMR (300 MHz,
DMSO, ppm): δ 10.13 (s, 1H), 7.51 (s, 1H), 7.36 – 7.39 (d, 2H, J = 9 Hz), 6.82 –
6.85 (d, 2H, J = 9 Hz), 3.92 (s, 2H); 13C NMR (75 MHz, DMSO, ppm): δ 164.18,
191
140.38, 121.83, 119.30, 118.43, 113.76, 105.73, 35.91; MS-APCI [M+H]+ 325.1
(324.39). Found (calcd. for C19H16O3S): C 70.33 % (70.35), H 4.76 % (4.97, 4.2
% of calcd. value).
3,5-Bis-(3-methoxy-benzylidene)-tetrahydro-thiopyran-4one (36)
Recrystallized with dichloromethane and ethanol. Yellow solid. Yield: 34%. 1H
NMR (300 MHz, CDCl3, ppm): δ 7.74 (s, 1H), 7.30 – 7.36 (m, 1H), 6.90 – 6.99
(m, 3H), 3.91 (s, 2H), 3.83 (s, 3H); 13C NMR (75 MHz, CDCl3, ppm): δ 188.98,
159.58, 136.78, 136.42, 134.12, 129.60, 122.35, 115.43, 114.56, 55.29, 30.09;
MS-APCI [M+H]+ 353.1 (352.11). Found (calcd. for C21H20O3S): C 71.38 %
(71.56), H 5.67 % (5.72, 0.9 % of calcd. value).
3,5-Bis-(4-methoxy-benzylidene)-tetrahydro-thiopyran-4one (37)102
Recrystallized with dichloromethane and ethanol. Yellow crystals. Yield: 35%.
1H NMR (300 MHz, CDCl3, ppm): δ 7.75 (s, 1H), 7.37 – 7.39 (d, 2H, J = 6Hz),
6.93 – 6.96 (d, 2H, J = 9 Hz), 3.93 (s, 2H), 3.85 (s, 3H); 13C NMR (75 MHz,
CDCl3, ppm): δ 188.86, 160.19, 132.08, 131.98, 127.77, 114.09, 55.34, 30.16;
MS-APCI [M+H]+ 353.1 (352.45). Found (calcd. for C21H20O3S): C 71.74 %
(71.56), H 5.75 % (5.72).
3,5-Bis-(3,4-dihydroxy-benzylidene)-tetrahydro-thiopyran-4one (38)124
Recrystallized with methanol and hexane. Yellow solid. Yield: 26%. 1H NMR
(300 MHz, CD3OD, ppm): δ 7.92 (s, 1H), 6.89 – 6.93 (d, 3H, J = 12 Hz), 4.59 (s,
2H); 13C NMR (75 MHz, CD3OD, ppm): δ 182.63, 148.95, 146.10, 142.16,
126.25, 124.55, 123.98, 118.03, 115.96, 45.26.
3,5-Bis-(2-fluoro-benzylidene)-1,1-dioxo-tetrahydro-thiopyran-4-one (40)
Recrystallized with chloroform and ethanol. Yellow solid. Yield: 11%. 1H NMR
(300 MHz, CDCl3, ppm): δ 8.03 (s, 2H), 7.48 – 7.14 (m, 8H), 4.33 (s, 4H); 13C
NMR (75 MHz, CDCl3, ppm): δ 184.47, 161.98, 158.64, 137.92, 132.15 –
132.03 (d), 130.53, 128.70, 124.57 – 124.52 (d), 121.62 – 121.42 (d), 116.45 –
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116.16 (d), 53.27; MS-APCI [M+H]+ 361.1 (360.06). Found (calcd. for
C19H14F2O3S): C 63.08 % (63.32), H 4.11 % (3.92, 4.9 % of calcd. value).
3,5-Bis-(3-fluoro-benzylidene)-1,1-dioxo-tetrahydro-1λ6-thiopyran-4-one (41)
Off-white solid. Yield: 73.2%. 1H NMR (300MHz, CDCl3, ppm): δ 7.95 (s, 2H),
7.48 – 7.43 (q, 2H), 7.41 – 7.09 (m, 6H), 4.42 (s, 4H); 13C NMR (75MHz, CDCl3,
ppm): δ 185.75, 164.38 – 161.10 (d), 142.88, 135.46 – 135.37 (d), 130.79 –
130.69 (d), 127.60, 125.27, 117.23 – 116.95 (d), 116.47 – 116.17, 52.97; MS-
APCI [M+H]+ 361.2 (360.06), HRMS (APCI) calcd for C19H14F2O3S: [M+H]+ =
361.0704. Found: 361.0709. Anal. Calcd. For C19H14F2O3S: C 63.32, H 3.92
found: C 65.45, H 4.08 %
3,5-Bis-(2-fluoro-benzylidene)-4-oxo-piperidinium hydrochloride (42)81
The procedure reported81 is sensitive to presence of water in the reaction
system. Basic aldol condensation87 was adopted followed by acidification.
The hydrochloride salt was obtained by dropwise addition of HCl (6M) to a
solution of the free base in ethyl acetate. The salt was removed by filtration
and washed with ethyl acetate.  Yellow solid. Yield: 56%. 1H NMR (300 MHz,
DMSO-d6, ppm): δ 9.83 (bp, 2H), 7.91 (s, 2H), 7.59 – 7.35 (m, 8H), 4.38 (s, 4H);
13C NMR (75 MHz, DMSO-d6, ppm): δ 181.92, 161.92 – 158.61 (d), 132.55 –
132.43 (d), 131.77 – 131.70 (d), 130.98, 129.85, 124.92 – 124.88 (d), 121.53 –
121.36 (d), 116.18 – 115.89 (d), 43.79; MS-APCI [M+H]+ 312.0 (311.11). Found
(calcd. for C19H16ClF2NO): C 65.54 % (65.62), H 4.69 % (4.64, 1.1 % of calcd.
value). HRMS (APCI) calcd for C19H16F2NO: [M+H]+ = 312.1194. Found:
312.1195.
3,5-Bis-(3-fluoro-benzylidene)-4-oxo-piperidinium hydrochloride (43)
The hydrochloride salt was obtained as described for 42. Yellow solid. Yield:
89%. 1H NMR (300 MHz, DMSO-d6, ppm): δ 9.96 (bp, 2H), 7.86 (s, 2H), 7.62 –
7.33 (m, 8H), 4.49 (s, 4H); 13C NMR (75 MHz, DMSO-d6, ppm): δ 182.81,
164.24, 161.00, 138.39, 136.51 – 136.41 (d), 131.51 – 131.40 (d), 129.46,
127.12, 117.62 – 117.50 (d), 117.32 – 117.22 (d), 44.15; MS-APCI [M+H]+
193
312.0 (311.11). Found (calcd. for C19H16ClF2NO): C 65.83 % (65.62), H 4.70 %
(4.64, 1.3 % of calcd. value).
3,5-Bis-(4-fluoro-benzylidene)-4-oxo-piperidinium hydrochloride (44)125
The hydrochloride salt was obtained as described for 42. Yellow solid. Yield:
61%. 1H NMR (300 MHz, DMSO-d6, ppm): δ 10.00 (bp, 2H), 7.86 (s, 2H), 7.63 –
7.56 (m, 4H), 7.40 – 7.34 (m, 4H), 4.45 (s, 4H); 13C NMR (75 MHz, DMSO-d6,
ppm): δ 182.33, 164.51, 161.21, 138.13, 133.16, 133.06, 130.34, 130.30,
127.65, 116.24, 115.96, 43.74; MS-APCI [M+H]+ 312.0 (311.11). Found (calcd.
for C19H16ClF2NO): C 65.64 % (65.62), H 4.63 % (4.64).
3,5-Bis-(3-hydroxy-benzylidene)-4-oxo-piperidinium hydrochloride (45)
The hydrochloride salt was obtained as described for 42. Greenish yellow
solid. Yield: 30%. 1H NMR (300 MHz, DMSO, ppm): δ 9.91 (s, 1H), 7.85 (s, 1H),
7.78 (s, 1H), 7.30 – 7.35 (t, 1H), 6.90 – 6.95 (m, 3H), 4.45 (s, 2H); 13C NMR (75
MHz, DMSO, ppm): δ 182.34, 157.62, 139.39, 134.82, 130.00, 127.64,
121.45, 117.30, 116.80, 43.95; MS-APCI [M+H]+ 308.0 (307.34). Found (calcd.
for C19H18ClNO3): C 66.56 % (66.38), H 5.30 % (5.28).
3,5-Bis-(4-hydroxy-benzylidene)-4-oxo- piperidinium hydrochloride (46)122
The hydrochloride salt was obtained as described for 42. Yellow solid. Yield:
30%. 1H NMR (300 MHz, DMSO, ppm): δ 10.32 (s, 1H), 7.77 (s, 1H), 7.38 –
7.41 (d, 2H, J = 9 Hz), 6.91 – 6.94 (d, 2H, J = 9 Hz), 4.44 (s, 2H); 13C NMR (75
MHz, DMSO, ppm): δ 181.65, 159.15, 138.71, 132.60, 124.33, 115.53, 43.78,
30.22; MS-APCI [M+H]+ 308.0 (307.12).
3,5-Bis-(3,4-dimethoxy-benzylidene)-4-oxo- piperidinium hydrochloride
(47)122
The hydrochloride salt was obtained as described for 42. Yellow solid. Yield:
30%. 1H NMR (300 MHz, DMSO, ppm): δ 9.62 (s, 1H), 7.85 (s, 1H), 7.12 – 7.16
(d, 3H, J =12 Hz), 4.53 (s, 2H), 3.83 – 3.84 (d, 6H, J = 3 Hz); 13C NMR (75 MHz,
DMSO, ppm): δ 182.54, 151.15, 149.24, 139.82, 127.00, 126.24, 124.80,
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114.93, 112.33, 56.20, 44.49; MS-APCI [M+H]+ 396.0 (395.45). Found (calcd.
for C23H26ClNO5 (chloride salt)): C 63.70 % (63.69), H 6.07 % (6.07, 5.7 % of
calcd. value).
2,6-Bis-(5,6-dimethoxy-pyridin-3-ylmethylene)-cyclohexanone (201)
Yellow solid. Yield: 37.0 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.92 (s, 2H), 7.71
(s, 2H), 7.15 (s, 2H), 4.06 (s, 6H), 3.91 (s, 6H), 2.96 – 2.92 (m, 4H), 1.881 – 1.82
(q, 2H, J = 6Hz); 13C NMR (100MHz, CDCl3, ppm): δ 189.22, 154.34, 143.66,
139.52, 135.48, 133.88, 125.75, 118.46, 55.69, 53.95, 28.46, 22.81; MS-APCI
[M+H]+ 397.3 (396.4)
2-(3,4-Dimethoxy-benzylidene)-6-(3-fluoro-benzylidene)-cyclohexanone (202)
Yellow solid. Yield: 34.3 %. 1H NMR (400MHz, CD3OD, ppm): δ 7.66 (s, 1H),
7.63 (s, 1H), 7.47 – 7.41 (m, 1H), 7.30 – 7.21 (m, 2H), 7.12 – 6.82 (m, 4H), 2.97
– 2.90 (m, 4H), 1.85 – 1.78 (q, 2H, J = 6.3 Hz); 13C NMR (100MHz, CD3OD,
ppm): δ 191.85, 165.31 – 162.88 (d), 148.32, 146.32, 139.72, 139.64 – 139.57
(d), 139.13, 135.82 – 135.79 (d), 134.40, 131.33 – 131.25 (d), 129.03, 127.31,
127.31 – 127.28 (d), 125.25, 118.73, 117.60 – 117.39 (d), 116.42, 116.22,
29.58, 29.27, 24.00; MS-APCI [M+H]+ 353.3 (352.2)
2-(3,4-Dihydroxy-benzylidene)-6-(3-fluoro-benzylidene)-cyclohexanone (203)
Yellow solid. Yield: 32.2 %. 1H NMR (400MHz, CD3OD, ppm): δ 7.66 (s, 1H),
7.63 (s, 1H), 7.47 – 7.41 (m, 1H), 7.30 – 7.21 (m, 2H), 7.12 – 7.07 (m, 1H), 7.03
(s, 1H), 6.96 – 6.93 (1H), 6.84 – 6.82 (d, J = 8.2 Hz), 2.97 – 2.90 (m, 4H), 1.85 –
1.78 (m, 2H); 13C NMR (100MHz, CD3OD, ppm): δ 191.85, 165.31 – 162.88 (d),
148.31, 146.32, 139.72, 139.64 – 139.57 (d), 139.13, 135.82, 134.40, 131.33 –
131.25 (d), 129.03, 127.31, 125.25, 118.73, 117.60 – 117.39, 116.42, 116.22,




Yellow solid. Yield: 87.5 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.72 (s, 2H), 7.39
– 7.34 (m, 1H), 7.23 – 7.12 (m, 3H), 7.05 – 7.01 (m, 2H), 6.90 – 6.88 (m, 1H),
5.63 (s, 1H), 3.94 (s, 3H), 2.96 – 2.88 (m, 4H), 1.84 – 1.78 (m, 2H); 13C NMR
(100MHz, CDCl3, ppm): δ 190.10, 163.82, 147.17, 145.30, 138.27, 137.38 –
137.35 (d), 135.01 – 134.39 (d), 129.87, 129.79, 129.43, 126.17, 124.09,
116.73 – 116.51 (d), 116.15, 115.40 – 115.19 (d), 110.40, 55.97, 28.49, 22.83;
MS-APCI [M+H]+ 339.4 (338.1)
2-(3-Fluoro-benzylidene)-6-(3-hydroxy-benzylidene)-cyclohexanone (205)
Yellow solid. Yield: 10.4 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.76 (s, 1H), 7.75
(s, 1H), 7.40 – 7.34 (m, 1H), 7.30 – 7.17 (m, 3H), 7.16 – 6.99 (m, 4H), 6.87 –
6.84 (m, 1H), 2.94 – 2.88 (m, 4H), 1.83 – 1.77 (q, 2H, J = 6.4 Hz); 13C NMR
(100MHz, CDCl3, ppm): δ 190.48, 163.81 – 161.36 (d), 155.75, 138.04 –
137.96 (d), 137.30, 137.11, 136.21, 135.80, 129.92 – 129.84 (d), 129.61,
126.27 – 126.24 (d), 122.79, 117.17, 116.79 – 116.58 (d), 116.00, 115.62 –
115.41 (d), 28.39, 22.78; MS-APCI [M+H]+ 309.3 (308.1)
2,6-Bis-(3-fluoro-4-methoxy-benzylidene)-cyclohexanone (206)
Yellow solid. Yield: 95.1 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.68 (s, 2H), 7.26
– 7.21 (m, 4H), 7.00 – 6.96 (m, 2H), 2.92 – 2.88 (m, 4H), 1.85 – 1.78 (q, 2H, J =
6.4 Hz); 13C NMR (100MHz, CDCl3, ppm): δ 187.80, 153.11, 150.66, 148.1 –
147.99 (d), 135.61 – 135.13 (d), 129.12 – 129.06 (d), 127.55 – 127.51 (d),
117.69 – 117.51 (d), 113.01 – 112.99 (d), 56.21, 28.32, 22.74; MS-APCI
[M+H]+ 371.1 (370.1)
3,5-Bis-pyridin-2-ylmethylene-tetrahydro-thiopyran-4-one (207)
Yellow solid. Yield: 41.0 %. 1H NMR (300MHz, CDCl3, ppm): δ 8.69 – 8.68 (d,
2H, J = 4.1 Hz), 7.75 – 7.69 (m, 2H), 7.58 (s, 2H), 7.45 – 7.42 (d, 2H, J = 7.5 Hz),
7.23 – 7.19 (m, 2H), 4.50 (s, 4H); 13C NMR (75MHz, CDCl3, ppm): δ 191.54,




Yellow solid. Yield: 12.2 %. 1H NMR (300MHz, CDCl3, ppm): δ 8.19 (s, 2H), 8.13
– 8.11 (d, 2H, J = 4.5 Hz), 7.23 (s, 4H), 6.92 – 6.88 (m, 2H), 3.45 (s, 4H); 13C
NMR (75MHz, CDCl3, ppm): δ 166.76, 136.61, 135.86, 125.44, 124.20, 122.60,
120.61, 114.59, 38.95; MS-APCI [M+H]+ 295.2 (294.1); Anal. Calcd. For
C17H14N2OS: C 69.36, H 4.79; found: C 68.85, H 4.63%
3,5-Bis-pyridin-4-ylmethylene-tetrahydro-thiopyran-4-one (209)
Yellow solid. Yield: 69.0 %. 1H NMR (400MHz, CDCl3, ppm): δ 8.53 (s, 4H), 7.47
(s, 2H), 7.20 – 7.19 (m, 4H), 3.90 (s, 4H); 13C NMR (100MHz, CDCl3, ppm): δ
177.80, 149.50, 148.11, 140.07, 134.08, 124.58, 37.36; MS-APCI [M+H]+ 295.3




Yellow solid. Yield: 87.0 %.1H NMR (400MHz, DMSO, ppm): δ 7.92 (s, 2H),
7.57 (s, 2H), 7.43 (s, 2H), 4.02 (s, 4H), 3.91 (s, 3H), 3.84 (s, 3H); 13C NMR
(400MHz, DMSO, ppm): δ 187.52, 154.10, 143.44, 139.11, 133.60, 132.47,
124.80, 119.12, 55.61, 53.38, 29.35; MS-APCI [M+H]+ 415.1 (414.1)
3,5-Bis-(3-fluoro-4-methoxy-benzylidene)-tetrahydro-thiopyran-4-one (211)
Yellow solid. Yield: 62.8 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.66 (s, 2H), 7.18
– 7.15 (m, 4H), 7.02 – 6.97 (m, 2H), 3.93 (s, 6H), 3.90 (s, 4H); 13C NMR
(100MHz, CDCl3, ppm): δ 188.43, 153.19 – 150.74 (d), 148.44, 148.33, 135.61,
132.88, 127.20, 127.13, 117.64 – 117.46 (d), 113.20, 56.25, 30.03; MS-APCI
[M+H]+ 389.4 (388.1); Anal. Calcd. For C21H18F2O3S: C 64.93, H 4.67; found: C
64.70, H 4.40 %
3,5-Bis-(3,4-dimethoxy-benzylidene)-tetrahydro-thiopyran-4one (39/212)
Yellow powder. Yield: 43.3 %. 1H NMR (300MHz, CDCl3, ppm): δ 7.75 (s, 1H),
7.23 – 7.47 (m, 3H), 5.38 – 5.40 (m, 8H); 13C NMR (75MHz, CDCl3, ppm): δ
197
188.63, 149.83, 148.79, 136.81, 132.25, 127.95, 123.48, 113.35, 110.95,
100.86, 55.86, 30.14; MS-APCI [M+H]+ 413.0 (412.5) Anal. Calcd. For
C23H24O5S: C 66.97, H 5.86; found: C 66.86, H 5.87 %
3,5-Bis-(2,5-dimethoxy-benzylidene)-tetrahydro-thiopyran-4-one (213)
Yellow solid. Yield: 72.5 %. 1H NMR (400MHz, CDCl3, ppm): δ 8.49 (2H), 7.27 –
7.18 (m, 6H), 3.45 (s, 4H), 3.47 (s, 6H), 3.43 (s, 6H); 13C NMR (100MHz, CDCl3,
ppm): δ 188.99, 152.91, 152.41, 134.53, 132.65, 124.91, 116.06, 114.94,
111.81, 55.95, 55.73, 30.17; MS-APCI [M+H]+ 413.2 (412.5)
3,5-Bis-(3,4,5-trimethoxy-benzylidene)-tetrahydro-thiopyran-4-one (214)
Yellow solid. Yield: 54.3 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.70 (s, 2H), 6.63
(s, 4H), 3.97 (s, 4H), 3.91 (s, 12H); 13C NMR (100MHz, CDCl3, ppm): δ 188.59,
153.11, 138.85, 133.21, 130.47, 108.48, 108.35, 61.88, 59.95, 59.05, 57.14,
55.22, 53.31; MS-APCI [M+H]+ 473.3 (472.2); Anal. Calcd. For C25H28O7S: C
63.54, H 5.97; found: C 63.26, H 5.96 %
3,5-Bis-(3-hydroxy-4-methoxy-benzylidene)-tetrahydro-thiopyran-4-one (215)
Yellow solid. Yield: 24.2 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.67 (s, 2H), 7.02
– 6.88 (m, 6H), 5.66 (bp), 3.93 (s, 10H); 13C NMR (100MHz, CDCl3, ppm): δ
188.92, 147.28, 145.47, 136.66, 132.56, 128.69, 123.45, 115.98, 110.54,
56.00, 30.18; MS-APCI [M+H]+ 385.3 (384.1); Anal. Calcd. For C21H20O5S: C
65.61, H 5.24; found: C 65.30, H 5.05 %
3,5-Bis-(4-hydroxy-3-methoxy-benzylidene)-tetrahydro-thiopyran-4-one (216)
Yellow solid. Yield: 35.1 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.72 (s, 2H), 6.98
– 6.92 (m, 6H), 5.85 (bp), 3.97 (s, 4H), 3.92 (s, 6H); 13C NMR (100MHz, CDCl3,
ppm): δ 188.77, 146.71, 146.78, 137.02, 132.13, 127.59, 124.10, 114.57,




Yellow solid. Yield: 25.0 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.75 (s, 1H), 7.71
(s, 1H), 7.41 – 7.36 (m, 1H) 7.17 – 7.15 (m, 1H), 7.10 – 7.03 (m, 3H), 6.95 –
6.91 (m, 2H), 3.96 (s, 2H), 3.93 (s, 3H), 3.91 (s, 3H), 3.88 (s, 2H); 13C NMR
(100MHz, CDCl3, ppm): δ 188.63, 163.90, 161.44, 150.09, 148.91, 137.67,
137.38 – 137.31 (d), 134.93 – 134.87 (d), 131.98, 130.20 – 130.12 (d), 127.86,
125.72, 123.71, 116.60 – 116.38 (d), 115.86 – 115.64 (d), 113.46, 111.05,
55.97, 30.27, 29.87; MS-APCI [M+H]+ 371.3 (370.1)
3-(3,4-Dihydroxy-benzylidene)-5-(3-fluoro-benzylidene)-tetrahydro-
thiopyran-4-one (218)
Yellow solid. Yield: 15.4 %. 1H NMR (400MHz, CD3OD, ppm): δ 7.63 (s, 1H),
7.61 (s, 1H), 7.49 – 7.43 (m, 1H), 7.27 – 7.10 (m, 3H), 6.97 – 6.83 (m, 3H), 3.99
(s, 2H), 3.91 (s, 2H); 13C NMR (100MHz, CD3OD, ppm): δ 190.54, 165.42 –
162.98 (d), 148.53, 146.51, 139.09, 137.14, 135.14, 132.69, 131.60, 131.52,
128.21, 127.00 – 126.97 (d) 124.84, 118.52, 117.54 – 117.32 (d), 116.74,
116.57 31.17, 30.62; MS-APCI [M+H]+ 343.2 (342.1).
3-(3-Fluoro-benzylidene)-5-(3-hydroxy-4-methoxy-benzylidene)-tetrahydro-
thiopyran-4-one (219)
Yellow solid. Yield: 44.1 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.70 (s, 2H), 7.41
– 7.36 (m, 1H), 7.17 – 7.15 (m, 1H), 7.09 – 6.89 (m, 5H), 3.95 (s, 2H), 3.94 (s,
3H), 3.87 (s, 2H); 13C NMR (100MHz, CDCl3, ppm): δ 187.92,163.30 – 160.88
(d), 148.99, 146.40, 137.12 – 127.04 (d), 136.21, 135.49, 133.21, 131.84,
130.68 – 130.60 (d), 127.28, 126.28, 123.01, 117.18, 116.66 – 116.45 (d),




Yellow solid. Yield: 15.4 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.87 (s, 2H), 7.38
– 6.83 (m, 8H), 5.02 (s, 1H), 3.91 – 3.88 (d, 4H, J = 16 Hz); 13C NMR (400MHz,
CDCl3, ppm): δ 188.85, 155.67, 136.81, 136.61, 135.38, 134.85, 134.06,
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130.25, 130.17, 129.90, 125.77, 122.61, 116.64, 116.43, 116.15, 115.99,
115.78 30.07, 29.94; MS-APCI [M+H]+ 327.2 (326.1)
3,5-Bis-(4-fluoro-benzylidene)-1,1-dioxo-tetrahydro-1λ6-thiopyran-4-one
(221)
Yellow solid. Yield: 51.9%. 1H NMR (300MHz, CDCl3, ppm): δ 7.95 (s, 2H), 7.48
– 7.43 (q, 2H), 7.41 – 7.09 (m, 6H), 4.42 (s, 4H); 13C NMR (300MHz, CDCl3,
ppm): δ 185.75, 164.38 – 161.10 (d), 142.88, 135.46 – 135.37 (d), 130.79 –
130.69 (d), 127.60, 125.27, 117.23 – 116.95 (d), 116.47 – 116.17, 52.97; MS-
APCI [M+H]+ 361.2 (360.06), Anal. Calcd. For C19H14F2O3S: C 63.32, H 3.92
found: C 62.70, H 3.80 %
3,5-Bis-(3,4-dimethoxy-benzylidene)-1,1-dioxo-tetrahydro-1λ6-thiopyran-4-
one (222)
Yellow solid. Yield: 36.4 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.93 (s, 2H), 7.07
– 6.93 (m, 6H), 4.48 (s, 4H), 3.94 (s, 6H), 3.92 (s, 6H); 13C NMR (100MHz,
CDCl3, ppm): δ 185.63, 152.43, 150.00, 136.88, 133.92, 128.77, 124.45,
112.32, 110.00, 100.21, 55.78, 53.23; MS-APCI [M+H]+ 445.1 (444.1); Anal.
Calcd. For C23H24O7S: C 62.14, H 5.44; found: C 61.49, H 5.34 %
3,5-Bis-(2,5-dimethoxy-benzylidene)-1,1-dioxo-tetrahydro-1λ6-thiopyran-4-
one (223)
Yellow solid. Yield: 31.8 %. 1H NMR (400MHz, CDCl3, ppm): δ 8.06 (s, 2H), 6.96
– 6.87 (m, 6H), 4.35 (s, 4H), 3.82 (s, 6H), 3.79 (s, 6H); 13C NMR (100MHz,
CDCl3, ppm): δ 186.56, 153.37, 152.22, 140.63, 127.34, 123.18, 116.91,
115.19, 112.30, 56.04, 55.91, 53.71; MS-APCI [M+H]+ 445.1 (444.1); Anal.
Calcd. C23H24O7S: C 62.14, H 5.44; found: C 59.47, H 5.17%
1,1-Dioxo-3,5-bis-(3,4,5-trimethoxy-benzylidene)-tetrahydro-1λ6-thiopyran-4-
one (224)
Off-white solid. Yield: 20.1 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.90 (s, 2H),
6.75 (s, 4H), 4.48 (s, 4H), 3.90 (s, 18H); 13C NMR (100MHz, CDCl3, ppm): δ
188.83, 153.62, 143.81, 139.78, 128.64, 126.24, 106.70, 60.99, 56.35, 53.76,
200
29.68; MS-APCI [M+H]+ 505.3 (504.2); Anal. Calcd. For C25H28O9S: C 59.51, H
5.59; found: C 58.83, H 5.39 %
3,5-Bis-(3-hydroxy-4-methoxy-benzylidene)-1,1-dioxo-tetrahydro-1l6-
thiopyran-4-one (225)
Yellow solid. Yield: 32.4 %. 1H NMR (400MHz, DMSO-d6, ppm): δ 7.75 (s, 2H),
7.05 – 6.97 (m, 6H), 4.64 (s, 4H), 3.83 (s, 6H);13C NMR (100MHz, DMSO-d6,
ppm): δ 183.94, 149.57, 146.59, 141.80, 126.34, 125.58, 123.06, 116.89,
112.25, 55.67, 52.22; MS-APCI [M+H]+ 417.2 (416.1); Anal. Calcd. For
C21H20O7S: C 60.57, H 4.84; found: C 59.08, H 4.73%
3,5-Bis-(3-hydroxy-benzylidene)-1,1-dioxo-tetrahydro-1l6-thiopyran-4-one
(226)
Yellow solid. Yield: 23.8 %. 1H NMR (300MHz, DMSO-d6, ppm): δ 7.82 (s, 2H),
7.27 – 7.26 (t, 2H, J = 7.9 Hz), 6.94 – 6.85 (m, 6H), 4.36 – 4.20 (dd, 4H, J =
14.7); 13C NMR (75MHz, DMSO-d6, ppm): δ 186.34, 157.46, 142.54, 135.44,
129.82, 127.08, 120.78, 116.57, 116.38, 48.13; MS-APCI [M+H]+ 357.1 (356.1)
3,5-Bis-(3-fluoro-4-methoxy-benzylidene)-1,1-dioxo-tetrahydro-1l6-
thiopyran-4-one (227)
Yellow solid. Yield: 30.5 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.90 (s, 2H), 7.21
– 7.16 (m, 4H), 7.05 – 7.01 (m, 2H), 4.44 (s, 4H), 3.95 (s, 6H); 13C NMR
(100MHz, CDCl3, ppm): δ 185.60, 15.43 – 150.96 (d), 149.49, 142.84, 126.87 –
126.83 (d), 126.41 – 126.35 (d), 125.63, 117.55 – 117.36 (d), 113.54, 56.32,
53.14; MS-APCI [M+H]+ 421.1 (420.1); Anal. Calcd. For C21H18F2O5S: C 59.99, H
4.32; found: C 59.47, H 4.17%
3,5-Bis-(2,5-dimethoxy-benzylidene)-4-oxo-piperidinium; chloride (228)
Yellow solid. Yield: 44.0 %. 1H NMR (400MHz, DMSO-d6, ppm): δ 9.35 (bp),
7.98 (s, 2H), 7.09 (s, 4H), 6.86 (s, 2H), 4.39 (s, 4H), 3.82 (s, 6H), 3.76 (s, 6H);
13C NMR (100MHz, DMSO-d6, ppm): δ 182.83, 153.24, 152.79, 135.61, 128.47,
123.33, 117.16, 116.22, 113.12, 56.57, 56.17, 44.56; MS-APCI [M+H]+ 432.1
201
(431.2); Anal. Calcd. For C23H26ClNO5: C 63.97, H 6.07; found: C 62.36, H 5.83
%
4-Oxo-3,5-bis-(3,4,5-trimethoxy-benzylidene)-piperidinium; chloride (229)
Yellow solid. Yield: 29.4 %. 1H NMR (400MHz, DMSO-d6, ppm): δ 9.30 (bp),
7.85 (s, 2H), 6.85 (s, 4H), 4.58 (s, 4H), 3.84 (s, 6H), 3.73 (s, 3H); 13C NMR
(100MHz, DMSO-d6, ppm): δ 182.15, 152.90, 139.47, 139.27, 129.16, 127.02,
108.43, 60.18, 56.15, 43.93; MS-APCI [M+H]+ 491.1 (491.2); Anal. Calcd. For
C25H30ClNO7: C 61.03, H 6.15; found: C 59.89, H 5.99 %
3,5-Bis-(3-hydroxy-4-methoxy-benzylidene)-4-oxo-piperidinium; chloride salt
(230)
Yellow solid. Yield: 60.0 %. 1H NMR (400MHz, DMSO-d6, ppm): δ 9.40 (s, 2H),
7.73 (s, 2H), 7.08 – 6.93 (m, 6H), 4.46 (s, 4H), 3.84 (s, 6H); 13C NMR (100MHz,
DMSO-d6, ppm): δ 182.00, 149.76, 146.62, 139.24, 126.53, 125.38, 123.63,
112.23, 55.72, 44.05; MS-APCI [M+H]+ 404.1 (403.1); Anal. Calcd. For
C21H22ClNO5: C 62.45, H 5.49; found: C 60.44, H 5.68%
3,5-Bis-(4-hydroxy-3-methoxy-benzylidene)-4-oxo-piperidinium; chloride
(231)
Yellow solid. Yield: 55.0 %. 1H NMR (400MHz, DMSO-d6, ppm): δ 9.88 (s, 2H),
9.33 (bp), 7.81 (s, 2H), 7.13 – 6.91 (m, 6H), 4.52 (s, 4H), 3.83 (s, 6H); 13C NMR
(100MHz, DMSO-d6, ppm): δ 181.40, 148.73, 147.25, 139.05, 124.72, 124.25,
124.22, 115.38, 114.81, 55.28 43.50; MS-APCI [M+H]+ 404.3 (403.1); Anal.
Calcd. For C21H22ClNO5: C 62.45, H 5.49; found: C 65.04, H 5.69 %
2-(3-Fluoro-benzylidene)-cyclohexanone (48)
Light yellow solid. Yield: 98.6 %.1H NMR (400MHz, CDCl3, ppm): δ 7.48 (s, 1H),
7.38 – 7.32 (m, 1H), 7.13 – 7.00 (m, 3H), 2.83 – 2.80 (m, 2H), 2.56 – 2.53 (t,




Light yellow solid. Yield: 98.6 %. 1H NMR (400MHz, CDCl3, ppm): δ 7.44 (s,
2H), 7.38 – 7.36 (m, 1H), 7.12 – 7.02 (m, 3H), 3.79 (s, 2H), 3.04 – 3.01 (m, 2H),
2.93 – 2.89 (m, 2H); 13C NMR (100MHz, CDCl3, ppm): δ 198.58, 163.88 –
161.42 (d), 136.88, 135.89, 134.16, 130.24, 125.50, 116.47 – 116.26 (d),
115.90 – 115.69 (d), 41.41, 28.56, 25.94; MS-APCI [M+H]+ 222.9 (222.1).
Appendix 2-2. Purity data of final compounds as determined by reverse
phase HPLC
The purity of the final compound was verified by reverse phase high pressure
liquid chromatography (HPLC) on an Agilent 1100 HPLC system. The test
compound was dissolved in methanol and injected through a 50 μl loop at a
flow rate of 1ml/min, with UV detection at 254 nm.  Each compound was
tested on two of three mobile phases: methanol-water, acetonitrile-water or
acetonitrile-methanol-water.  Retention time (RT in min) and peak area of
test sample (Area %) were recorded in each case from at least two separate
determinations.  A Zorbax Eclipse XDB-C18 column (4.6x150mm, 5μm) from



















1 A1 5.0 99.5 B1 3.1 99.7
4 A1 2.7 98.5 B1 3.3 99.8
5e A1 3.1 95.5 B2 2.8 94.6
6 A1 22.0 97.1 B1 4.2 99.3
10 A1 6.6 99.3 B1 3.1 99.8
11 A1 7.7 96.9 B1 2.4 96.6
12 A1 12.1 98.7 B1 5.5 98.6
17 A1 7.5 98.3 B1 3.1 97.7
18 A1 5.0 95.4 B1 4.0 96.8
20 A2 2.8 97.9 B4 2.8 99.0
21 A1 5.7 100.0 B1 2.8 97.8
22 A1 4.8 100.0 B1 1.7 99.8
38 A1 2.5 99.0 C1 2.3 100.0
46 A2 4.0 98.8 B3 4.2 98.2
201 e A1 5.02 94.75 B1 3.68 94.65
202 A1 6.46 95.98 B1 4.54 97.08






205 A1 4.88 95.76 B1 2.86
100.0
0
206 A1 7.83 98.32 B1 4.46
100.0
0
207 A2 3.10 95.50 B1 2.88 98.01
208 A2 2.41 99.11 B2 1.71
100.0
0
209 A2 1.56 95.07 B2 3.81 97.94
210 A1 3.84 96.59 B1 2.48 96.65
212 A1 5.49 97.86 B1 3.46 96.38
213 A1 6.42 98.90 B1 3.81 97.93






217 e A1 5.55 94.82 B1 3.45 95.52
218 e A2 6.96 91.56 B2 2.51 95.58
219 A1 4.06 98.12 B1 2.53 98.44
220 A1 4.18 96.23 B1 2.52 98.68





0 B2 2.13 99.15
223 A2 5.27 97.13 B2 3.21 96.32
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224 A1 2.18 95.71 B1 1.94
100.0
0








227 e A1 2.35 92.78 B1 2.02
100.0
0
a Composition of Mobile Phase A: Methanol and Water
A1: 80% methanol
A2: 70% methanol
b Composition of Mobile Phase B: Acetonitrile and Water
B1: 80% acetonitrile
B2: 70% acetonitrile
c Retention time of Major Peak in chromatogram. Chromatogram was run for
at least 15 min for the detection of the major peak
d Area (%) of Major Peak = [Area of Major Peak / Total Area of All Peaks] x
100
e Did not comply with > 95% purity on two solvent systems.
Appendix 3-1.  Cell Viability (%) of NB4-R1 cells treated with fixed
concentrations (5 µM, 20 µM) of “Inactives”
Compound % NB4-R1 cell viability ± SDa
Ref no. Linker Substituents 5 µM 20 µM
Cur Keto-enol 3OCH3, 4OH 4.63 ± 2.5 0.85 ± 0.6
1 H 43.83 ± 32.7 1.25 ± 0.6
3 4F 59.60 ± 8.5 0.99 ± 1.8
6 H 83.08 ± 4.6 36.48 ± 5.7
7 2F 60.11 ± 10.7 47.12 ± 11.9
8 3F 90.40 ± 10.0 71.60 ± 5.0
9 4F 91.30 ± 11.2 87.81 ± 9.1
10 3OH, 4OCH3 83.18 ± 4.7 73.84 ± 3.7
12 H 75.15 ± 12.1 0.52 ± 0.5
13 2F 56.20 ± 27.9 1.70 ± 2.1
15 4F 69.24 ± 11.4 1.36 ± 2.0
205
27 4F 93.83 ± 9.4 86.95 ± 6.5
28 3F 89.08 ± 10.1 69.05 ± 5.7
29 4F 92.11 ± 9.5 77.19 ± 6.9
aPercent growth inhibition of NB4-R1, human acute promyelocytic leukemia
(APL) cells resistant to retinoic acid.  Activity data performed on three
independent experiments, two concentrations (5 and 20 µM), each
experiment performed in triplicate.
Appendix 4-1.  IC50 determination of curcumin and 41 on trypsin-, caspase-
and chymotrypsin-like active sites of 20S proteasome.
Inhibition of Proteasome T -like
activity by Curcumin
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Appendix 4-2. Determination of substrates Km. Initial rate of reaction
containing each substrate from 4 µM to 200 µM with 2 µg protein of NB4
lysate was measured and Km and Vmax was calculated using the Michaelis-
Menten equation.
Appendix 5-1. qRT -PCR reaction conditions.
Total RNA was isolated as described in Section 5.2.3 and converted to cDNA
as described in Section 5.2.6. Real-time PCR of selected genes was carried out
using the TaqMan® Gene Expression Assay System (Applied Biosystems, CA,
USA) and recorded using the ABI 7500 Fast PCR System (Applied Biosystems,
CA, USA). The PCR reaction, conditions and list of TaqMan primers were as
follows:




TaqMan® Gene Expression Master Mix (2X) 10
TaqMan® Gene Expression Assay or ACTB control (20X) 1
RNase-free H2O 4
Km Determination


























Step Temperature (˚C) Time Number of Cycles




95 10 min Hold
Denaturation 95 15 sec 40 cyclesAnneal/Extention 60 1 min
Appendix 5-2. List of TaqMan® primers for real-time PCR








Calculation of fold-change (with respect to vehicle control) using the
comparative Ct method was described as follows:
ΔCt =Ct (sample) - Ct (endogenous control)
ΔΔCt = ΔCt (sample) - ΔCt (vehicle control)
Fold-change = 2-ΔΔCt
Where Ct refers to the cycle number at which the increase in fluorescence (i.e.
amount of cDNA) crosses a preset threshold. Sample refers to individual gene
investigated and endogenous control refers to the housekeeping gene ACTB.
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Appendix 5-3. List of genes involved in DNA replication, cell cycle,
apoptosis and proteasomal structure that are significantly regulated by
both curcumin and 41.
Class Symbol Function Log2FCa41 Log2FCaCur
DNA
replication
MCM6 Req for DNA replication initiation andelongation 2.806 2.909
DNA2
DNA2 is a conserved helicase/nuclease
involved in the maintenance of
mitochondrial and nuclear DNA stability
2.689 2.674
RFC4
Replication factor-4 involved in the
elongation of primed DNA templates by
DNA polymerase delta
2.549 2.482
POLD3 Required for optimal DNA polymerasedelta activity 2.425 2.656
Cell cycle
BUB1B Required for normal mitosis progression. 3.241 3.425
BUB3 Mitotic checkpoint protein to ensurecorrect chromosome segregation 3.214 3.337
STAG2
Component of cohesin complex, a complex
required for the cohesion of sister
chromatids after DNA replication.
2.963 3.092
CUL1
Mediate the ubiquitination of proteins
involved in cell cycle progression, signal
transduction and transcription
3.107 3.274
MCM6 Req for DNA replication initiation andelongation 2.806 2.909
RB1
Active form of RB1 interacts with E2F1 and
represses its transcription activity, leading
to cell cycle arrest.
3.068 3.212
NRAS
N-Ras membrane protein that bind




14-3-3 family, interact with RAF1 and
CDC25 phosphatases, play a role in linking





Calcium-binding protein involved in
regulation of vesicular trafficking, plasma
membrane Na(+)/H(+) exchanger and gene
transcription
3.545 3.952
PRKAR1A A cAMP-dependent protein kinase is acomponent of the signal transduction 2.346 2.512
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mechanism of certain GPCRs and
transduces the signal through
phosphorylation of different target
proteins
PIK3R1 Phosphoinositide 3-kinases capable of
phosphorylating 3'OH of inositol ring of
phosphoinositides. They are responsible for
proliferation, cell survival, degranulation,




PSMB4 β7 subunit of 20S proteasome - catalytic
activity not known
3.272 3.310




This gene encodes the largest non-ATPase
subunit of 19S regulator lid, which is




An ATPase subunit of 19S regulatory
complex involved in ATP-dependent
degradation of ubiquitinated proteins
2.636 2.456
a Log fold change of gene expression in treated cells relative to vehicle control
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